US20200108154A1 - Anti-tpbg antibodies and methods of use - Google Patents
Anti-tpbg antibodies and methods of use Download PDFInfo
- Publication number
- US20200108154A1 US20200108154A1 US16/553,498 US201916553498A US2020108154A1 US 20200108154 A1 US20200108154 A1 US 20200108154A1 US 201916553498 A US201916553498 A US 201916553498A US 2020108154 A1 US2020108154 A1 US 2020108154A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- seq
- tpbg
- cancer
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 183
- 210000004027 cell Anatomy 0.000 claims description 341
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 219
- 101710190034 Trophoblast glycoprotein Proteins 0.000 claims description 218
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 182
- 206010028980 Neoplasm Diseases 0.000 claims description 131
- 201000011510 cancer Diseases 0.000 claims description 90
- 229940127121 immunoconjugate Drugs 0.000 claims description 88
- 229940127089 cytotoxic agent Drugs 0.000 claims description 61
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 42
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims description 30
- 239000002254 cytotoxic agent Substances 0.000 claims description 30
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 21
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 21
- 239000003937 drug carrier Substances 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 8
- 230000027455 binding Effects 0.000 description 159
- 239000004698 Polyethylene Substances 0.000 description 124
- 102000006388 human trophoblastic glycoprotein 5T4 Human genes 0.000 description 123
- 101100425826 Homo sapiens TPBG gene Proteins 0.000 description 122
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 119
- 244000309715 mini pig Species 0.000 description 81
- 238000006467 substitution reaction Methods 0.000 description 65
- 239000003814 drug Substances 0.000 description 64
- 108020001507 fusion proteins Proteins 0.000 description 63
- 102000037865 fusion proteins Human genes 0.000 description 60
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 57
- 108090000623 proteins and genes Proteins 0.000 description 56
- 238000003556 assay Methods 0.000 description 54
- 239000000872 buffer Substances 0.000 description 50
- 239000000427 antigen Substances 0.000 description 47
- 102000004169 proteins and genes Human genes 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 46
- 108091007433 antigens Proteins 0.000 description 45
- 102000036639 antigens Human genes 0.000 description 45
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 42
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 42
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 42
- 235000001014 amino acid Nutrition 0.000 description 40
- 239000002246 antineoplastic agent Substances 0.000 description 36
- 229940124597 therapeutic agent Drugs 0.000 description 36
- 229940024606 amino acid Drugs 0.000 description 35
- 238000011282 treatment Methods 0.000 description 35
- 238000005859 coupling reaction Methods 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 33
- 238000010168 coupling process Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 33
- 239000012634 fragment Substances 0.000 description 32
- 239000002609 medium Substances 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 31
- 230000008878 coupling Effects 0.000 description 31
- 239000002953 phosphate buffered saline Substances 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 238000010790 dilution Methods 0.000 description 27
- 239000012895 dilution Substances 0.000 description 27
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 26
- 125000000539 amino acid group Chemical group 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- 241000283973 Oryctolagus cuniculus Species 0.000 description 25
- 210000003719 b-lymphocyte Anatomy 0.000 description 25
- 239000012894 fetal calf serum Substances 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 22
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 22
- 206010006187 Breast cancer Diseases 0.000 description 21
- 108090001126 Furin Proteins 0.000 description 21
- 230000003013 cytotoxicity Effects 0.000 description 21
- 231100000135 cytotoxicity Toxicity 0.000 description 21
- 238000005516 engineering process Methods 0.000 description 21
- 230000005847 immunogenicity Effects 0.000 description 21
- 108700012359 toxins Proteins 0.000 description 21
- 208000026310 Breast neoplasm Diseases 0.000 description 20
- 102000004961 Furin Human genes 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- 238000012217 deletion Methods 0.000 description 20
- 230000037430 deletion Effects 0.000 description 20
- 239000003053 toxin Substances 0.000 description 20
- 231100000765 toxin Toxicity 0.000 description 20
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 19
- 208000005718 Stomach Neoplasms Diseases 0.000 description 19
- 206010017758 gastric cancer Diseases 0.000 description 19
- 238000011534 incubation Methods 0.000 description 19
- 238000003780 insertion Methods 0.000 description 19
- 230000037431 insertion Effects 0.000 description 19
- 230000035772 mutation Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 201000011549 stomach cancer Diseases 0.000 description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 18
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 18
- 230000001413 cellular effect Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 238000000684 flow cytometry Methods 0.000 description 18
- 201000005202 lung cancer Diseases 0.000 description 18
- 208000020816 lung neoplasm Diseases 0.000 description 18
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 208000002495 Uterine Neoplasms Diseases 0.000 description 16
- 238000012054 celltiter-glo Methods 0.000 description 16
- 210000003169 central nervous system Anatomy 0.000 description 16
- 238000003776 cleavage reaction Methods 0.000 description 16
- 230000001472 cytotoxic effect Effects 0.000 description 16
- 239000010432 diamond Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 208000014829 head and neck neoplasm Diseases 0.000 description 16
- 230000007017 scission Effects 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 206010046766 uterine cancer Diseases 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 108010076504 Protein Sorting Signals Proteins 0.000 description 15
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- 210000004899 c-terminal region Anatomy 0.000 description 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000007405 data analysis Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 210000003000 inclusion body Anatomy 0.000 description 13
- -1 poly(n-vinyl pyrrolidone) Polymers 0.000 description 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- 229910003460 diamond Inorganic materials 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 10
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 101100446038 Mus musculus Fabp5 gene Proteins 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000002285 radioactive effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 10
- 239000004475 Arginine Substances 0.000 description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- 206010025323 Lymphomas Diseases 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 206010033128 Ovarian cancer Diseases 0.000 description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 230000004075 alteration Effects 0.000 description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 9
- 235000009697 arginine Nutrition 0.000 description 9
- 208000019065 cervical carcinoma Diseases 0.000 description 9
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 9
- 239000000562 conjugate Substances 0.000 description 9
- 238000010494 dissociation reaction Methods 0.000 description 9
- 230000030583 endoplasmic reticulum localization Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 238000004020 luminiscence type Methods 0.000 description 9
- 230000004481 post-translational protein modification Effects 0.000 description 9
- 206010041823 squamous cell carcinoma Diseases 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 206010003571 Astrocytoma Diseases 0.000 description 8
- 206010004593 Bile duct cancer Diseases 0.000 description 8
- 206010005949 Bone cancer Diseases 0.000 description 8
- 208000018084 Bone neoplasm Diseases 0.000 description 8
- 206010006143 Brain stem glioma Diseases 0.000 description 8
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 8
- 206010009944 Colon cancer Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 206010014967 Ependymoma Diseases 0.000 description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 8
- 208000006168 Ewing Sarcoma Diseases 0.000 description 8
- 101710082714 Exotoxin A Proteins 0.000 description 8
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 8
- 208000017604 Hodgkin disease Diseases 0.000 description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 8
- 206010061252 Intraocular melanoma Diseases 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 208000000172 Medulloblastoma Diseases 0.000 description 8
- 206010027406 Mesothelioma Diseases 0.000 description 8
- 229930012538 Paclitaxel Natural products 0.000 description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 8
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 8
- 208000002471 Penile Neoplasms Diseases 0.000 description 8
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 8
- 201000005746 Pituitary adenoma Diseases 0.000 description 8
- 206010061538 Pituitary tumour benign Diseases 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- 208000015634 Rectal Neoplasms Diseases 0.000 description 8
- 208000006265 Renal cell carcinoma Diseases 0.000 description 8
- 208000000453 Skin Neoplasms Diseases 0.000 description 8
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 8
- 208000024770 Thyroid neoplasm Diseases 0.000 description 8
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 8
- 206010046458 Urethral neoplasms Diseases 0.000 description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 8
- 201000005969 Uveal melanoma Diseases 0.000 description 8
- 201000003761 Vaginal carcinoma Diseases 0.000 description 8
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- 208000030381 cutaneous melanoma Diseases 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 229960004679 doxorubicin Drugs 0.000 description 8
- 210000000750 endocrine system Anatomy 0.000 description 8
- 201000003914 endometrial carcinoma Diseases 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 8
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 208000003747 lymphoid leukemia Diseases 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 208000026037 malignant tumor of neck Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 206010027191 meningioma Diseases 0.000 description 8
- 201000002575 ocular melanoma Diseases 0.000 description 8
- 229960001592 paclitaxel Drugs 0.000 description 8
- 201000002528 pancreatic cancer Diseases 0.000 description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 description 8
- 210000002990 parathyroid gland Anatomy 0.000 description 8
- 208000021310 pituitary gland adenoma Diseases 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- 206010038038 rectal cancer Diseases 0.000 description 8
- 201000001275 rectum cancer Diseases 0.000 description 8
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 8
- 201000000849 skin cancer Diseases 0.000 description 8
- 201000003708 skin melanoma Diseases 0.000 description 8
- 210000000813 small intestine Anatomy 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 210000001685 thyroid gland Anatomy 0.000 description 8
- 210000000626 ureter Anatomy 0.000 description 8
- 208000013013 vulvar carcinoma Diseases 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108010053187 Diphtheria Toxin Proteins 0.000 description 7
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000001516 cell proliferation assay Methods 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- 238000000159 protein binding assay Methods 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 6
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 101000801451 Rattus norvegicus Trophoblast glycoprotein Proteins 0.000 description 6
- 108010039491 Ricin Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000005917 in vivo anti-tumor Effects 0.000 description 6
- 235000018977 lysine Nutrition 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 6
- 229960001756 oxaliplatin Drugs 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000004153 renaturation Methods 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 5
- 108010066676 Abrin Proteins 0.000 description 5
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 5
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 5
- 102000016607 Diphtheria Toxin Human genes 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 241000282567 Macaca fascicularis Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 244000302512 Momordica charantia Species 0.000 description 5
- 235000009811 Momordica charantia Nutrition 0.000 description 5
- 101150030083 PE38 gene Proteins 0.000 description 5
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 229940123237 Taxane Drugs 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 240000001866 Vernicia fordii Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 108010001818 alpha-sarcin Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000004330 calcium propionate Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 229930191339 dianthin Natural products 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 108010028531 enomycin Proteins 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 235000014304 histidine Nutrition 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 5
- 108010010621 modeccin Proteins 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 108010076042 phenomycin Proteins 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101001022148 Homo sapiens Furin Proteins 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 4
- 229940028652 abraxane Drugs 0.000 description 4
- 108010076089 accutase Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- 229960004562 carboplatin Drugs 0.000 description 4
- 190000008236 carboplatin Chemical compound 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 235000004554 glutamine Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002637 immunotoxin Effects 0.000 description 4
- 229940051026 immunotoxin Drugs 0.000 description 4
- 239000002596 immunotoxin Substances 0.000 description 4
- 231100000608 immunotoxin Toxicity 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 4
- ZPUHVPYXSITYDI-HEUWMMRCSA-N xyotax Chemical compound OC(=O)[C@@H](N)CCC(O)=O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 ZPUHVPYXSITYDI-HEUWMMRCSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000869050 Homo sapiens Caveolae-associated protein 2 Proteins 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101150112800 PE35 gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000009824 affinity maturation Effects 0.000 description 3
- 239000001132 aluminium potassium sulphate Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000015861 cell surface binding Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 229960003668 docetaxel Drugs 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000033581 fucosylation Effects 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000001194 polyoxyethylene (40) stearate Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229960003048 vinblastine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102100035233 Furin Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101001051709 Homo sapiens Ribosomal protein S6 kinase-related protein Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 101100425828 Mus musculus Tpbg gene Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102100024914 Ribosomal protein S6 kinase-related protein Human genes 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 238000012867 alanine scanning Methods 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 108010044540 auristatin Proteins 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000010370 cell cloning Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011157 data evaluation Methods 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000006481 glucose medium Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940065638 intron a Drugs 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229940124303 multikinase inhibitor Drugs 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000013492 plasmid preparation Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000007828 protein synthesis assay Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JKHVDAUOODACDU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCN1C(=O)C=CC1=O JKHVDAUOODACDU-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- VLARLSIGSPVYHX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-(2,5-dioxopyrrol-1-yl)hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O VLARLSIGSPVYHX-UHFFFAOYSA-N 0.000 description 1
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZMRMMAOBSFSXLN-UHFFFAOYSA-N 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanehydrazide Chemical compound C1=CC(CCCC(=O)NN)=CC=C1N1C(=O)C=CC1=O ZMRMMAOBSFSXLN-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
- PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
- MECFLTFREHAZLH-ACZMJKKPSA-N Asn-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N MECFLTFREHAZLH-ACZMJKKPSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 description 1
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 102100027285 Fanconi anemia group B protein Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 108010015133 Galactose oxidase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 1
- YYOBUPFZLKQUAX-FXQIFTODSA-N Glu-Asn-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YYOBUPFZLKQUAX-FXQIFTODSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- 101001041117 Homo sapiens Hyaluronidase PH-20 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000984620 Homo sapiens Low-density lipoprotein receptor-related protein 1B Proteins 0.000 description 1
- 101000896414 Homo sapiens Nuclear nucleic acid-binding protein C1D Proteins 0.000 description 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 102100038609 Lactoperoxidase Human genes 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100027121 Low-density lipoprotein receptor-related protein 1B Human genes 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- WEMYTDDMDBLPMI-DKIMLUQUSA-N Phe-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N WEMYTDDMDBLPMI-DKIMLUQUSA-N 0.000 description 1
- KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 101000611441 Solanum lycopersicum Pathogenesis-related leaf protein 6 Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 101150073130 ampR gene Proteins 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000006800 cellular catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- JLYVRXJEQTZZBE-UHFFFAOYSA-N ctk1c6083 Chemical compound NP(N)(N)=S JLYVRXJEQTZZBE-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000010265 fast atom bombardment Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108010083654 human trophoblastic glycoprotein 5T4 Proteins 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 229940044700 hylenex Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- VBCVPMMZEGZULK-NRFANRHFSA-N indoxacarb Chemical compound C([C@@]1(OC2)C(=O)OC)C3=CC(Cl)=CC=C3C1=NN2C(=O)N(C(=O)OC)C1=CC=C(OC(F)(F)F)C=C1 VBCVPMMZEGZULK-NRFANRHFSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 229950005692 larotaxel Drugs 0.000 description 1
- SEFGUGYLLVNFIJ-QDRLFVHASA-N larotaxel dihydrate Chemical compound O.O.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 SEFGUGYLLVNFIJ-QDRLFVHASA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 108010029942 microperoxidase Proteins 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003956 nonsteroidal anti androgen Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229950001094 ortataxel Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- QHGVXILFMXYDRS-UHFFFAOYSA-N pyraclofos Chemical compound C1=C(OP(=O)(OCC)SCCC)C=NN1C1=CC=C(Cl)C=C1 QHGVXILFMXYDRS-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000007420 radioactive assay Methods 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001403 relative X-ray reflectometry Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- MKNJJMHQBYVHRS-UHFFFAOYSA-M sodium;1-[11-(2,5-dioxopyrrol-1-yl)undecanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCCCCCCN1C(=O)C=CC1=O MKNJJMHQBYVHRS-UHFFFAOYSA-M 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229950009016 tesetaxel Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003412 trans-golgi network Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229940065658 vidaza Drugs 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-OUBTZVSYSA-N water-17o Chemical compound [17OH2] XLYOFNOQVPJJNP-OUBTZVSYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Definitions
- the present invention relates to anti-TPBG antibodies and methods of using the same.
- Trophoblast glycoprotein (TPBG) is a leucine-rich transmembrane glycoprotein involved in cell adhesion. In adults this protein is highly expressed in many tumor cells and is associated with poor clinical outcome in numerous cancers.
- Antibodies binding to TPBG are, e.g. disclosed in Shaw et al. (2002) Biochem. J. 363: 137-45 and WO98/55607. Those documents disclose antibody “H8”, which specifically binds to a conformational epitope of TPBG. Amino acid sequences of original murine H8 antibody and of a humanized version of H8 antibody are disclosed in WO 2006/031653.
- antibodies binding to TPGB are, e.g. disclosed and characterized in WO 2007/106744, referred to as antibodies A1, A2 and A3.
- Therapeutic use of antibodies binding to TPBG in treatment of cancer is, e.g., disclosed in Myers et al. (2002) Cancer Gene Ther. 9: 884-896, Shaw et al. (2000) Biochim. Biophys. Acta. 1524: 238-246; and US 2003/0018004, disclosing that anti-TPBG antibody antibody sequences fused to the human IgG constant domain or to the extracellular domain of murine B7.1 induces cytolysis of TPBG-expressing tumor cell lines.
- the invention provides anti-TPBG antibodies, conjugates thereof and methods of using the same. Also provided are isolated anti-TPBG polypeptides and isolated nucleic acids encoding the same.
- the invention relates to an isolated antibody that binds to trophoblast glycoprotein (TPBG), wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2).
- TPBG trophoblast glycoprotein
- the invention relates to an isolated antibody that binds to TPBG, wherein the antibody specifically binds to human and minipig TPBG with a KD of 10-8 M or less.
- the antibody specifically binds to human TPBG with a KD of 10-8 M or less and the antibody specifically binds to minipig TPBG with a KD of 10-8 M or less.
- the Fab fragment of the antibody specifically binds to human and minipig TPBG with a KD of 10-8 M or less.
- the invention in another aspect relates to an isolated antibody that binds to TPBG, wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.4.
- the invention in another aspect relates to an isolated antibody that binds to TPBG, wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.4 with a KD of 10-8 M or less.
- the invention relates to an isolated antibody that binds to TPBG, wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2.
- the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2.
- the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2.
- the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2, wherein binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- the binding is detected via flow cytomentry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2, wherein binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- the binding is detected via flow cytomentry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2, wherein binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- the binding is detected via flow cytomentry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- the antibody binds to cell surface expressed human TPBG and to cell surface expressed minipig TPBG.
- the antibody is internalized into a human or minipig-TPBG-expressing cell upon binding to cell surface expressed TPBG.
- the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 5, a CDR3 of the light chain of SEQ ID NO: 8, and a CDR2 of the heavy chain of SEQ ID NO: 4 (corresponding to the aforementioned CDRs of the antibody “051” as disclosed herein).
- the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 3, a CDR2 of the heavy chain of SEQ ID NO: 4, a CDR3 of the heavy chain of SEQ ID NO: 5, a CDR1 of the light chain of SEQ ID NO: 6, a CDR2 of the light chain of SEQ ID NO: 7, and a CDR3 of the light chain of SEQ ID NO: 8 (corresponding to the six CDRs of the antibody “051” as disclosed herein).
- the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 13, a CDR3 of the light chain of SEQ ID NO: 16, and a CDR2 of the heavy chain of SEQ ID NO: 12 (corresponding to the aforementioned CDRs of the antibody “091” as disclosed herein).
- the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 11, a CDR2 of the heavy chain of SEQ ID NO: 12, and a CDR3 of the heavy chain of SEQ ID NO: 13, a CDR1 of the light chain of SEQ ID NO: 14, a CDR2 of the light chain of SEQ ID NO: 15, and a CDR3 of the light chain of SEQ ID NO: 16 (corresponding to the six CDRs of the antibody “091” as disclosed herein).
- the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 21, a CDR3 of the light chain of SEQ ID NO: 24, and a CDR2 of the heavy chain of SEQ ID NO: 20 (corresponding to the aforementioned CDRs of the antibody “097” as disclosed herein).
- the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 19, a CDR2 of the heavy chain of SEQ ID NO: 20, and a CDR3 of the heavy chain of SEQ ID NO: 21, a CDR1 of the light chain of SEQ ID NO: 22, a CDR2 of the light chain of SEQ ID NO: 23, and a CDR3 of the light chain of SEQ ID NO: 24 (corresponding to the six CDRs of the antibody “097” as disclosed herein).
- the antibody is a humanized antibody derived from one of the aforementioned antibodies.
- the antibody comprises
- the invention provides an antibody comprising a VH sequence of SEQ ID NO: 9 and a VL sequence of SEQ ID NO: 10 (corresponding to the variable domains of the antibody “051” as disclosed herein).
- the antibody comprises
- the invention provides an antibody comprising a VH sequence of SEQ ID NO: 17 and a VL sequence of SEQ ID NO: 18 (corresponding to the variable domains of the antibody “091” as disclosed herein).
- the antibody comprises
- the invention provides an antibody comprising a VH sequence of SEQ ID NO: 25 and a VL sequence of SEQ ID NO: 26 (corresponding to the variable domains of the antibody “097” as disclosed herein).
- the antibody is an antibody fragment that binds TPBG. In one embodiment of the invention, the antibody is a Fab fragment that binds TPBG.
- the invention provides an isolated nucleic acid encoding the antibody of the invention. In one aspect the invention provides a host cell comprising said nucleic acid.
- the invention provides a method of producing an antibody comprising culturing said host cell of the invention so that the antibody is produced. In one embodiment of said method the method further comprises recovering the antibody from the host cell.
- the invention provides an immunoconjugate comprising the antibody of the invention and a cytotoxic agent.
- the cytotoxic agent is an enzymatically active toxin or fragment thereof.
- the cytotoxic agent is selected from the group consisting of exotoxin A chain (from Pseudomonas aeruginosa ), diphtheria toxin, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
- the cytotoxic agent is Pseudomonas exotoxin A or a variant thereof.
- the invention provides a method of producing the immunoconjugate of the invention, including the step of coupling the antibody to the cytotoxic agent.
- said method further includes the step of providing the antibody before the step of coupling, wherein the antibody is provided by culturing the host cell of the invention, which comprises a nucleic acid encoding the antibody of the invention, so that the antibody is produced.
- said method further includes the step of recovering the antibody from the host cell before the step of coupling.
- the invention provides a recombinant fusion protein comprising an antibody of the invention and any other polypeptide.
- the other polypeptide is fused to at least one of the heavy chains of the antibody.
- the other polypeptide is fused to the C-terminus of at least one of the heavy chains of the antibody.
- the polypeptide is a cytotoxic agent (in consequence, in this embodiment, the recombinant fusion protein is an immunoconjugate).
- the cytotoxic agent is an enzymatically active toxin or fragment thereof.
- the cytotoxic agent is selected from the group consisting of exotoxin A chain (from Pseudomonas aeruginosa ), diphtheria toxin, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
- the cytotoxic agent is Pseudomonas exotoxin A chain (from
- the invention provides an isolated nucleic acid encoding the recombinant fusion protein of the invention.
- the nucleic acid encodes the recombinant fusion protein of the invention, wherein the recombinant fusion protein is an immunoconjugate (in this embodiment, the polypeptide comprised in the recombinant fusion protein is a cytotoxic agent).
- the invention provides a host cell comprising said nucleic acid.
- the invention provides a method of producing a recombinant fusion protein comprising culturing said host cell so that the recombinant fusion protein is produced.
- the recombinant fusion protein is an immunoconjugate.
- the method further comprises recovering the recombinant fusion protein from the host cell.
- the method further comprises isolating inclusion bodies of the host cell and solubilizing the inclusion bodies.
- the method further comprises the step of renaturation of the material from the solubilized inclusion bodies.
- host cell is a bacterial cell.
- said method host cell is an Escherichia coli cell.
- the invention provides a pharmaceutical formulation comprising the antibody of the invention and a pharmaceutically acceptable carrier.
- said pharmaceutical composition further comprises an additional therapeutic agent.
- said additional therapeutic agent is a chemotherapeutic agent.
- the invention provides a pharmaceutical formulation comprising the recombinant fusion protein of the invention and a pharmaceutically acceptable carrier.
- said pharmaceutical composition further comprises an additional therapeutic agent.
- said additional therapeutic agent is a chemotherapeutic agent.
- the invention provides a pharmaceutical formulation comprising the immunoconjugate of the invention and a pharmaceutically acceptable carrier.
- said pharmaceutical composition further comprises an additional therapeutic agent.
- said additional therapeutic agent is a chemotherapeutic agent.
- the invention provides the antibody of the invention for use as a medicament. In one aspect the invention provides the antibody of the invention for use in the treatment of cancer.
- the invention provides the use of the antibody of the invention in the manufacture of a medicament.
- the invention provides a method of treating an individual having cancer comprising administering to the individual an effective amount of the antibody of the invention. In one embodiment said method further comprises administering an additional therapeutic agent to the individual. In one embodiment said additional therapeutic agent is a chemotherapeutic agent.
- the invention provides the recombinant fusion protein of the invention for use as a medicament. In one aspect the invention provides the recombinant fusion protein of the invention for use in the treatment of cancer.
- the invention provides the use of the recombinant fusion protein of the invention in the manufacture of a medicament.
- the medicament is for treatment of cancer
- the invention provides a method of treating an individual having cancer comprising administering to the individual an effective amount of the recombinant fusion protein of the invention.
- said method further comprises administering an additional therapeutic agent to the individual.
- said additional therapeutic agent is a chemotherapeutic agent.
- the invention provides the immunoconjugate of the invention for use as a medicament. In one aspect the invention provides the immunoconjugate of the invention for use in the treatment of cancer.
- the invention provides the use of the immunoconjugate of the invention in the manufacture of a medicament.
- the medicament is for treatment of cancer.
- the invention provides a method of treating an individual having cancer comprising administering to the individual an effective amount of the immunoconjugate of the invention. In one embodiment said method further comprises administering an additional therapeutic agent to the individual. In one embodiment said additional therapeutic agent is a chemotherapeutic agent.
- the invention provides a method of screening for an antibody that binds to human TPBG and to minipig TPBG, the method comprising the steps of testing the binding of a test antibody to human TPBG and to minipig TPBG, and selecting the antibody that binds to human TPBG and to minipig TPBG.
- the method is for the screening of an antibody for therapeutic application.
- the method comprises the step of testing the binding of a test antibody in monovalent form.
- the method comprises the steps of testing the binding of a test antibody to human TPBG at pH 5.5 and at pH 7.2, and selecting the antibody that binds to human TPBG at both pH (pH 5.5 and pH 7.2).
- the invention provides an antibody obtained by a method of screening of the invention.
- the invention provides a method of generating an antibody that binds to human TPBG and to minipig TPBG, the method comprising the steps of (a) immunizing an animal with human TPBG or with human TBPG extracellular domain (ECD), (b) isolating B cells specific for human TPBG from the blood of the animal, (c) identifying the amino acid sequence of the variable domains (VH and VL) of the antibodies produced by the isolated B cells, (d) providing an antibody comprising the variable domains identified, (e) testing the binding of a the provided antibody to human TPBG and to minipig TPBG, and (f) selecting the antibody that binds to human TPBG and to minipig TPBG.
- ECD extracellular domain
- the method is for generating an antibody for therapeutic application.
- the animal is a rodent. In one embodiment the animal is a rabbit.
- the method comprises the step of testing the binding of the provided antibody in monovalent form.
- the method comprises the steps of testing the binding of the provided antibody to human TPBG at pH 5.5 and at pH 7.2, and selecting the antibody that binds to human TPBG at both pH (pH 5.5 and pH 7.2).
- the invention provides an antibody obtained by a method of generating an anti-TPBG antibody of the invention.
- the invention provides antibodies that bind to TPBG which are cross-reactive between TPBG of human and minipig species, and thereby are suitable for clinical development as they can be used for studies in minipig species (hence avoiding necessity of monkey studies).
- the antibodies of the invention that bind to TPBG bind to their target, i.e. human TPBG, both at neutral as well as slightly acidic pH thereby assuring antigen binding in the slightly acidic microenvironment of a tumor, which is advantageous for a therapeutic application of the antibodies in cancer therapy.
- antibodies of the invention exhibit superior potency for treatment of several types of cancer, e.g. human non-small cell lung cancer.
- the human cell line SW620 clone 4 stably expressing TPBG, was incubated with different Fabs at varying pH.
- a secondary antibody coupled to a fluorescent dye signals were detected by flow cytometry. Baseline corrected mean fluorescent intensities (MFI) are shown.
- the y-axis displays the loss of signal for cell surface bound Fabs as function of time.
- MFI mean fluorescent intensities
- FIG. 6A-D Cytotoxicity mediated by anti-TPBG antibodies (anti-TPBG Fab antibodies bound by anti-kappa chain antibody-PE fusion protein, prior art antibodies H8, A1, A2, A3 as well as antibodies 051, 091 and 097 of the invention) on human and minipig-TPBG expressing CHO cells (Example 22). Viability was determined by ATP-release assay (CellTiter-Glo) and set in relation to buffer treated control cells.
- FIG. 6B CHO-K1 stably transfected with human TPBG.
- FIG. 6C CHO-K1 stably transfected with minipig TPBG.
- FIG. 6D CHO-K1 stably transfected with minipig TPBG.
- FIG. 7A CHO-K1 cells stably transfected with full length human TPBG were incubated with immunoconjugates.
- FIG. 7B CHO-K1 cells stably transfected with full length minipig TPBG were incubated with immunoconjugates.
- FIG. 7C Parental CHO-K1 cells were incubated with immunoconjugates.
- FIG. 11 Cytotoxicity of immunoconjugates comprising anti-TPBG antibodies (Fabs coupled to PE fragment via sortase coupling) on human TPBG expressing MCF7 cells (Example 26).
- the human breast cancer cell line MCF7 was incubated with sortase coupled Fab-PE constructs. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h.
- FIG. 12 Cytotoxicity mediated by anti-TPBG antibodies (anti-TPBG Fab antibodies bound by anti-kappa chain antibody-PE fusion protein) on human TPBG expressing H1975 non-small cell lung cancer cells (Example 27). H1975 cells were incubated with the complex of Fab:Fab-PE constructs. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h.
- FIG. 13 Cytotoxicity of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) on human TPBG expressing H1975 non-small cell lung cancer cells (Example 28).
- the human tumor cell line H1975 was incubated with Fab-PE fusion proteins.
- Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h.
- FIG. 14A-D Time course proliferation assay of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) applied to human TPBG expressing H1975 non-small cell lung cancer cells (Example 29).
- the human tumor cell line H1975 was incubated for different periods of time with the respective Fab-PE constructs. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h.
- FIG. 14A Continuos incubation with Fab-PE.
- FIG. 14B Incubation with Fab-PE for 60 min.
- FIG. 14C Incubation with Fab-PE for 30 min.
- FIG. 14D Incubation with Fab-PE for 10 min.
- FIG. 17A-B Protein synthesis assay using BxPC3/luc cells contacted with immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) (Example 32). Viability was determined by luciferase assay and set in relation to buffer treated control cells. BxPC-3 stably transfected with a luciferase reporter were treated.
- FIG. 17A Comparison of immunoconjugates comprising prior art antibody H8 with sandwich constructs comprising antibodies 051, 091 or 097 of the invention.
- FIG. 17B Comparison of immunoconjugates comprising prior art antibodies.
- FIG. 18 Binding of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) to human TPBG at pH 5.5 and pH 7.4 (association-dissociation-plot, Example 35).
- FIG. 19 Binding of anti-TPBG antibodies (Fab fragments) to minipig TPBG.
- acceptor human framework for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below.
- An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less.
- the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
- an “affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.
- HVRs hypervariable regions
- an antibody that binds to TPBG refers to an antibody that is capable of binding TPBG with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting TPBG.
- an antibody that binds to TPBG has a dissociation constant (Kd) of ⁇ 1 ⁇ M, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g. 10 ⁇ 8 M or less, e.g. from 10 ⁇ 8 M to 10 ⁇ 13 M, e.g., from 10 ⁇ 9 M to 10 ⁇ 13 M).
- an anti-TPBG antibody binds to an epitope of TPBG that is conserved among TPBG from different species.
- test antibody refers to an antibody with unknown characteristics with respect to its binding properties to TPBG.
- antibody herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
- antibody fragment refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds.
- antibody fragments include but are not limited to Fv, Fab, Fab′, Fab′-SH, F(ab′) 2 ; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.
- an “antibody that binds to the same epitope” as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more.
- An exemplary competition assay is provided herein.
- chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
- the “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain.
- the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
- cytotoxic agent refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction.
- Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal
- “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
- an “effective amount” of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
- Fc region herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region.
- the term includes native sequence Fc regions and variant Fc regions.
- a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
- the C-terminal lysine (Lys447) of the Fc region may or may not be present.
- numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991), NIH Publication 91-3242.
- “Framework” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues.
- the FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
- full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
- host cell refers to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
- Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
- a “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
- a “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences.
- the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
- the subgroup of sequences is a subgroup as in Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, 5th ed., Bethesda Md. (1991), NIH Publication 91-3242, Vols. 1-3.
- the subgroup is subgroup kappa I as in Kabat et al., supra.
- the subgroup is subgroup III as in Kabat et al., supra.
- a “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs.
- a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody.
- a humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.
- a “humanized form” of an antibody, e.g., a non-human antibody refers to an antibody that has undergone humanization.
- hypervariable region refers to each of the regions of an antibody variable domain which are hypervariable in sequence (“complementarity determining regions” or “CDRs”) and/or form structurally defined loops (“hypervariable loops”) and/or contain the antigen-contacting residues (“antigen contacts”).
- CDRs complementarity determining regions
- hypervariable loops form structurally defined loops
- antigen contacts antigen contacts
- antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3).
- Exemplary HVRs herein include:
- HVR residues and other residues in the variable domain are numbered herein according to Kabat et al., supra.
- an “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
- mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).
- domesticated animals e.g., cows, sheep, cats, dogs, and horses
- primates e.g., humans and non-human primates such as monkeys
- rabbits e.g., mice and rats
- rodents e.g., mice and rats.
- the individual or subject is a human.
- an “isolated” antibody is one which has been separated from a component of its natural environment.
- an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC).
- electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
- chromatographic e.g., ion exchange or reverse phase HPLC
- nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment.
- An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
- isolated nucleic acid encoding an anti-TPBG antibody refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.
- the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
- polyclonal antibody preparations typically include different antibodies directed against different determinants (epitopes)
- each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
- the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
- the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
- “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures.
- native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain.
- VH variable heavy domain
- VL variable region
- the light chain of an antibody may be assigned to one of two types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequence of its constant domain.
- package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
- Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
- % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
- the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
- the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code.
- the ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
- % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
- pharmaceutical formulation refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
- a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
- a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
- TPBG refers to any native TPBG from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g., mice and rats), unless otherwise indicated.
- the term encompasses “full-length,” unprocessed TPBG as well as any form of TPBG that results from processing in the cell.
- the term also encompasses naturally occurring variants of TPBG, e.g., splice variants or allelic variants.
- the amino acid sequence of an exemplary human TPBG is shown in SEQ ID NO: 1.
- the amino acid sequence of an exemplary minipig TPBG is shown in SEQ ID NO: 2.
- treatment refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
- antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.
- variable region refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
- the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs).
- FRs conserved framework regions
- HVRs hypervariable regions
- antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano, S. et al., J. Immunol. 150 (1993) 880-887; Clackson, T. et al., Nature 352 (1991) 624-628).
- vector refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked.
- the term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced.
- Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors”.
- “Cancer” as used herein include both solid and haematologic cancers, such as lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of
- Native, wild-type Pseudomonas exotoxin A is a 66 kD bacterial toxin secreted by Pseudomonas aeruginosa , having the 613 amino acid sequence shown in SEQ ID NO:52 and also disclosed in U.S. Pat. No. 5,602,095. This sequence is shown without the native signal peptide, which is shown as the first 25 amino acids of UniProt accession number P11439.2 (gi: 12231043).
- the native protein has three major structural domains.
- the N-terminal domain I comprises two subdomains Ia (amino acids 1-252) and Ib (amino acids 365-399) that are structurally adjacent but separated in the primary amino acid sequence.
- Domain I and in particular domain Ia is the cell-binding domain.
- the function of domain Ib remains undefined.
- Domain I forms the major component of the B subunit.
- forms of PE in which the native domain Ia sequence is omitted or disrupted, and which consequently are unable to bind to LRP1 or LRP1B, are greatly preferred.
- Domain III (amino acids 400-613) mediates ADP ribosylation of elongation factor 2.
- the structural boundary between domain Ib and domain III is not fully settled. According to WO2013/040141 it lies between residues 399 and 400, but Weldon and Pastan 2011 place it between residues 404 and 405.
- full catalytic activity requires a portion of domain Ib as well as domain III.
- the functional domain III of the native toxin is defined to start at residue 395.
- Amino acids 602-613 have been found to be inessential for NAD(+)-ribosyltransferase activity, but amino acids 609-613 of the native sequence are required for cytotoxic activity.
- Cytotoxicity can be maintained or enhanced by replacing the native ER localisation sequence with one or more other ER localisation sequences. Accordingly the functional domain III of native PE is considered to consist of residues 395-601.
- Pseudomonas exotoxin A Pseudomonas exotoxin A chain (from Pseudomonas aeruginosa )” and “PE” as used herein are intended to encompass these and other variants and improvements of native PE that retain cytotoxic activity.
- Pseudomonas exotoxin A Pseudomonas exotoxin A
- Pseudomonas exotoxin and “PE” are specifically intended to include the variants and improvements disclosed in WO88/02401A1, WO90/12592A1, WO91/09949, WO91/09965, WO93/25690, WO97/13529, WO98/20135, WO2005/052006, WO2007/016150, WO2007/031741, WO2009/32954, WO2011/32022, WO2012/154530, WO2012/170617, WO2013/40141, Mazor R, et al PNAS 111 (2014) 8571-8576, and Alewine C, et al, Mol Cancer Ther.
- PE Pseudomonas exotoxin A
- a PE toxin will have a polypeptide sequence comprising a PE functional domain III having at least 50% amino acid sequence identity over the full length of residues 395-601 of SEQ ID NO: 52, wherein the PE toxin has cytotoxic activity when introduced into a eukaryotic (preferably mammalian) cell.
- Preferred forms of PE comprise (1) a PE functional domain III having at least 50% amino acid sequence identity over the full length of residues 395-601 of SEQ ID NO: 52 and having NAD(+)-diphthamide ADP ribosyltransferase activity, and (2) at least one endoplasmic reticulum localisation sequence.
- the PE in embodiments in which the PE is coupled to a cell-binding agent as a fusion polypeptide, the PE preferably also comprises (3) a cleavable linker sequence such as a furin-cleavable sequence (FCS) that permits cleavage of the PE functional domain III from the cell-binding agent following uptake into the target cell.
- a cleavable linker sequence such as a furin-cleavable sequence (FCS) that permits cleavage of the PE functional domain III from the cell-binding agent following uptake into the target cell.
- FCS furin-cleavable sequence
- the cleavable linker (such as an FCS) will generally be on the N-terminal side of the PE functional domain III.
- cleavable linkers may be used provided that they permit cleavage of the PE from the cell-binding agent following uptake into the target cell.
- other means of coupling the PE to the cell-binding agent are contemplated, provided again that they permit separation of the PE from the cell-binding agent following uptake into the target cell.
- the cell-binding agent may be non-covalently linked to the PE, or linked by disulfide bonds which permit release of the PE moiety under reducing conditions, or linked by other conjugation chemistries that are known in the field of immunoconjugate production.
- the PE for use in accordance with the present invention will generally lack a functional cell-binding domain I.
- PE40 is a truncated derivative of PE (Pai et al 1991 Proc. Natl. Acad. Sci. USA 88:3358-62 and Kondo et al. 1988 J. Biol. Chem. 263:9470-9475).
- PE35 is a 35 kD carboxyl-terminal fragment of PE in which amino acid residues 1-279 have been deleted and the molecule commences with a Met at position 280 followed by amino acids 281-364 and 381-613 of PE as defined by reference to SEQ ID NO: 52.
- PE35 and PE40 are disclosed, for example, in U.S. Pat. Nos. 5,602,095, 4,892,827, WO93/25690 and WO88/02401, each of which is incorporated herein by reference in its entirety.
- PE38 contains the translocating and ADP ribosylating domains of PE but not the cell-binding portion (Hwang et al. 1987 Cell 48:129-136).
- PE38 (SEQ ID NO: 53) is a truncated PE pro-protein composed of amino acids 253-364 and 381-613 of SEQ ID NO: 52 which is activated to its cytotoxic form upon processing within a cell (see U.S. Pat. No. 5,608,039, which is incorporated by reference in its entirety herein, and Pastan et al. 1997 Biochim. Biophys. Acta, 1333:C1-C6).
- PE38QR is a variant of PE38 having mutations of the lysines at positions 590, 606 and 613 of domain III, to permit conjugation to antibodies.
- PE-LR contains a deletion of domain II except for a furin-cleavable sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 52 (RHRQPRGWEQL (SEQ ID NO: 54)) and a deletion of amino acid residues 365-394 of domain 1b.
- FCS furin-cleavable sequence
- PE-LR contains amino acid residues 274-284 and 395-613 of SEQ ID NO: 52.
- PE-LR is described in WO 2009/032954 and Weldon et al 2009 Blood 113:3792-3800, which are each incorporated herein by reference in their entirety.
- WO2012/154530 describes that the addition of a short, flexible linker of between 3 and 8 amino acids each independently selected from glycine and serine between the FCS and the PE functional domain III improves the cytotoxicity of the PE-LR molecule without disrupting binding by furin.
- exemplary linkers are GGS and GGSGGS (SEQ ID NO: 55).
- WO2012/154530 reports that substitutions at the following amino acid residues within PE domain III reduce immunogenicity:
- Preferred substitutions are with a glycine, serine or alanine residue.
- WO2012/170617 reports that substitutions at these residues may reduce immunogenicity of B cell epitopes, and that substitutions at one or more of residues R427, R458, R467, R490, R505 and F538 are preferred, particularly with alanine.
- WO2013/040141 reports that substitutions at the following additional amino acid residues may reduce the immunogenicity of B cell epitopes within PE domain III:
- Preferred substitutions are with a glycine, serine, alanine or glutamine residue.
- WO2012/170617 reports that substitutions at the following residues can reduce the immunogenicity of T-cell epitopes within PE domain III:
- Preferred substitutions are at one or more of residues D463, Y481 and L516, which may also reduce the immunogenicity of B cell epitopes.
- Preferred substitutions are with a glycine, serine, alanine or glutamine residue.
- WO2012/170617 also reports that substitutions at the following amino acid residues can reduce the immunogenicity of T cell epitopes within PE domain II:
- Preferred substitutions are with a glycine, serine, alanine or glutamine residue.
- WO2012/170617 also reports that substitutions at the following amino acid residues can reduce the immunogenicity of B cell epitopes within PE domain II:
- WO2012/170617 also reports that a particularly preferred combination of substitutions is D463A/R427A/R458A/R467A/R490A/R505A/R538A.
- the PE functional domain III may comprise mutations at any one or any combination of more than one of the following sites:
- the mutation(s) reduce(s) the immunogenicity compared to the unmutated sequence of the amino acids 395-613 of SEQ ID NO: 52.
- the PE contains some or all of domain II, it may comprise mutations at any one or any combination of more than one of the following sites:
- the mutation(s) reduce(s) the immunogenicity compared to the unmutated sequence from domain II.
- the FCS is derived from the native furin-cleavable sequence of PE consisting of amino acids 274-284 (RHRQPRGWEQL, SEQ ID NO: 54) may comprise a substitution of the E282 residue, especially if the adjacent sequence from the native PE sequence is included downstream of the FCS.
- the adjacent sequence from the native PE sequence is not included (such as PE-LR, in which the FCS is fused to domain III either directly or via a non-native linker sequence)
- the epitope from the native sequence may anyway be disrupted such that a mutation at the E282 residue may not be advantageous.
- Reduced immunogenicity in variant PE toxins may refer to a reduced ability of the variant sequence to induce a T cell response and/or a reduced ability of the variant sequence to induce a B cell (antibody) response, preferably both.
- Techniques for assessing the effect of mutations on T cell immunogenicity are well known in the art and described in the examples of WO 2012/170617.
- Techniques for assessing the effect of mutations on the B cell immunogenicity are likewise well known in the art and described in WO 2013/040141, for example.
- Human antibodies may be raised against the native PE sequence by phage display using a human antibody library. The ability of mutations in the PE sequence to disrupt binding of such antibodies to the variant PE molecule is indicative of reduced immunogenicity.
- the titre of PE-specific antibodies raised in transgenic mice carrying the human antibody repertoire may be compared for the native and mutated PE sequences.
- the C-terminal end of the PE functional domain III may contain the native sequence of residues 609-613, namely REDLK (SEQ ID NO: 55). Additionally or alternatively to any other modifications of the native PE sequence, the PE functional domain III may contain a variant of the REDLK sequence, or other sequences, that function to maintain the PR protein in the endoplasmic reticulum or to recycle proteins into the endoplasmic reticulum. Such sequences are referred to here as “endoplasmic reticulum localisation sequences” or “ER localisation sequences”.
- Preferred ER localisation sequences include such as KDEL (SEQ ID NO: 57), REDL (SEQ ID NO: 58), RDEL (SEQ ID NO: 59) or KEDLK (SEQ ID NO: 60).
- KDEL SEQ ID NO: 57
- REDL SEQ ID NO: 58
- RDEL SEQ ID NO: 59
- KEDLK SEQ ID NO: 60
- One or more additional ER localisation sequences preferably independently selected from KDEL, REDL, REDLK, RDEL and KEDLK, may be added to the C-terminal end of the PE polypeptide sequence.
- KDEL, or 2 or 3 tandem repeats of KDEL KDELKDEL, SEQ ID NO 61; KDELKDELKDEL, SEQ ID NO: 62
- WO91/09949 discloses that the C-terminal end of the PE functional domain III may lack some or all of residues 602-608, which are not essential for the NAD(+)-diphthamide ADP ribosyltransferase activity.
- FCS Furin-Cleavable Sequence
- the furin-cleavable sequence can be any polypeptide sequence cleavable by furin.
- Duckert et al. 2004, Protein Engineering, Design & Selection 17(1):107-112 (hereafter, “Duckert et al.”) is incorporated herein by reference in its entirety and particularly with regard to the furin-cleavable sequences and motifs it discloses.
- Duckert et al. discloses that furin is an enzyme in a family of evolutionarily conserved dibasic- and monobasic-specific CA2+-dependent serine proteases called substilisin/kexin-like proprotein convertases. See page 107.
- Furin also known as “paired basic amino acid cleaving enzyme”, “PACE”, or PCSK3 is one of several mammalian members of the PCSK family and is involved in processing several endogenous human proteins. See generally, Thomas 2002 Nat Rev Mol Cell Biol 10:753-66. It is a membrane-associated protein found mainly in the trans-Golgi network. The sequence of human furin has been known since the early 1990s. See for example Hatsuzawa et al. 1992 J Biol Chem 267: 16094-16099; and Molloy et al. 1992 J Biol Chem 267:16396-16402.
- the minimal furin-cleavable sequence typically is, in the single letter code for amino acid residues, R-X-X-R (SEQ ID NO: 63), with cleavage occurring after the second “R”.
- Duckert et al. summarizes the information available on the sequences of 38 proteins reported in the literature to have furin-cleavable sequences, including mammalian proteins, proteins of pathogenic bacteria, and viral proteins. It reports that 31, or 81%, of the cleavage motifs reviewed had the R-X-[R/K]-R (SEQ ID NO: 64, SEQ ID NO.
- FIG. 65 consensus sequence, of which 11, or 29%, had R-X-R-R (SEQ ID NO: 65), and 20, or 52%, were R-X-K-R (SEQ ID NO: 64).
- Three of the cleavage motifs contained only the minimal cleavage sequence.
- Duckert et al. further aligned the motifs and identified the residues found at each position in each furin both for the cleavage motif itself and in the surrounding residues.
- FIG. 1A of Duckert et al. shows by relative size the residues most commonly found at each position. By convention, the residues surrounding the furin cleavage site are numbered from the scissile bond (which is typically indicated by a downward arrow).
- the minimal furin-cleavable sequence is numbered as P4-P1.
- Duckert et al.'s alignment of 38 sequences cleaved by furin identifies the variations permitted depending on the residues present at various positions. For example, if the residue at P4 is not an R, that can be compensated for by having arginine or lysine residues at P2 and P6. See page 109.
- furin cleavage occurs between arginine 279 and glycine 280 in an arginine-rich loop located in domain II of the toxin.
- the native furin-cleavable sequence in domain II of PE is set forth below (with numbers indicating the positions of the residues in the 613-amino acid native PE sequence), and aligned to show its numbering under the convention noted above:
- This sequence has shown a cleavage rate faster than that of the native sequence, and when used in an exemplary immunotoxin resulted in cytotoxicity to target cells approximately the same as that of the native sequence.
- a furin-cleavable sequence used to attach the targeting molecule to PE domain III can be the minimal furin-cleavable sequence, R-X-X-R (wherein each X is independently any naturally occurring amino acid), preferably R-X-[R/K]-R (wherein X is any naturally occurring amino acid and [R/K] denotes either arginine or lysine), or any of the other furin-cleavable sequences known in the art or permitted by FIG.
- the sequence can be RKKR (SEQ ID NO: 68), RRRR (SEQ ID NO: 69), RKAR (SEQ ID NO: 70), SRVARS (SEQ ID NO: 71), TSSRKRRFW (SEQ ID NO: 72), or ASRRKARSW (SEQ ID NO: 73).
- the furin-cleavable sequence is RRVKKRFW (SEQ ID NO: 74), RNVVRRDW (SEQ ID NO: 75), or TRAVRRRSW (SEQ ID NO: 76).
- the residue at position PI can be the arginine present in the native sequence, or lysine.
- a lysine can be substituted for the arginine at position PI in, for example, any the sequences set forth above.
- the furin-cleavable sequence contains the native furin-cleavable sequence of PE: R-H-R-Q-P-R-G-W-E-Q-L (SEQ ID NO: 66) or a truncated version of the native sequence, so long as it contains the minimal furin-cleavable sequence and is cleavable by furin.
- the furin-cleavable sequence can be RQPR (SEQ ID NO: 77), RHRQPRGW (SEQ ID NO: 78), RHRQPRGWE (SEQ ID NO: 79), HRQPRGWEQ (SEQ ID NO: 80), or RQPRGWE (SEQ ID NO: 81).
- the sequence is RHRSKRGWEQL (SEQ ID NO: 67) or a truncated version of this sequence, so long as it contains the minimal furin-cleavable sequence and is cleavable by furin.
- the furin-cleavable sequence can be RSKR (SEQ ID NO: 82), RHRSKRGW (SEQ ID NO: 83), HRSKRGWE (SEQ ID NO: 84), RSKRGWEQL (SEQ ID NO: 85), HRSKRGWEQL (SEQ ID NO: 86), or RHRSKR (SEQ ID NO: 87).
- the E282 residue at the P3′ position of FCS sequences derived from PE may be replaced by another amino acid to reduce B cell immunogenicity. Where the sequence lacks native PE residues downstream of this residue, or where the FCS contains other mutations relative to the native PE sequence, such replacement may not be necessary.
- Whether or not any particular sequence is cleavable by furin can be determined by methods known in the art. For example, whether or not a sequence is cleavable by furin can be tested by incubating the sequence with furin in furin buffer (0.2 M NaOAc (pH 5.5), 5 mM CaCl2) at a 1:10 enzyme:substrate molar ratio at 25° C. for 16 hours. These conditions have previously been established as optimal for furin cleavage of PE.
- the furin used is human furin. Recombinant truncated human furin is commercially available, for example, from New England Biolabs (Beverly, Mass.). See also, Bravo et al. 1994 J Biol Chem 269(14):25830-25837.
- a furin-cleavable sequence can be tested by making it into an immunotoxin with an antibody against a cell surface protein and testing the resulting immunotoxin on a cell line expressing that cell surface protein.
- Suitable antibody sequences are disclosed in, for example, WO2012/154530 and WO2009/032954.
- Preferred PE toxins for use in accordance with the present invention have the following structure:
- the invention is based, in part, on antibodies that are crossreactive with human and minipig TPGF.
- antibodies that bind to human TPBG at neutral as well as at slightly acidic pH are provided.
- Antibodies of the invention are useful, e.g., for the diagnosis or treatment of cancer.
- the invention provides isolated antibodies that bind to TPBG.
- an anti-TPBG antibody of the invention binds to human TPBG according to SEQ ID NO: 1 and binds to to minipig TPBG according to SEQ ID NO: 2.
- an anti-TPBG antibody of the invention binds to human TPBG at a pH of 5.5 and at a pH of 7.2.
- the invention provides an anti-TPBG antibody comprising at least one, two, three, four, five, or six CDRs selected from (a) CDR1 of the heavy chain of SEQ ID NO: 3, (b) CDR2 of the heavy chain of SEQ ID NO: 4, (c) CDR3 of the heavy chain of SEQ ID NO: 5, (d) CDR1 of the light chain of SEQ ID NO: 6, (e) CDR2 of the light chain of SEQ ID NO: 7, and (f) CDR3 of the light chain of SEQ ID NO: 8 (corresponding to the aforementioned CDRs of the antibody “051” as disclosed herein).
- the invention provides an antibody comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR1 of the heavy chain of SEQ ID NO: 3, (b) CDR2 of the heavy chain of SEQ ID NO: 4, (c) CDR3 of the heavy chain of SEQ ID NO: 5 (corresponding to the aforementioned CDRs of the antibody “051” as disclosed herein).
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 5.
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 5 and CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 5, CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 5, and CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 4.
- the antibody comprises (a) CDR3 of the heavy chain of SEQ ID NO: 5, (b) CDR3 of the light chain of SEQ ID NO: 8, and (c) CDR2 of the heavy chain of SEQ ID NO: 4.
- the invention provides an antibody comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- the antibody comprises (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 4, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 5; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- the invention provides an antibody comprising (a) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, (b) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 4, and (c) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 5, (d) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6, (e) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7, and (f) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- the anti-TPBG antibody is a humanized antibody derived from an antibody comprising the aforementioned CDRs.
- the invention provides an anti-TPBG antibody comprising at least one, two, three, four, five, or six CDRs selected from (a) CDR1 of the heavy chain of SEQ ID NO: 11, (b) CDR2 of the heavy chain of SEQ ID NO: 12, (c) CDR3 of the heavy chain of SEQ ID NO: 13, (d) CDR1 of the light chain of SEQ ID NO: 14, (e) CDR2 of the light chain of SEQ ID NO: 15, and (f) CDR3 of the light chain of SEQ ID NO: 16 (corresponding to the aforementioned CDRs of the antibody “091” as disclosed herein).
- the invention provides an antibody comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR1 of the heavy chain of SEQ ID NO: 11, (b) CDR2 of the heavy chain of SEQ ID NO: 12, (c) CDR3 of the heavy chain of SEQ ID NO: 13 (corresponding to the aforementioned CDRs of the antibody “091” as disclosed herein).
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 13.
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 13, CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 13, and CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 12.
- the antibody comprises (a) CDR3 of the heavy chain of SEQ ID NO: 13, (b) CDR3 of the light chain of SEQ ID NO: 16, and (c) CDR2 of the heavy chain of SEQ ID NO: 12.
- the invention provides an antibody comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- the antibody comprises (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 11, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 13; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- the invention provides an antibody comprising (a) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 11, (b) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and (c) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 13, (d) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14, (e) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15, and (f) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- the anti-TPBG antibody is a humanized antibody derived from an antibody comprising the aforementioned CDRs.
- the invention provides an anti-TPBG antibody comprising at least one, two, three, four, five, or six CDRs selected from (a) CDR1 of the heavy chain of SEQ ID NO: 19, (b) CDR2 of the heavy chain of SEQ ID NO: 20, (c) CDR3 of the heavy chain of SEQ ID NO: 21, (d) CDR1 of the light chain of SEQ ID NO: 22, (e) CDR2 of the light chain of SEQ ID NO: 23, and (f) CDR3 of the light chain of SEQ ID NO: 24 (corresponding to the aforementioned CDRs of the antibody “097” as disclosed herein).
- the invention provides an antibody comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR1 of the heavy chain of SEQ ID NO: 19, (b) CDR2 of the heavy chain of SEQ ID NO: 20, (c) CDR3 of the heavy chain of SEQ ID NO: 21 (corresponding to the aforementioned CDRs of the antibody “097” as disclosed herein).
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 21.
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 21 and CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 21, CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 21, and CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 20.
- the antibody comprises (a) CDR3 of the heavy chain of SEQ ID NO: 21, (b) CDR3 of the light chain of SEQ ID NO: 24, and (c) CDR2 of the heavy chain of SEQ ID NO: 20.
- the invention provides an antibody comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- the antibody comprises (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 19, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 21; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- the invention provides an antibody comprising (a) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 19, (b) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and (c) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 21, (d) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22, (e) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23, and (f) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- the anti-TPBG antibody is a humanized antibody derived from an antibody comprising the aforementioned CDRs.
- an anti-TPBG antibody is humanized.
- an anti-TPBG antibody comprises CDRs as in any of the above embodiments, and further comprises an acceptor human framework, e.g. a human immunoglobulin framework or a human consensus framework.
- an anti-TPBG antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9 (corresponding to the variable heavy chain domain of the antibody “051” as disclosed herein).
- VH heavy chain variable domain
- a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to TPBG.
- the anti-TPBG antibody comprises the VH sequence in SEQ ID NO: 9, including post-translational modifications of that sequence.
- the VH comprises one, two or three CDRs selected from: (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 4, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 5.
- an anti-TPBG antibody comprising a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10.
- VL light chain variable domain
- a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to PRO.
- the anti-TPBG antibody comprises the VL sequence in SEQ ID NO: 10, including post-translational modifications of that sequence.
- the VL comprises one, two or three HVRs selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- an anti-TPBG antibody comprising a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.
- the antibody comprises the VH and VL sequences in SEQ ID NO: 9 and SEQ ID NO: 10, respectively, including post-translational modifications of those sequences.
- the invention provides an antibody that binds to the same epitope as an anti-TPBG antibody provided herein.
- an antibody is provided that binds to the same epitope as an anti-TPBG antibody comprising a VH sequence of SEQ ID NO: 9 and a VL sequence of SEQ ID NO: 10.
- an anti-TPBG antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17 (corresponding to the variable heavy chain domain of the antibody “091” as disclosed herein).
- VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to TPBG.
- the anti-TPBG antibody comprises the VH sequence in SEQ ID NO: 17, including post-translational modifications of that sequence.
- the VH comprises one, two or three CDRs selected from: (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 11, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 13.
- an anti-TPBG antibody comprising a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18.
- VL light chain variable domain
- a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to PRO.
- the anti-TPBG antibody comprises the VL sequence in SEQ ID NO: 18, including post-translational modifications of that sequence.
- the VL comprises one, two or three HVRs selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- an anti-TPBG antibody comprising a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.
- the antibody comprises the VH and VL sequences in SEQ ID NO: 17 and SEQ ID NO: 18, respectively, including post-translational modifications of those sequences.
- the invention provides an antibody that binds to the same epitope as an anti-TPBG antibody provided herein.
- an antibody is provided that binds to the same epitope as an anti-TPBG antibody comprising a VH sequence of SEQ ID NO: 17 and a VL sequence of SEQ ID NO: 18.
- an anti-TPBG antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 25 (corresponding to the variable heavy chain domain of the antibody “097” as disclosed herein).
- VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to TPBG.
- the anti-TPBG antibody comprises the VH sequence in SEQ ID NO: 25, including post-translational modifications of that sequence.
- the VH comprises one, two or three CDRs selected from: (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 19, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 21.
- an anti-TPBG antibody comprising a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 26.
- VL light chain variable domain
- a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to PRO.
- the anti-TPBG antibody comprises the VL sequence in SEQ ID NO: 26, including post-translational modifications of that sequence.
- the VL comprises one, two or three HVRs selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- an anti-TPBG antibody comprising a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above.
- the antibody comprises the VH and VL sequences in SEQ ID NO: 25 and SEQ ID NO: 26, respectively, including post-translational modifications of those sequences.
- the invention provides an antibody that binds to the same epitope as an anti-TPBG antibody provided herein.
- an antibody is provided that binds to the same epitope as an anti-TPBG antibody comprising a VH sequence of SEQ ID NO: 17 and a VL sequence of SEQ ID NO: 18.
- an anti-TPBG antibody is a monoclonal antibody, including a chimeric, humanized or human antibody.
- an anti-TPBG antibody is an antibody fragment, e.g., a Fv, Fab, Fab′, scFv, diabody, or F(ab′)2 fragment.
- the antibody is a full length antibody, e.g., an intact IgG1 antibody or other antibody class or isotype as defined herein.
- the invention relates to an isolated antibody that binds to TPBG, wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2.
- the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2.
- the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2.
- binding ratio is herein defined as the ratio of the mean fluorescence intensity detected by flow cytometry in a cell surface binding assay (in one embodiment an assay as described in Example 18) at pH 7.2 to the mean fluorescence intensity detected by flow cytometry at pH 5.5 (in one embodiment an assay as described in Example 18).
- the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2, wherein the binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- the binding is detected via flow cytometry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2, wherein the binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- the binding is detected via flow cytometry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2, wherein a binding ratio, which is defined as the ratio of the mean fluorescence intensity detected by flow cytometry in a cell surface binding assay (in one embodiment an assay as described in Example 18) at pH 7.2 to the mean fluorescence intensity detected by flow cytometry at pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- a binding ratio which is defined as the ratio of the mean fluorescence intensity detected by flow cytometry in a cell surface binding assay (in one embodiment an assay as described in Example 18) at pH 7.2 to the mean fluorescence intensity detected by flow cytometry at pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2, wherein binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- the binding is detected via flow cytometry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2, wherein a binding ratio, which is defined as the ratio of the mean fluorescence intensity detected by flow cytometry in a cell surface binding assay (in one embodiment an assay as described in Example 18) at pH 7.2 to the mean fluorescence intensity detected by flow cytometry at pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- an anti-TPBG antibody may incorporate any of the features, singly or in combination, as described in Sections 1-7 below:
- an antibody provided herein has a dissociation constant (Kd) of ⁇ 1 ⁇ M, ⁇ 100 nM, ⁇ 10 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM (e.g. 10 ⁇ 8 M or less, e.g. from 10 ⁇ 8 M to 10 ⁇ 13 M, e.g., from 10 ⁇ 9 M to 10 ⁇ 13 M).
- Kd dissociation constant
- Kd is measured by a radiolabeled antigen binding assay (RIA) performed with the Fab version of an antibody of interest and its antigen as described by the following assay.
- Solution binding affinity of FABs for antigen is measured by equilibrating Fab with a minimal concentration of ( 125 I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen, Y. et al., J. Mol. Biol. 293 (1999) 865-881).
- MICROTITER® multi-well plates (Thermo Scientific) are coated overnight with 5 ⁇ g/ml of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23° C.).
- a non-adsorbent plate (Nunc #269620)
- 100 pM or 26 pM [ 125 I]-antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta, L. G.
- the Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. When the plates have dried, 150 ⁇ l/well of scintillant (MICROSCINT-20TM; Packard) is added, and the plates are counted on a TOPCOUNTTM gamma counter (Packard) for ten minutes. Concentrations of each Fab that give less than or equal to 20% of maximal binding are chosen for use in competitive binding assays.
- Kd is measured using surface plasmon resonance assays using a BIACORE®-2000 or a BIACORE®-3000 (BIAcore, Inc., Piscataway, N.J.) at 25° C. with immobilized antigen CM5 chips at ⁇ 10 response units (RU).
- CM5 carboxymethylated dextran biosensor chips
- EDC N-ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride
- NHS N-hydroxysuccinimide
- Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 ⁇ g/ml ( ⁇ 0.2 ⁇ M) before injection at a flow rate of 5 ⁇ l/minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20TM) surfactant (PBST) at 25° C. at a flow rate of approximately 25 ⁇ l/min.
- TWEEN-20TM polysorbate 20
- association rates (k on ) and dissociation rates (k off ) are calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams.
- the equilibrium dissociation constant (Kd) is calculated as the ratio k off /k on . See, e.g., Chen, Y. et al., J. Mol. Biol. 293 (1999) 865-881.
- an antibody provided herein is an antibody fragment.
- Antibody fragments include, but are not limited to Fab, Fab′, Fab′-SH, F(ab′) 2 , Fv, and scFv fragments, and other fragments described below.
- Fab fragment-specific antibody fragment
- Fab′ fragment-specific Fab′-SH
- F(ab′) 2 fragment-specific antibody fragment
- Fv fragment-specific Fab fragment-specific Fab fragmentse.g., fragmentsesized by a single chain consisting of antibodies to antibodies.
- scFv fragments see, e.g., Plueckthun, A., In; The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore (eds.), Springer-Verlag, New York (1994), pp.
- Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 0 404 097; WO 1993/01161; Hudson, P. J. et al., Nat. Med. 9 (2003) 129-134; and Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448. Triabodies and tetrabodies are also described in Hudson, P. J. et al., Nat. Med. 9 (20039 129-134).
- Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
- a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516 BI).
- Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.
- recombinant host cells e.g. E. coli or phage
- an antibody provided herein is a chimeric antibody.
- Certain chimeric antibodies are described, e.g., in U.S. Pat. No. 4,816,567; and Morrison, S. L. et al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855).
- a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region.
- a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
- a chimeric antibody is a humanized antibody.
- a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
- a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences.
- HVRs e.g., CDRs, (or portions thereof) are derived from a non-human antibody
- FRs or portions thereof
- a humanized antibody optionally will also comprise at least a portion of a human constant region.
- some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
- a non-human antibody e.g., the antibody from which the HVR residues are derived
- Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the “best-fit” method (see, e.g., Sims, M. J. et al., J. Immunol. 151 (1993) 2296-2308; framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter, P. et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; and Presta, L. G. et al., J. Immunol.
- an antibody provided herein is a human antibody.
- Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk, M. A. and van de Winkel, J. G., Curr. Opin. Pharmacol. 5 (2001) 368-374 and Lonberg, N., Curr. Opin. Immunol. 20 (2008) 450-459.
- Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge.
- Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes.
- the endogenous immunoglobulin loci have generally been inactivated.
- Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor, D., J. Immunol. 133 (1984) 3001-3005; Brodeur, B. R. et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York (1987), pp. 51-63; and Boerner, P. et al., J. Immunol. 147 (1991) 86-95) Human antibodies generated via human B-cell hybridoma technology are also described in Li, J. et al., Proc. Natl. Acad.
- Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.
- Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom, H. R. et al., Methods in Molecular Biology 178 (2001) 1-37 and further described, e.g., in the McCafferty, J. et al., Nature 348 (1990) 552-554; Clackson, T. et al., Nature 352 (1991) 624-628; Marks, J. D. et al., J. Mol. Biol.
- repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter, G. et al., Ann. Rev. Immunol. 12 (1994) 433-455.
- Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments.
- Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas.
- naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths, A. D. et al., EMBO J. 12 (1993) 725-734.
- naive libraries can also be made synthetically by cloning non-rearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom, H. R. and Winter, G., J. Mol. Biol. 227 (1992) 381-388.
- Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.
- Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
- an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody.
- Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites.
- one of the binding specificities is for TPBG and the other is for any other antigen.
- bispecific antibodies may bind to two different epitopes of TPBG.
- Bispecific antibodies may also be used to localize cytotoxic agents to cells which express TPBG.
- Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
- Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein, C. and Cuello, A. C., Nature 305 (1983) 537-540, WO 93/08829, and Traunecker, A. et al., EMBO J. 10 (1991) 3655-3659), and “knob-in-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168).
- Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan, M. et al., Science 229 (1985) 81-83); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny, S. A. et al., J. Immunol. 148 (1992) 1547-1553; using “diabody” technology for making bispecific antibody fragments (see, e.g., Holliger, P. et al., Proc. Natl. Acad.
- the antibody or fragment herein also includes a “Dual Acting Fab” or “DAF” comprising an antigen binding site that binds to TPBG as well as another, different antigen (see, US 2008/0069820, for example).
- the antibody or fragment herein also includes multispecific antibodies described in WO 2009/080251, WO 2009/080252, WO 2009/080253, WO 2009/080254, WO 2010/112193, WO 2010/115589, WO 2010/136172, WO 2010/145792, and WO 2010/145793.
- amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody.
- Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
- antibody variants having one or more amino acid substitutions are provided.
- Sites of interest for substitutional mutagenesis include the HVRs and FRs.
- Exemplary changes are provided in the following Table under the heading of “exemplary substitutions”, and as further described below in reference to amino acid side chain classes. Conservative substitutions are shown in Table 1 under the heading of “preferred substitutions”.
- Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.
- Amino acids may be grouped according to common side-chain properties:
- Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
- substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody).
- a parent antibody e.g. a humanized or human antibody
- the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody.
- An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).
- Alterations may be made in HVRs, e.g., to improve antibody affinity.
- Such alterations may be made in HVR “hotspots,” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, P. S., Methods Mol. Biol. 207 (2008) 179-196), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity.
- Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom, H. R. et al.
- affinity maturation diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis).
- a secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity.
- Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.
- substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen.
- conservative alterations e.g., conservative substitutions as provided herein
- Such alterations may be outside of HVR “hotspots” or SDRs.
- each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.
- a useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham, B. C. and Wells, J. A., Science 244 (1989) 1081-1085.
- a residue or group of target residues e.g., charged residues such as arg, asp, his, lys, and glu
- a neutral or negatively charged amino acid e.g., alanine or polyalanine
- Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions.
- a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution.
- Variants may be screened to determine whether they contain the desired properties.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
- terminal insertions include an antibody with an N-terminal methionyl residue.
- Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.
- an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated.
- Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
- the carbohydrate attached thereto may be altered.
- Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright, A. and Morrison, S. L., TIBTECH 15 (1997) 26-32.
- the oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure.
- modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.
- antibody variants having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region.
- the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%.
- the amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example.
- Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ⁇ 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US 2003/0157108; US 2004/0093621.
- Examples of publications related to “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO 2005/053742; WO 2002/031140; Okazaki, A. et al., J. Mol. Biol. 336 (2004) 1239-1249; Yamane-Ohnuki, N.
- Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka, J. et al., Arch. Biochem. Biophys. 249 (1986) 533-545; US 2003/0157108; and WO 2004/056312, especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki, N. et al., Biotech. Bioeng. 87 (2004) 614-622; Kanda, Y. et al., Biotechnol. Bioeng. 94 (2006) 680-688; and WO 2003/085107).
- Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878; U.S. Pat. No. 6,602,684; and US 2005/0123546. Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087; WO 1998/58964; and WO 1999/22764.
- one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant.
- the Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.
- the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious.
- In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
- Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks Fc ⁇ R binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
- NK cells express Fc(RIII only, whereas monocytes express Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ RIII.
- FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch, J. V. and Kinet, J. P., Annu. Rev. Immunol. 9 (1991) 457-492.
- Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g. Hellstrom, I. et al., Proc. Natl. Acad. Sci. USA 83 (1986) 7059-7063; and Hellstrom, I.
- non-radioactive assays methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.).
- Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
- ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes, R. et al., Proc. Natl. Acad. Sci. USA 95 (1998) 652-656.
- C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
- a CDC assay may be performed (see, for example, Gazzano-Santoro, H. et al., J. Immunol.
- FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al., Int. Immunol. 18 (2006: 1759-1769).
- Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056).
- Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).
- an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
- alterations are made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie, E. E. et al., J. Immunol. 164 (2000) 4178-4184.
- CDC Complement Dependent Cytotoxicity
- Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus are described in US 2005/0014934.
- Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn.
- Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. Pat. No. 7,371,826).
- cysteine engineered antibodies e.g., “thioMAbs”
- one or more residues of an antibody are substituted with cysteine residues.
- the substituted residues occur at accessible sites of the antibody.
- reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein.
- any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.
- Cysteine engineered antibodies may be generated as described, e.g., in U.S. Pat. No. 7,521,541.
- an antibody provided herein may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available.
- the moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers.
- water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., g
- Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
- the polymer may be of any molecular weight, and may be branched or unbranched.
- the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
- conjugates of an antibody and non-proteinaceous moiety that may be selectively heated by exposure to radiation are provided.
- the non-proteinaceous moiety is a carbon nanotube (Kam, N. W. et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605).
- the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.
- Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567.
- isolated nucleic acid encoding an anti-TPBG antibody described herein is provided.
- Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody).
- one or more vectors e.g., expression vectors
- a host cell comprising such nucleic acid is provided.
- a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody.
- the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell).
- a method of making an anti-TPBG antibody comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
- nucleic acid encoding an antibody is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
- nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
- Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
- antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
- For expression of antibody fragments and polypeptides in bacteria see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, K. A., In: Methods in Molecular Biology, Vol. 248, Lo, B. K. C. (ed.), Humana Press, Totowa, N.J. (2003), pp. 245-254, describing expression of antibody fragments in E. coli .)
- the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
- eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, T. U., Nat. Biotech. 22 (2004) 1409-1414; and Li, H. et al., Nat. Biotech. 24 (2006) 210-215.
- Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
- Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants).
- Vertebrate cells may also be used as hosts.
- mammalian cell lines that are adapted to grow in suspension may be useful.
- Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham, F. L. et al., J. Gen Virol. 36 (1977) 59-74); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, J. P., Biol. Reprod.
- monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather, J. P. et al., Annals N.Y. Acad. Sci. 383 (1982) 44-68; MRC 5 cells; and FS4 cells.
- Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR ⁇ CHO cells (Urlaub, G. et al., Proc. Natl.
- Anti-TPBG antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.
- an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, Western blot, etc.
- competition assays may be used to identify an antibody that competes with an antibody selected from the group of antibodies 051, 091, or 097 as disclosed herein and defined by their respective amino acid sequences of VH and VL domains for binding to TPBG.
- a competing antibody binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by an antibody selected from the group of antibodies 051, 091, or 097 as disclosed herein and defined by their respective amino acid sequences of VH and VL domains.
- epitope e.g., a linear or a conformational epitope
- Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris, G. E. (ed.), Epitope Mapping Protocols, In: Methods in Molecular Biology, Vol. 66, Humana Press, Totowa, N.J. (1996).
- immobilized TPBG is incubated in a solution comprising a first labeled antibody that binds to TPBG (e.g., an antibody selected from the group of antibodies 051, 091, or 097 as disclosed herein and defined by their respective amino acid sequences of VH and VL domains) and a second unlabeled antibody that is being tested for its ability to compete with the first antibody for binding to TPBG.
- the second antibody may be present in a hybridoma supernatant.
- immobilized TPBG is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody.
- assays are provided for identifying anti-TPBG antibodies thereof having biological activity.
- Biological activity may include, e.g., binding to TPBG-expressing tumor cells.
- Antibodies having such biological activity in vivo and/or in vitro are also provided.
- an antibody of the invention is tested for such biological activity.
- the invention also provides immunoconjugates comprising an anti-TPBG antibody herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes.
- cytotoxic agents such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes.
- an immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more drugs, including but not limited to a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 and EP 0 425 235 BI); an auristatin such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483, 5,780,588, and 7,498,298); a dolastatin; a calicheamicin or derivative thereof (see U.S. Pat. Nos.
- ADC antibody-drug conjugate
- drugs including but not limited to a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 and EP 0 425 235 BI); an auristatin such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF)
- an immunoconjugate comprises an antibody as described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, nonbinding active fragments of exotoxin A chain (from Pseudomonas aeruginosa ), diphtheria toxin, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
- the enzymatically active toxin is Pseudomonas exotoxin A or a variant thereof.
- an immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate.
- a variety of radioactive isotopes are available for the production of radioconjugates. Examples include At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu.
- the radioconjugate When used for detection, it may comprise a radioactive atom for scintigraphic studies, for example TC 99m or I 123 , or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
- NMR nuclear magnetic resonance
- Conjugates of an antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as
- a ricin immunotoxin can be prepared as described in Vitetta, E. S. et al., Science 238 (1987) 1098-1104.
- Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triamine pentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO 94/11026.
- the linker may be a “cleavable linker” facilitating release of a cytotoxic drug in the cell.
- an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari, R. V. et al., Cancer Res. 52 (1992) 127-131; U.S. Pat. No. 5,208,020) may be used.
- the immunuoconjugates or ADCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill., U.S.A).
- cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC
- Conjugates of the antibody and cytotoxic agents which are polypeptides, may also be provided as recombinant fusion proteins, e.g. by direct expression of said fusion protein within a host cell, thereby not requiring an additional coupling step for provision.
- any of the anti-TPBG antibodies provided herein is useful for detecting the presence of TPBG in a biological sample.
- the term “detecting” as used herein encompasses quantitative or qualitative detection.
- a biological sample comprises a cell or tissue, such as tumor cells.
- an anti-TPBG antibody for use in a method of diagnosis or detection is provided.
- a method of detecting the presence of TPBG in a biological sample comprises contacting the biological sample with an anti-TPBG antibody as described herein under conditions permissive for binding of the anti-TPBG antibody to TPBG, and detecting whether a complex is formed between the anti-TPBG antibody and TPBG.
- Such method may be an in vitro or in vivo method.
- an anti-TPBG antibody is used to select subjects eligible for therapy with an anti-TPBG antibody, e.g. where TPBG is a biomarker for selection of patients.
- Exemplary disorders that may be diagnosed using an antibody of the invention include cancer, e.g. lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of
- labeled anti-TPBG antibodies include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction.
- Exemplary labels include, but are not limited to, the radioisotopes 32 P, 14 C, 125 I, 3 H, and 131 I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No.
- luciferin 2,3-dihydrophthalazinediones
- horseradish peroxidase HRP
- alkaline phosphatase alkaline phosphatase
- ⁇ -galactosidase glucoamylase
- lysozyme saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase
- heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like.
- compositions of an anti-TPBG antibody as described herein are prepared by mixing such antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980)), in the form of lyophilized formulations or aqueous solutions.
- Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyl dimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as poly(vinylpyrrolidone); amino acids such as glycine, glutamine, asparagine, histidine, arg
- sHASEGP soluble neutral-active hyaluronidase glycoproteins
- rhuPH20 HYLENEX®, Baxter International, Inc.
- Certain exemplary sHASEGPs and methods of use, including rhuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968.
- a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
- Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958.
- Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO 2006/044908, the latter formulations including a histidine-acetate buffer.
- the formulation herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
- active ingredients preferably those with complementary activities that do not adversely affect each other.
- chemotherapeutic agent preferably a chemotherapeutic agent listed below.
- Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
- Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
- colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
- Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules.
- the formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
- any of the anti-TPBG antibodies provided herein, or the recombinant fusion proteins or immunoconjugates comprising the anti-TPBG antibodies provided herein, may be used in therapeutic methods.
- an anti-TPBG antibody for use as a medicament is provided.
- an anti-TPBG antibody for use in treating cancer is provided.
- an anti-TPBG antibody for use in a method of treatment is provided.
- the invention provides an anti-TPBG antibody for use in a method of treating an individual having cancer comprising administering to the individual an effective amount of the anti-TPBG antibody.
- the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.
- An “individual” according to any of the above embodiments is preferably a human.
- the invention provides for the use of an anti-TPBG antibody in the manufacture or preparation of a medicament.
- the medicament is for treatment of cancer.
- the medicament is for use in a method of treating cancer comprising administering to an individual having cancer an effective amount of the medicament.
- the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below.
- An “individual” according to any of the above embodiments may be a human.
- the invention provides a method for treating cancer.
- the method comprises administering to an individual having cancer an effective amount of an anti-TPBG antibody.
- the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described below.
- An “individual” according to any of the above embodiments may be a human.
- the invention provides pharmaceutical formulations comprising any of the anti-TPBG antibodies provided herein, e.g., for use in any of the above therapeutic methods.
- a pharmaceutical formulation comprises any of the anti-TPBG antibodies provided herein and a pharmaceutically acceptable carrier.
- a pharmaceutical formulation comprises any of the anti-TPBG antibodies provided herein and at least one additional therapeutic agent, e.g., as described below.
- Antibodies of the invention can be used either alone or in combination with other agents in a therapy.
- an antibody of the invention may be co-administered with at least one additional therapeutic agent.
- an additional therapeutic agent is a chemotherapeutic agent.
- chemotherapeutic agents include, but are not limited to, anti-neoplastic agents including alkylating agents including: nitrogen mustards, such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU); TemodalTM (temozolamide), ethylenimines/methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil (5FU), fluorodeoxyuridine, gemcitabine,
- the chemotherapeutic agent is selected from the group consisting of taxanes (like e.g. paclitaxel (Taxol), docetaxel (Taxotere), modified paclitaxel (e.g., Abraxane and Opaxio), doxorubicin, sunitinib (Sutent), sorafenib (Nexavar), and other multikinase inhibitors, oxaliplatin, cisplatin and carboplatin, etoposide, gemcitabine, and vinblastine.
- the chemotherapeutic agent is selected from the group consisting of taxanes (like e.g.
- the additional chemotherapeutic agent is selected from 5-fluorouracil (5-FU), leucovorin, irinotecan, or oxaliplatin.
- the chemotherapeutic agent is 5-fluorouracil, leucovorin and irinotecan (FOLFIRI).
- the chemotherapeutic agent is 5-fluorouracil, and oxaliplatin (FOLFOX).
- therapeutic appliacations of antibodies of the invention with additional chemotherapeutic agents include, for instance,
- the additional chemotherapeutic agent is selected from the group of taxanes (docetaxel or paclitaxel or a modified paclitaxel (Abraxane or Opaxio), doxorubicin, capecitabine and/or bevacizumab for the treatment of breast cancer.
- the antibodies of the invention are administered in absence of an additional chemotherapeutic agent.
- Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant.
- Antibodies of the invention can also be used in combination with radiation therapy.
- An antibody of the invention can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
- Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
- Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
- Antibodies of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
- the antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
- an antibody of the invention when used alone or in combination with one or more other additional therapeutic agents, will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
- the antibody is suitably administered to the patient at one time or over a series of treatments.
- about 1 ⁇ g/kg to 15 mg/kg (e.g. 0.5 mg/kg-10 mg/kg) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
- One typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs.
- One exemplary dosage of the antibody would be in the range from about 0.05 mg/kg to about 10 mg/kg.
- one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient.
- Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody).
- other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
- any of the above formulations or therapeutic methods may be carried out using an immunoconjugate of the invention or a recombinant fusion protein of the invention in place of or in addition to an anti-TPBG antibody.
- an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above comprises a container and a label or package insert on or associated with the container.
- Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- At least one active agent in the composition is an antibody of the invention.
- the label or package insert indicates that the composition is used for treating the condition of choice.
- the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
- the article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
- the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
- BWFI bacteriostatic water for injection
- phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered sa
- any of the above articles of manufacture may include an immunoconjugate of the invention or a recombinant fusion protein of the invention in place of or in addition to an anti-TPBG antibody.
- DNA sequences were determined by double strand sequencing performed at SequiServe (Vaterstetten, Germany) and Geneart AG (Regensburg, Germany).
- Desired gene segments were prepared by Geneart AG (Regensburg, Germany) from synthetic oligonucleotides and PCR products by automated gene synthesis.
- the gene segments which are flanked by singular restriction endonuclease cleavage sites were cloned into pGA18 (ampR) plasmids.
- the plasmid DNA was purified from transformed bacteria and concentration determined by UV spectroscopy. The DNA sequence of the sub-cloned gene fragments was confirmed by DNA sequencing.
- Cynomolgus monkey was previously used to evaluate TPBG-specific antibodies or conjugates thereof for their tolerability (Sapra et al. (2013) Mol Canc Ther 12: 38-47). 14 different tissues of cynomolgus monkey and minipig were prepared and the mRNA expression profile evaluated. Transcription profiling by sequencing of tissue RNAs coming from Roche cynomolgus monkey and minipig RNAseq-projects was evaluated on Illumina NextSeq500 as indexed, 75 bp, paired-end run with an average depth of 30 million reads pairs. Gene expression signals are indicated as unique reads per kilobase exon model per million reads (rpkm) in log scale indicating median expression levels and standard deviation.
- minipig is a suitable toxicology species to evaluate novel minipig cross-reactive anti-TPBG antibodies and Fab-PE constructs ( FIG. 1 ).
- the cDNA of either full length TPBG, thus comprising extracellular domain, transmembrane domain and intracellular domain or fragments thereof was cloned in eukaryotic expression vectors. Cloning was performed by standard restriction digest. For plasmids containing a C-terminal PreScission site followed by a HIS 6 -Avi epitope tag or a C-terminal PreScission site followed by a huIgG 1 -Fc-HIS 6 epitope tag, site-directed cloning was performed with BamHI and NotI restriction enzymes. Plasmids were sequence verified and amplified according to standard molecular biology techniques.
- Plasmids containing the extracellular domain of TPBG or fragments thereof were transiently transfected in HEK293F (Life Technologies) cells. Briefly, cells were cultured in FreeStyle 293-F (Life Technologies) expression medium. The day before transfection cells were seeded at a density of 1 ⁇ 10 6 /ml culture medium. The following day 1 ⁇ g of plasmid DNA was used per ml culture medium. 293Free (Life Technologies) transfection reagent was used for transient transfection. Transfected cells were incubated at 37° C. and 8% CO 2 for 7 d while shaking at 125-130 rpm in Erlenmeyer flasks. Supernatant was harvested and either frozen at ⁇ 80° C. or directly processed for protein purification.
- TPBG containing a huIgG 1 -Fc-HIS 6 epitope tag human TPBG: SEQ ID NO: 28; minipig TPGB: SEQ ID NO: 30; cynomolgus TPBG: SEQ ID NO: 32; murine TPBG: SEQ ID NO: 34, rat TPBG: SEQ ID NO: 36; the listed sequences all include signal peptides
- TPBG containing a huIgG 1 -Fc-HIS 6 epitope tag
- Recombinant TPBG containing a HIS 6 -Avi epitope tag (human TPBG: SEQ ID NO: 27; minipig TPGB: SEQ ID NO: 29; cynomolgus TPBG: SEQ ID NO: 31; murine TPBG: SEQ ID NO: 33, rat TPBG: SEQ ID NO: 35, the listed sequences all include signal peptides) was purified from cell culture supernatant using a HisTrap HP (GE Healthcare) column. Elution occurred with an imidazole step gradient. Affinity purified protein was subsequently loaded on a HiLoad 16/60 Superdex 200 prep grade (GE Healthcare) size exclusion column. The product peak was collected and volume adjusted by ultracentrifugation with Amicon Ultra Filters (Merck Millipore). The final storage buffer consisted of 20 mM Histidine, 140 mM NaCl, pH 5.5.
- One set of 3 rabbits was immunized with 400 ⁇ g of recombinant human TPBG extracellular domain (ECD) coupled to huFc, emulsified with complete Freund's adjuvant, at day 0 by intradermal application, and with 200 ⁇ g each of TPBG-huFc, emulsified with complete Freund's adjuvant, at days 7, 14, 28, 56 and 84, by alternating intramuscular and subcutaneous applications.
- Blood (10% of estimated total blood volume) was taken at days 20, 34, 62 and 90. Serum was prepared, which was used for titer determination by ELISA (see below), and peripheral mononuclear cells were isolated, which were used as a source of antigen-specific B cells in the B cell cloning process.
- Another set of 3 rabbits was immunized genetically, using a plasmid expression vector coding for full-length human TPBG, by intradermal application of 400 ⁇ g vector DNA, followed by electroporation (5 square pulses of 750 V/cm, duration 10 ms, interval 1 s). Rabbits received 7 consecutive immunizations at days 0, 14, 28, 49, 70, 98 and 126. Blood (10% of estimated total blood volume) was taken at days 35, 77, 105 and 133. Serum was prepared, which was used for titer determination by ELISA (see below), and peripheral mononuclear cells were isolated, which were used as a source of antigen-specific B cells in the B cell cloning process.
- Human recombinant soluble TPBG extracellular domain was immobilized on a 96-well NUNC Maxisorp plate at 2 ⁇ g/ml, 100 ⁇ l/well, in PBS, followed by: blocking of the plate with 2% Crotein C in PBS, 200 ⁇ l/well; application of serial dilutions of antisera, in duplicates, in 0.5% Crotein C in PBS, 100 ⁇ l/well; detection with either (1) HRP-conjugated donkey anti-rabbit IgG antibody (Jackson Immunoresearch/Dianova), or (2) HRP-conjugated rabbit anti-human IgG antibody (Pierce/Thermo Scientific; 1/5000), or (3) biotinylated goat anti-human kappa antibody (Southern Biotech/Biozol; 1/5000) and streptavidin-HRP; each diluted in 0.5% Crotein C in PBS, 100 ⁇ l/well.
- EDTA-containing whole blood was diluted twofold with 1 ⁇ PBS (PAA, Pasching, Austria) before density centrifugation using lympholyte mammal (Cedarlane Laboratories, Burlington, Ontario, Canada) according to the specifications of the manufacturer.
- PBMCs were washed twice with 1 ⁇ PBS.
- Sterile streptavidin coated 6-well plates (Microcoat, Bernried, Germany) were coated with 2 ⁇ g/ml of the biotinylated extracellular domain of human TPBG protein in PBS for 3 h at room temperature. Prior to the panning step these 6-well plates were washed three times with sterile PBS.
- the PBMCs were seeded on sterile 6-well plates (cell culture grade) to deplete macrophages and monocytes through unspecific adhesion. Each well was filled at maximum with 4 ml medium and up to 6 ⁇ 10e6 PBMCs from the immunized rabbit and were allowed to bind for 1 h at 37° C. and 5% CO 2 .
- the cells in the supernatant peripheral blood lymphocytes (PBLs)) were used for the antigen panning step.
- 6-well plates coated with TPBG protein were seeded with up to 6 ⁇ 10e6 PBLs per 4 ml medium and allowed to bind for 1 h at 37° C. and 5% CO 2 to enrich TPBG-specific B cells.
- Non-adherent cells were removed by carefully washing the wells 1-2 times with 1 ⁇ PBS. The remaining sticky cells were detached by trypsin for 10 min at 37° C. and 5% CO 2 . Trypsination was stopped with EL-4 B5 medium (EL-4 B5: RPMI 1640 (Pan Biotech, Aidenbach, Germany) supplemented with 10% fetal calf serum (Hyclone, Logan, Utah, USA), 2 mM Glutamin, 1% penicillin/streptomycin solution (PAA, Pasching, Austria), 2 mM sodium pyruvate, 10 mM HEPES (PAN Biotech, Aidenbach, Germany) and 0.05 mM b-mercaptoethanole (Gibco, Paisley, Scotland).
- EL-4 B5 RPMI 1640 (Pan Biotech, Aidenbach, Germany) supplemented with 10% fetal calf serum (Hyclone, Logan, Utah, USA), 2 mM Glutamin, 1%
- the cells were kept on ice until the immune fluorescence staining.
- Anti-IgG FITC AbD Serotec, Dusseldorf, Germany
- For surface staining cells from the depletion and enrichment step were incubated with anti-IgG FITC antibody in PBS and incubated for 45 min in the dark at 4° C. After staining the PBLs were washed two times with ice cold PBS. Finally the PBLs were resuspended in ice cold PBS and immediately subjected to the FACS analyses.
- Propidium iodide at a concentration of 5 ⁇ g/ml was added prior to FACS analyses to discriminate between dead and live cells.
- a Becton Dickinson FACSAria equipped with a computer and the FACSDiva software (BD Biosciences, USA) was used for single cell sort.
- the cultivation of the rabbit B cells was done by a method described by Seeber S. et al., PLoS One. 2014 Feb. 4; 9(2):e86184.
- single sorted rabbit B cells were incubated in 96-well plates with 200 ⁇ l/well EL-4 B5 medium containing Pansorbin cells (1:100000) (Calbiochem (Merck), Darmstadt, Germany), 5% rabbit thymocyte supernatant (MicroCoat, Bernried, Germany) and gamma-irradiated murine EL-4 B5 thymoma cells (2.5 ⁇ 10e4 cells/well) for 7 days at 37° C. in the incubator.
- the supernatants of the B-cell cultivation were removed for screening and the remaining cells were harvested immediately and were frozen at ⁇ 80° C. in 100 ⁇ l RLT buffer (Qiagen, Hilden, Germany).
- the PCR conditions for the HuVL were as follows: Hot start at 94° C. for 5 min; 40 cycles of 20 s at 94° C., 20 s at 52° C., 45 s at 68° C., and a final extension at 68° C. for 7 min.
- anti-TPBG samples were added in a 1:2 dilution series starting at 2 ⁇ g/ml and incubated 1 h at RT.
- TMB substrate (Calbiochem, # CL07) was added and incubated 2 min for human and minipig TPBG, 3 min for cyno TPBG and 4 min for mouse and rat TPBG. Measurement took place at 370/492 nm on a Safire2 reader (Tecan).
- the human breast cancer tumor cell line MFC7 endogenously expressing TPBG was seeded at a concentration of 21000 cells/well in 384-well cellcoat Poly-D-Lysine plates (Greiner, #781940). Cells were allowed to attach over night at 37° C. After removing the supernatant, 25 ⁇ l/well of supernatant containing anti-TPBG antibodies were added in a 1:2 dilution series starting at 5 ⁇ g/ml and incubated 1 h at 4° C.
- Fab fragments of 051, 091, and 097 were found to be crossreactive between human and minipig TPBG. Cell binding of human TPBG expressed on cells of a human breast cancer cell line was confirmed.
- Nunc maxisorp plates (Nunc, 464718) were coated with 25 ⁇ l/well Fc-TPBG at a concentration of 1 ⁇ g/ml for rat, minipig, mouse, cyno and at a concentration of 500 ng/ml for human TPBG. Plates were incubated at 4° C. overnight. After washing (3 ⁇ 90 ⁇ l/well; PBS-T buffer) plates were blocked with 90 ⁇ l blocking buffer (PBS with 2% BSA and 0.05% Tween-20) for 1 h at room temperature.
- PBS-T buffer 90 ⁇ l blocking buffer
- anti-TPBG antibodies were added in a 1:2 dilution series starting at 1 ⁇ g/ml and incubated 1 h at RT.
- anti-TPBG antibodies were added in a 1:2 dilution series starting at 1 ⁇ g/ml and incubated 1 h at RT.
- goat anti kappa antibody-POD conjugate (Millipore, AP502P) or donkey anti rabbit Fc antibody-POD conjugate (Amersham, NA9310V) was added in a 1:4000 dilution or a 1:1000 dilution, respectively and incubated at RT for 1 h on a shaker.
- 384-well TRSA-SA Maxisorp (MicroCoat) plates were coated with 25 ⁇ l/well biotinylated human TPBG-AviHis at a concentration of 200 ng/ml followed by an incubation at 4° C. overnight. After washing 3 times with 90 ⁇ l/well PBS-T, antibodies A1, A2, A3 were added at a concentration of 4 ⁇ g/ml followed by an incubation for 1 h at room temperature. Wells were washed 3 times with 90 ⁇ l/well PBS-T. Anti-TPBG antibodies were added at a concentration of 0.1 ⁇ g/ml and incubated for 1 h at room temperature on a shaker.
- PCR-products coding for VH or VL were cloned as cDNA into expression vectors by the overhang cloning method (R S Haun et al., Biotechniques (1992) 13, 515-518; MZ Li et al., Nature Methods (2007) 4, 251-256).
- the expression vectors contained an expression cassette consisting of a 5′ CMV promoter including intron A, and a 3′ BGH poly adenylation sequence.
- the plasmids contained a pUC18-derived origin of replication and a beta-lactamase gene conferring ampicillin resistance for plasmid amplification in E. coli .
- Three variants of the basic plasmid were used: one plasmid containing the rabbit IgG constant region designed to accept the VH regions while two additional plasmids containing rabbit or human kappa LC constant region to accept the VL regions.
- Linearized expression plasmids coding for the kappa or gamma constant region and VL/VH inserts were amplified by PCR using overlapping primers.
- plasmid and insert were combined and incubated with recA which induced site specific recombination.
- the recombined plasmids were transformed into E. coli .
- the next day the grown colonies were picked and tested for correct recombined plasmid by plasmid preparation, restriction analysis and DNA-sequencing.
- the isolated HC and LC plasmids were transiently co-transfected into HEK293 cells and the supernatants were harvested after 1 week.
- the PCR conditions for the VH and VL chain amplification were as follows: Hot start at 94° C. for 5 min; 35 cycles of 20 s at 94° C., 20 s at 68° C., 45 s at 68° C., and a final extension at 68° C. for 7 min.
- PCR-products coding for VH or VL were cloned as cDNA into expression vectors by the overhang cloning method (R S Haun et al., Biotechniques (1992) 13, 515-518; MZ Li et al., Nature Methods (2007) 4, 251-256).
- the expression vectors contained an expression cassette consisting of a 5′ CMV promoter including intron A, and a 3′ BGH poly adenylation sequence.
- the plasmids contained a pUC18-derived origin of replication and a beta-lactamase gene conferring ampicillin resistance for plasmid amplification in E. coli .
- Two variants of the basic plasmid were used: one plasmid containing the human IgG constant region designed to accept the new amplified VH chain and a second plasmid containing the human kappa LC constant region to accept the VL chain.
- Linearized expression plasmids coding for the kappa or gamma constant region and VL/VH inserts were amplified by PCR using overlapping primers.
- plasmid and insert were combined and incubated with recA which induced site specific recombination.
- the recombined plasmids were transformed into E. coli .
- the next day the grown colonies were picked and tested for correct recombined plasmid by plasmid preparation, restriction analysis and DNA-sequencing.
- An immunoconjugate of an anti-TPBG antibody Fab fragment and a truncated variant of exotoxin A chain of P. aeruginosa was generated via enzymatic coupling with sortase.
- Fab fragments transiently expressed in HEK293-F (with LPETG-HIS6 motif at the C-terminus) and GGG-PE24 LR8M (purified from E. coli extract as published in the literature) were concentrated to 7-8 mg/ml in 20 mM Tris, 150 mM NaCl, 5 mM CaCl 2 , pH 7.5. Both proteins were combined in a 1:1 molar ratio. Coupling reaction was started by adding HIS-tagged Sortase (0.8 molar equivalent). After incubation for 1 h at 37° C. the reaction mixture was chromatographed on a Ni HiTrap column (GE Healthcare) to remove uncoupled Fab and Sortase.
- Coupled Fab-PE24 eluted in the flow through and was further purified on a Superdex200 gel filtration column in 20 mM His, 140 mM NaCl, pH 6.0. The final product was concentrated to 1 mg/ml and frozen in aliquots at ⁇ 80° C.
- An immunoconjugate of an anti-TPBG antibody Fab fragment and a truncated variant of exotoxin A chain of P. aeruginosa was generated via expression of the immunoconjugate as recombinant fusion protein in E. coli cells.
- the toxin was fused to the C-terminus of the heavy chain of the anti-TPBG antibody.
- variable light chain constructs LC
- variable heavy chain constructs HC-PE
- E. coli cells applying the Roche in-house antibiotic free expression system (EP 0 972 838 and U.S. Pat. No. 6,291,245) and a fermentation process on chemical defined medium with alkaline feeding (WO2012/028522).
- the product was located in the insoluble fraction of the cytoplasm as inclusion bodies which were isolated and solubilized.
- the solubilized IB material was then combined during the renaturation process with its respective partner to form the TPBG binding Fab-PE fusion molecules.
- E. coli K12 strain CSPZ-25 (thi-1, ⁇ ompT, ⁇ pyrF, ⁇ lon, ⁇ galE) was transformed by electroporation with the relevant expression plasmids.
- the transformed E. coli cells were first grown at 37° C. on agar plates. For each transformation a colony picked from this plate was transferred to a 3 mL roller culture and grown at 37° C. to an optical density of 1-2 (measured at 578 nm). Then 1000 ⁇ l culture were mixed with 1000 ⁇ l sterile 86%-glycerol and immediately frozen at ⁇ 80° C. for long time storage. The correct product expression of these clones was verified in small scale shake flask experiments and analyzed with SDS-Page.
- IBP Inclusion body preparations of the 10 L fermentations were routinely started directly after the harvest of the bacteria with the re-suspension of the cell pellet in buffer containing 12.1 g/l Tris, 0.246 g/l MgSO4*7H2O and 12 ml/l 25%-HCl.
- the buffer volume was calculated in dependence of the dry matter content of the biomass. Lysozyme (100 kU/mg) and a small amount of BenzonaseTM were added. Then the suspension was homogenized at 900 bar (APV Rannie 5, 1 pass) to disrupt the bacteria cells followed by further addition of Benzonase and an incubation for 30 min at 30-37° C.
- the first wash buffer 60 g/l Brij, 87.6 g/l NaCl, 22.5 g/1 EDTA, 6 ml/l 10N NaOH
- the second wash buffer (12.1 ⁇ g/l Tris, 7.4 g/l EDTA, 1 ml/l 25%-HCl) and incubated for 20 min.
- a further separation step yielded the inclusion bodies which are stored frozen at ⁇ 20° C. or immediately transferred to the DSP department.
- Inclusion bodies of HC-PE and LC were solubilized separately in 6.7 M Guanidinium-Hydrochloride, 100 mM Tris/HCl, 5 mM acetate, 1 mM EDTA pH 8.0+100 mM Dithiothreitol (DTT) 2 h at room temperature. Solubilized material was adjusted to pH 5 and microfiltrated (6.7 M Guanidinium-HCl, 100 mM Tris, 1 mM EDTA, 5 mM acetate, 100 mM DTT pH 5.0) using a 1000 kDa membrane.
- the renaturation solution was kept at 2-10° C. overnight.
- the renaturate was diafiltrated against 20 mM Tris/HCl, 40 mM NaCl pH7.4 (pH 8.0 for TPBG-0199) and pumped onto an anion exchange column (AIEX) equilibrated in 20 mM Tris/HCl, 40 mM NaCl pH 7.4 (pH 8.0 for TPBG-0199). After washing the column with equilibration buffer the protein was eluted with a gradient up to 20 mM Tris/HCl, 320 mM NaCl, pH 7.4 (pH 8.0 for TPBG-0199).
- Peak fractions containing Fab-PE were pooled, concentrated and applied onto a preparative Size Exclusion Column (SEC) in 20 mM Tris, 150 mM NaCl, pH 7.4 to remove aggregates, fragments and E. coli proteins.
- SEC Size Exclusion Column
- the final protein pool was adjusted to the required protein concentration and analyzed via Bioanalyzer (Agilent Technologies), analytical SEC and UV 280 , identity was confirmed by mass spectrometry
- ESI Electrospray ionization
- MS parameter settings were as follows: Transfer: Funnel RF, 400 Vpp; ISCID Energy, 0 or 85 eV; Multipole RF, 400 Vpp; Quadrupole: Ion Energy, 3.0 eV; Low Mass, 850 m/z; Source: Dry Gas, 8 L/min; Dry Gas Temperature, 160° C.; Collision Cell: Collision Energy, 8 eV; Collision RF: 3800 Vpp; Ion Cooler: Ion Cooler RF, 800 Vpp; Transfer Time: 140 s; Pre Puls Storage, 20 s; scan ranges m/z 600 to 2000 and m/z 1000 to 4000.
- the MassAnalyzer software (developed in-house) was used for data evaluation.
- CHO-K1 cells were stably transfected with full length TPBG from different species, namely human, or minipig, to evaluate cellular binding properties and potency of novel TPBG-specific antibodies.
- CHO-K1 cells ATCC
- DMEM/F12 medium no phenol red
- fetal calf serum 10% fetal calf serum
- 2 mM L-Glutamine 10% fetal calf serum
- 80-90% confluency lipid/DNA complexes were prepared with TPBG expression vectors using Roche's XtremeGeneHP transfection reagent.
- lipid/DNA complexes were added to 2 ⁇ 10 5 CHO-K1 cells in suspension at a total volume of 2 ml of selection medium (DMEM/F12, 10% fetal calf serum, 400 ⁇ g/ml (3418). Cells were cultivated for 14 days under selection pressure and then stained with in-house TPBG antibodies. Briefly, 2 ⁇ 10 5 cells were stained with 2 ⁇ g/ml primary anti-TPBG antibody for 30 min on ice, washed and counterstained with PE-labelled anti-human kappa antibody (1:50 in PBS containing 2% fetal calf serum, 30 min on ice).
- selection medium DMEM/F12, 10% fetal calf serum, 400 ⁇ g/ml (3418).
- Single cell sorting of high or medium to low expressing clones was performed on a FacsARIA (BD) and single cells were deposited into 96--well flat bottom cell culture plates. After 12 days a variety of clones for each species (human, cynomolgus, minipig TPBG) were transferred to 24-well plates and cultivated for three more days. Clones were stained with above mentioned internal reference TPBG antibodies as formerly described and analyzed on a FacsCanto (BD). Selected clones were cultivated for one more week and stored in FCS containing 7.5% DMSO in liquid nitrogen. For stability testing, cells were further cultivated for two more weeks, then stained and analyzed on a FacsCanto (BD) resulting in the final selection of TPBG--expressing CHO cells that were stable over the observed time period.
- FacsARIA FacsARIA
- a SW620 clone (clone 4), stably expressing high level of TPBG, was chosen as cellular model.
- Cells growing in the logarithmic growth phase were detached using Accutase (Sigma) and a cell suspension was prepared in a PBS buffer (bufferA) containing 1% fetal calf serum and pH adjusted to pH 7.2, 6.0, and 5.5. Respective Fabs were added to cell suspension and binding occurred for 30 min on ice. Cells were subsequently washed twice with buffer of the same pH (buffer A).
- Cells in the logarithmic growth phase were detached using Accutase (Sigma). 2.5 ⁇ 10e5 cells per sample were resuspended in ice-cold buffer (PBS containing 2% fetal calf serum) and 10 ⁇ g/mL of the respective Fabs and kept for 15 min on ice. Cells were spun down at 300 g for 5 min at 4° C. and washed twice with 150 L ice-cold buffer. Cells were resuspended in 100 ⁇ L buffer and incubated for 30, 60 or 180 min at 37° C. Samples for time point zero remained on ice. Plates for time course at 37° C. were pre-warmed prior sample addition.
- ice-cold buffer PBS containing 2% fetal calf serum
- the GeoMean fluorescence signal of each Fab sample was corrected by the mean fluorescence intensity (MFI) of the corresponding isotype control.
- MFI mean fluorescence intensity
- the MFI for each time point was set in relation to time point zero and calculated as percentage value.
- the percentage of internalization was calculated by subtracting the percentage of detected antibody from 100%.
- TPBG-specific Fabs as expressed in Example 11 was assessed using stably transfected CHO cells (Example 16) and a flow cytometry based assay.
- Stable transfectants expressing cell surface levels of TPBG in a similar range were used for the flow cytometry based analysis of cellular binding.
- Dilution series of antibodies were prepared spanning a concentration range from 0.01-20 ⁇ g/ml.
- cell suspensions were prepared in ice cold PBS (Gibco) containing 2% fetal calf serum (PAN Biotech).
- 2.5 ⁇ 10e5 cells were dispensed per well in a v-shaped 96well-MTP.
- Antibody dilution series prepared in the same buffer were added as twofold concentrated solution. Samples were incubated on ice for 45 min upon which they were washed twice with 150 ⁇ L ice cold PBS containing 2% fetal calf serum.
- Antibodies 051, 091 and 097 of the invention bound to cell surface expressed TPBG to a similar degree, while prior art antibody H8 did not bind to cell surface expressed TPBG in sufficient extent ( FIG. 4A ).
- TPBG-specific antibodies to either human (hu) or minipig (pg) TPBG was evaluated using CHO-K1 cells stably transfected with the respective full length antigen (Example 16). Stable transfectants expressing cell surface levels of TPBG in a similar range were used for flow cytometry based analysis of cellular binding. Dilution series of Fab-PEs (anti-TPBG Fab-PE fusion proteins as expressed in Examples 13 and 14) were prepared spanning a concentration range from 400-0.002 nM. In brief, cell suspensions were prepared in ice cold PBS (Gibco) containing 2% fetal calf serum (PAN Biotech).
- Fab-PE constructs Fabs coupled to PE fragment via sortase coupling as provided in Example 12
- pg minipig
- CHO-K1 cells were transiently transfected with TPBG and luciferase containing plasmids in a ratio of 2:1 in suspension using Lipofectamine 3000 at a ratio of 3:1 and 3 ⁇ g total DNA per 1 ⁇ 10e6 cells. 30.000 cells per well were then seeded in a 98well-MTP in 100 ⁇ L medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 21 h prior addition of compounds. Dilution series of Fab-PEs were prepared in medium spanning a concentration range from 15 to 0.0003 nM. Individual data points were measured as triplicates.
- luciferase reporter activity as a surrogate marker for cellular protein synthesis capacity was quantified using Steady Glo (Promega). Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- TPBG-specific Fabs were co-incubated in a 1:3 molar ratio for 30 min prior addition to cells with a second Fab binding to the kappa-light chain of the TPBG-specific Fab.
- the kappa binding Fab carried in addition a pseudomonas exotoxin (PE) moiety.
- PE pseudomonas exotoxin
- the so formed complex was added to CHO-K1 cells stably expressing either human or minipig TPBG.
- CHO-K1 cells were stably transfected with full length TPBG from the respective species (Example 16). Single clones were selected and expanded. Clones expressing cell surface TPBG in a similar range were selected for subsequent proliferation assays. While the clones were maintained under selection pressure, the actual proliferation assays were performed in medium without selection pressure.
- Fabs derived vom antibodies A1, A2, and A3 do not display significant potency on CHO-K1 stably transfected with minipig TPBG. Also, the Fab fragment derived from antibody H8 displays a significantly lower potency in this assay and has an about 100 ⁇ lower potency on cells expressing minipig than on cell expressing human TPBG ( FIG. 6 A-D).
- a surrogate assay to evaluate the potency of Fab-PE constructs (anti-TPBG Fab-PE fusion proteins as expressed in Examples 13 and 14) on cells expressing human (hu) or minipig (pg) TPBG was established.
- CHO-K1 cells were stably transfected with full length TPBG from the respective species. Single clones were selected and expanded. Clones expressing cell surface TPBG in a similar range were selected for subsequent proliferation assays. While the clones were maintained under selection pressure, the actual proliferation assays were performed in medium without selection pressure.
- All immunoconjugates comprising antibodies of the invention (i.e. antibodies 051, 091, and 097) displayed potent activity on cells expressing either human or minipig TPBG.
- An unspecific Fab-PE which does not bind to transfected CHO-K1 cells has no activity in the measured concentration range ( FIG. 7 A).
- Binding of anti-TPBG Fab-PE fusion proteins as provided in Example 13 and 14, as well as binding of Fabs coupled to PE fragment via sortase coupling as provided in Example 12 to human tumor cells was studied using the breast cancer tumor cell line MCF7. Cells growing in the logarithmic growth pase were detached using Accutase (Sigma). In brief, cell suspensions were prepared in ice cold PBS (Gibco) containing 2% fetal calf serum (PAN Biotech).
- All anti-TPBG Fab-PE fusion proteins display low nM or sub-nM EC50 values in their binding to the human breast tumor cell line MCF7 ( FIG. 8 ).
- TPBG-specific Fabs were co-incubated in a 1:3 molar ratio for 30 min prior addition to cells with a second Fab binding to the kappa-light chain of the TPBG-specific Fab.
- the kappa binding Fab carried in addition a pseudomonas exotoxin (PE) moiety.
- PE pseudomonas exotoxin
- TPBG-specific Fabs were co-incubated in a 1:3 molar ratio for 30 min prior addition to cells with a second Fab binding to the kappa-light chain of the TPBG-specific Fab.
- the kappa binding Fab carried in addition a pseudomonas exotoxin (PE) moiety.
- PE pseudomonas exotoxin
- Fab-PE constructs Fabs coupled to PE fragment via sortase coupling as provided in Example 12
- the breast cancer cell line MCF7 was selected. 20.000 cells were seeded per well in a 98well-MTP in 100 ⁇ L medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series of sortase-coupled Fab-PEs were prepared in medium spanning a concentration range from 133 to 0.002 nM. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- TPBG-specific Fabs expressed as described in Example 11 were co-incubated in a 1:3 molar ratio for 30 min prior addition to cells with a second Fab binding to the kappa-light chain of the TPBG-specific Fab.
- the kappa binding Fab carried in addition a pseudomonas exotoxin (PE) moiety.
- PE pseudomonas exotoxin
- the so formed complex was added to human H1975 lung cancer cells.
- 10.000 cells were seeded per well in a 98well-MTP in 100 ⁇ L medium (Gibco) containing 10% fetal calf serum (PAN Biotech) and penicillin/streptomycin (Gibco). Cells were allowed to attach for 24 h prior addition of compounds.
- Dilution series were prepared in medium spanning a concentration range from 133 to 0.002 nM as calculated for the respective TPBG-specific Fab. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- Sandwich constructs comprising Fab fragments of prior art antibodies A1, A2 and A3 displayed no (for A1 and A2) or significantly lower cytotoxicity than the other tested constructs ( FIG. 12 ).
- TPBG tumor cell line H1975
- the number of cell surface TPBG molecules was approximately 30.000/cell as determined by flow cytometry based receptor quantitation. 10.000 cells were seeded per well in a 98well-MTP in 100 ⁇ L medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series of Fab-PEs were prepared in medium spanning a concentration range from 3 to 0.00005 nM. Individual data points were measured as triplicates.
- Example 13 and 14 In a different experimental setup the exposure time of of anti-TPBG Fab-PE fusion proteins as expressed in Example 13 and 14 to tumor cells was varied.
- the non-small cell lung cancer cell line H1975 was used to evaluate, if shorter incubation time with Fab-PE constructs has an impact on potency in a proliferation assay.
- NCI-H1975 displays cell surface TPBG as was independently confirmed.
- NCI-H1975 were cultured in RPMI high glucose medium with 1.0 mM sodium pyruvate supplemented with 10% fetal calf serum, 2.0 mM L-glutamine, and 10 mM HEPES at 37° C. in a water-saturated atmosphere at 5% CO 2 . Culture passages were performed with trypsin/EDTA (Life Technologies) splitting every third day. Nude mice were purchased from breeder (e.g. Charles River, Sulzfeld, Germany) and maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government.
- Fab-PE fusion proteins were administered as single agent at 1 mg/kg i.v. once daily every second day for several times. The corresponding vehicle was administered on the same days.
- Fab-PE proteins were provided as stock solution from Roche, Penzberg, Germany. Buffer included histidine and injection solution was diluted appropriately in buffer from stock prior injections.
- NCI-H1975 NSCLC xenograft bearing mice were treated with the Fab-PE fusion proteins from study day 17 to 44 at dose of 1.0 mg/kg for a total of 8 times (days 17, 19, 21, 24, 26, 28, 42 and 44). Each treatment group consisted of 10 animals.
- treatments with the Fab-PE fusion proteins comprising antibodies of the invention showed significant anti-tumor efficacy with strong tumor regression of s.c. NCI-H1975 xenografts. Notably, a majority of complete tumor remissions were achieved.
- the strong efficacy of the immunoconjugated of the invention was statistically different from the immunoconjugated comprising prior art antibody H8 ( FIG. 15 ).
- NCI-N87 were cultured in RPMI high glucose medium with 1.0 mM sodium pyruvate supplemented with 10% fetal calf serum, 2.0 mM L-glutamine, and 10 mM HEPES at 37° C. in a water-saturated atmosphere at 5% CO 2 . Culture passages were performed with trypsin/EDTA (Life Technologies) splitting every third day. Nude mice were purchased from breeder (e.g. Charles River, Sulzfeld, Germany) and maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government.
- Fab-PE fusion proteins were administered as single agent at 1 mg/kg i.v. once daily every second day for several times. The corresponding vehicle was administered on the same days.
- Fab-PE fusion proteins were provided as stock solution from Roche, Penzberg, Germany. Buffer included histidine and injection solution was diluted appropriately in buffer from stock prior injections.
- NCI-N87 gastic cancer xenograft model tumor mice were treated with Fab-PE fusion proteins from study day 15 to 33 at dose of 1.0 mg/kg for a total of 7 times (days 15, 17, 19, 22, 24, 26 and 33). Each treatment group consisted of 10 animals. As a result, treatments with the Fab-PE fusion proteins as well as the reference (H8 antibody) showed anti-tumor efficacy with distinct tumor regression of s.c. N87 xenografts ( FIG. 16 ).
- BxPC3 cells were stably transfected with a plasmid encoding for a luciferase which contains cellular degradation signals (Promega) and has a half-life of about 0.4 h. Single clones were derived and re-assessed for stable plasmid incorporation. Inhibition of protein synthesis by ADP-ribosylation conferred by the pseudomonas exotoxin results in a rapid loss of luciferase and can thus be measured upon cell lysis and incubation with luciferin as loss of signal in comparison to controls.
- BxPC3/luc in the logarithmic growth phase were detached with Accutase (Sigma) and counted. 40.000 BxPC3/luc cells were seeded per well in 96well-MTP in 100 ⁇ l medium containing 10% fetal calf serum and were incubated 24 h prior compound addition. TPBG-specific immunoconjugates were added in a concentration range from 3-0.0001 nM. All samples were measured in triplicates.
- An unspecific immunoconjugate has no effect on the luciferase signal (ct). All TPBG-specific immunoconjugates display sub-nM potency. Antibodies of this invention display higher potency than the prior art antibody H8 ( FIG. 17A and Table 21).
- TPBG-specific Fabs were mixed with anti-human kappa Fab-PE ( pseudomonas exotoxin) in a 1:3 molar ratio and kept at room temperature for 15 min to allow for sandwich construct formation. Dilution series of this mixture were prepared in medium. Final concentrations on cells ranged from 133 nM to 0.002 nM as calculated for the TPBG-specific Fab. 24 h post-addition Steady-Glo luciferase assay (Promega) was performed. All samples were measured in triplicates.
- Affinity of Fab fragments of antibodies 051, 091, and 097 of the invention (as expressed in Example 11) to human TPBG was assessed by BiacoreTM.
- Fab fragments of prior art antibody H8 were assessed as a control.
- a CM5 sensor chip was mounted into a Biacore T200 System. Flow cell one was prepared as reference flow cell, by blank immobilization. On flow cell two, about 500 RU of 1.5 ⁇ g/ml huTPBG in pH 4.5 acetate buffer were immobilized (120 s at 10 ⁇ l/min). The amine-coupling was done as described by the manufacturer.
- the samples were injected in a concentration series of 4.9 nM, 14.8 nM, 44.4 nM, 133.3 nM, 400 nM and 0 nM for 150 s at a flow speed of 50 ⁇ l/min, followed by a dissociation phase of 660 seconds.
- the sample-antigen-complex was regenerated after every sample injection by one 40 s pulse of Glycine-HCl pH 1.5 at 30 ⁇ l/min and one 40 s long injection of a regeneration solution containing 0.31 M KSCN, 1.22 M MgCl 2 , 0.61 M urea, 1.22 M Gua-HCl and 6.7 mM EDTA at 30 ⁇ /min followed by an extra wash after injection with buffer.
- Affinity of Fab fragments of antibodies 051, 091, and 097 of the invention (as expressed in Example 11) to minipig TPBG was assessed by BiacoreTM.
- Fab fragments of prior art antibody H8 were assessed as a control.
- a CM5 sensor chip was mounted into a Biacore T200 System. Flow cell one was prepared as reference flow cell by blank immobilization. An ⁇ huFab> capture antibody (#28958325, GE-HC) was immobilized via amine coupling onto the flow cells 2, 3 and 4 with an injection time of 1200 s at a concentration of 20 ⁇ g/ml (diluted in the buffer, also provided in the capturing-kit #28958325, GE-HC) and a flow speed of 5 ⁇ l/min.
- the samples were successively captured on flow cells 2, 3 and 4 with an injection time of 60 s and a flow speed of 20 ⁇ l/min, followed by a 120 seconds long injection of one minipig TPBG dilution out of a dilution series (4.9 nM, 14.8 nM, 44.4 nM, 133.3 nM, 400 nM and 2 ⁇ 0 nM).
- a dissociation phase of 660 s except the 14.8 nM, 4.9 nM and one 0 nM dilution, for which the diss. time was set to 0 s
- the ⁇ huFab> surface was regenerated according to the manufacturer's instructions with the regeneration solution provided in the Fab-capture-kit and the next cycle was carried out.
- a CM5 sensor chip was mounted into a Biacore T200 System. Flow cell one was prepared as reference flow cell, by blank immobilization. On flow cell two, 80 RU were the aim for the immobilization with 1.5 ⁇ g/ml huTPBG in pH 4.5 acetate buffer. The amine-coupling was done as described by the manufacturer.
- HBS-EP+pH 5.5 was used as running and sample buffer
- HBS-EP+pH 7.4 was used.
- the samples were injected in a concentration series of 1.9 nM, 5.6 nM, 2 ⁇ 16.7 nM, 50 nM, 150 nM and 2 ⁇ 0 nM for 300 s at a flow speed of 50 ⁇ l/min.
- the 50 nM, one 0 nM and one 16.7 nM sample were allowed to dissociate for 1200 s, all other dissociation phases were only 10 s long.
- the sample-antigen-complex was regenerated after every sample injection by one 40 s pulse of Glycine-HCl pH 1.5 at 30 ⁇ l/min and one 40 s long injection of a regeneration solution containing 0.31 M KSCN, 1.22 M MgCl 2 , 0.61 M urea, 1.22 M Gua-HCl and 6.7 mM EDTA at 30 ⁇ /min followed by an extra wash after injection with buffer.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides anti-TPBG antibodies and methods of using the same.
Description
- The present invention relates to anti-TPBG antibodies and methods of using the same.
- Trophoblast glycoprotein (TPBG) is a leucine-rich transmembrane glycoprotein involved in cell adhesion. In adults this protein is highly expressed in many tumor cells and is associated with poor clinical outcome in numerous cancers.
- Antibodies binding to TPBG (also referred to as “5T4”) are, e.g. disclosed in Shaw et al. (2002) Biochem. J. 363: 137-45 and WO98/55607. Those documents disclose antibody “H8”, which specifically binds to a conformational epitope of TPBG. Amino acid sequences of original murine H8 antibody and of a humanized version of H8 antibody are disclosed in WO 2006/031653.
- Further antibodies binding to TPBG are, e.g. disclosed in Woods et al. (2002) Biochem. J. 366: 353-65 (which discloses a rat monoclonal antibody) and U.S. Pat. No. 5,869,053 (which discloses a mouse monoclonal antibody).
- Further antibodies binding to TPGB are, e.g. disclosed and characterized in WO 2007/106744, referred to as antibodies A1, A2 and A3.
- Therapeutic use of antibodies binding to TPBG in treatment of cancer is, e.g., disclosed in Myers et al. (2002) Cancer Gene Ther. 9: 884-896, Shaw et al. (2000) Biochim. Biophys. Acta. 1524: 238-246; and US 2003/0018004, disclosing that anti-TPBG antibody antibody sequences fused to the human IgG constant domain or to the extracellular domain of murine B7.1 induces cytolysis of TPBG-expressing tumor cell lines. A phase I clinical trial using PNU-214936, a murine Fab fragment of a monoclonal anti-TPGB antibody fused to a mutated superantigen staphylococcal enterocytotoxin A (SEA), showed limited toxicity and some anti-tumor response (Cheng et al. (2004) J. Clin. Oncol. 22(4):602-9).
- The invention provides anti-TPBG antibodies, conjugates thereof and methods of using the same. Also provided are isolated anti-TPBG polypeptides and isolated nucleic acids encoding the same.
- The invention relates to an isolated antibody that binds to trophoblast glycoprotein (TPBG), wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2).
- In one aspect, the invention relates to an isolated antibody that binds to TPBG, wherein the antibody specifically binds to human and minipig TPBG with a KD of 10-8 M or less.
- In one embodiment the antibody specifically binds to human TPBG with a KD of 10-8 M or less and the antibody specifically binds to minipig TPBG with a KD of 10-8 M or less.
- In one embodiment the Fab fragment of the antibody specifically binds to human and minipig TPBG with a KD of 10-8 M or less.
- In another aspect the invention relates to an isolated antibody that binds to TPBG, wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.4.
- In another aspect the invention relates to an isolated antibody that binds to TPBG, wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.4 with a KD of 10-8 M or less.
- In another aspect, the invention relates to an isolated antibody that binds to TPBG, wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2.
- In one embodiment of the invention, the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2, wherein binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2. In one embodiment the binding is detected via flow cytomentry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18. In one embodiment of the invention, the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2, wherein binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2. In one embodiment the binding is detected via flow cytomentry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2, wherein binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2. In one embodiment the binding is detected via flow cytomentry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- In one embodiment of the invention, the antibody binds to cell surface expressed human TPBG and to cell surface expressed minipig TPBG.
- In one embodiment of the invention, the antibody is internalized into a human or minipig-TPBG-expressing cell upon binding to cell surface expressed TPBG.
- In one embodiment of the invention, the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 5, a CDR3 of the light chain of SEQ ID NO: 8, and a CDR2 of the heavy chain of SEQ ID NO: 4 (corresponding to the aforementioned CDRs of the antibody “051” as disclosed herein).
- In one embodiment of the invention, the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 3, a CDR2 of the heavy chain of SEQ ID NO: 4, a CDR3 of the heavy chain of SEQ ID NO: 5, a CDR1 of the light chain of SEQ ID NO: 6, a CDR2 of the light chain of SEQ ID NO: 7, and a CDR3 of the light chain of SEQ ID NO: 8 (corresponding to the six CDRs of the antibody “051” as disclosed herein).
- In one embodiment of the invention, the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 13, a CDR3 of the light chain of SEQ ID NO: 16, and a CDR2 of the heavy chain of SEQ ID NO: 12 (corresponding to the aforementioned CDRs of the antibody “091” as disclosed herein).
- In one embodiment of the invention, the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 11, a CDR2 of the heavy chain of SEQ ID NO: 12, and a CDR3 of the heavy chain of SEQ ID NO: 13, a CDR1 of the light chain of SEQ ID NO: 14, a CDR2 of the light chain of SEQ ID NO: 15, and a CDR3 of the light chain of SEQ ID NO: 16 (corresponding to the six CDRs of the antibody “091” as disclosed herein).
- In one embodiment of the invention, the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 21, a CDR3 of the light chain of SEQ ID NO: 24, and a CDR2 of the heavy chain of SEQ ID NO: 20 (corresponding to the aforementioned CDRs of the antibody “097” as disclosed herein).
- In one embodiment of the invention, the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 19, a CDR2 of the heavy chain of SEQ ID NO: 20, and a CDR3 of the heavy chain of SEQ ID NO: 21, a CDR1 of the light chain of SEQ ID NO: 22, a CDR2 of the light chain of SEQ ID NO: 23, and a CDR3 of the light chain of SEQ ID NO: 24 (corresponding to the six CDRs of the antibody “097” as disclosed herein).
- In one embodiment of the invention, the antibody is a humanized antibody derived from one of the aforementioned antibodies.
- In one embodiment of the invention, the antibody comprises
- (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9;
- (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10; or
- (c) a VH sequence as in (a) and a VL sequence as in (b).
- In one aspect the invention provides an antibody comprising a VH sequence of SEQ ID NO: 9 and a VL sequence of SEQ ID NO: 10 (corresponding to the variable domains of the antibody “051” as disclosed herein).
- In one embodiment of the invention, the antibody comprises
- (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17;
- (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 18; or
- (c) a VH sequence as in (a) and a VL sequence as in (b).
- In one aspect the invention provides an antibody comprising a VH sequence of SEQ ID NO: 17 and a VL sequence of SEQ ID NO: 18 (corresponding to the variable domains of the antibody “091” as disclosed herein).
- In one embodiment of the invention, the antibody comprises
- (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25;
- (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 26; or
- (c) a VH sequence as in (a) and a VL sequence as in (b).
- In one aspect the invention provides an antibody comprising a VH sequence of SEQ ID NO: 25 and a VL sequence of SEQ ID NO: 26 (corresponding to the variable domains of the antibody “097” as disclosed herein).
- In one embodiment of the invention, the antibody is an antibody fragment that binds TPBG. In one embodiment of the invention, the antibody is a Fab fragment that binds TPBG.
- In one aspect the invention provides an isolated nucleic acid encoding the antibody of the invention. In one aspect the invention provides a host cell comprising said nucleic acid.
- In one aspect the invention provides a method of producing an antibody comprising culturing said host cell of the invention so that the antibody is produced. In one embodiment of said method the method further comprises recovering the antibody from the host cell.
- In one aspect the invention provides an immunoconjugate comprising the antibody of the invention and a cytotoxic agent. In one embodiment the cytotoxic agent is an enzymatically active toxin or fragment thereof. In one embodiment the cytotoxic agent is selected from the group consisting of exotoxin A chain (from Pseudomonas aeruginosa), diphtheria toxin, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. In one embodiment the cytotoxic agent is Pseudomonas exotoxin A or a variant thereof.
- In one aspect the invention provides a method of producing the immunoconjugate of the invention, including the step of coupling the antibody to the cytotoxic agent. In one embodiment said method further includes the step of providing the antibody before the step of coupling, wherein the antibody is provided by culturing the host cell of the invention, which comprises a nucleic acid encoding the antibody of the invention, so that the antibody is produced. In one embodiment said method further includes the step of recovering the antibody from the host cell before the step of coupling.
- In one aspect the invention provides a recombinant fusion protein comprising an antibody of the invention and any other polypeptide. In one embodiment the other polypeptide is fused to at least one of the heavy chains of the antibody. In one embodiment the other polypeptide is fused to the C-terminus of at least one of the heavy chains of the antibody.
- In one embodiment the polypeptide is a cytotoxic agent (in consequence, in this embodiment, the recombinant fusion protein is an immunoconjugate). In one embodiment the cytotoxic agent is an enzymatically active toxin or fragment thereof. In one embodiment the cytotoxic agent is selected from the group consisting of exotoxin A chain (from Pseudomonas aeruginosa), diphtheria toxin, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. In one embodiment the cytotoxic agent is Pseudomonas exotoxin A or a variant thereof.
- In one aspect the invention provides an isolated nucleic acid encoding the recombinant fusion protein of the invention. In one embodiment the nucleic acid encodes the recombinant fusion protein of the invention, wherein the recombinant fusion protein is an immunoconjugate (in this embodiment, the polypeptide comprised in the recombinant fusion protein is a cytotoxic agent). In one aspect the invention provides a host cell comprising said nucleic acid.
- In one aspect the invention provides a method of producing a recombinant fusion protein comprising culturing said host cell so that the recombinant fusion protein is produced. In one embodiment the recombinant fusion protein is an immunoconjugate. In one embodiment of said method the method further comprises recovering the recombinant fusion protein from the host cell. In one embodiment of said method the method further comprises isolating inclusion bodies of the host cell and solubilizing the inclusion bodies. In one embodiment of said method the method further comprises the step of renaturation of the material from the solubilized inclusion bodies. In one embodiment of said method host cell is a bacterial cell. In one embodiment of said method host cell is an Escherichia coli cell.
- In one aspect the invention provides a pharmaceutical formulation comprising the antibody of the invention and a pharmaceutically acceptable carrier. In one embodiment said pharmaceutical composition further comprises an additional therapeutic agent. In one embodiment said additional therapeutic agent is a chemotherapeutic agent.
- In one aspect the invention provides a pharmaceutical formulation comprising the recombinant fusion protein of the invention and a pharmaceutically acceptable carrier. In one embodiment said pharmaceutical composition further comprises an additional therapeutic agent. In one embodiment said additional therapeutic agent is a chemotherapeutic agent.
- In one aspect the invention provides a pharmaceutical formulation comprising the immunoconjugate of the invention and a pharmaceutically acceptable carrier. In one embodiment said pharmaceutical composition further comprises an additional therapeutic agent. In one embodiment said additional therapeutic agent is a chemotherapeutic agent.
- In one aspect the invention provides the antibody of the invention for use as a medicament. In one aspect the invention provides the antibody of the invention for use in the treatment of cancer.
- In one aspect the invention provides the use of the antibody of the invention in the manufacture of a medicament.
- In one aspect the invention provides a method of treating an individual having cancer comprising administering to the individual an effective amount of the antibody of the invention. In one embodiment said method further comprises administering an additional therapeutic agent to the individual. In one embodiment said additional therapeutic agent is a chemotherapeutic agent.
- In one aspect the invention provides the recombinant fusion protein of the invention for use as a medicament. In one aspect the invention provides the recombinant fusion protein of the invention for use in the treatment of cancer.
- In one aspect the invention provides the use of the recombinant fusion protein of the invention in the manufacture of a medicament. In one embodiment the medicament is for treatment of cancer In one aspect the invention provides a method of treating an individual having cancer comprising administering to the individual an effective amount of the recombinant fusion protein of the invention. In one embodiment said method further comprises administering an additional therapeutic agent to the individual. In one embodiment said additional therapeutic agent is a chemotherapeutic agent.
- In one aspect the invention provides the immunoconjugate of the invention for use as a medicament. In one aspect the invention provides the immunoconjugate of the invention for use in the treatment of cancer.
- In one aspect the invention provides the use of the immunoconjugate of the invention in the manufacture of a medicament. In one embodiment the medicament is for treatment of cancer.
- In one aspect the invention provides a method of treating an individual having cancer comprising administering to the individual an effective amount of the immunoconjugate of the invention. In one embodiment said method further comprises administering an additional therapeutic agent to the individual. In one embodiment said additional therapeutic agent is a chemotherapeutic agent.
- In one aspect the invention provides a method of screening for an antibody that binds to human TPBG and to minipig TPBG, the method comprising the steps of testing the binding of a test antibody to human TPBG and to minipig TPBG, and selecting the antibody that binds to human TPBG and to minipig TPBG.
- In one embodiment the method is for the screening of an antibody for therapeutic application.
- In one embodiment the method comprises the step of testing the binding of a test antibody in monovalent form.
- In one embodiment the method comprises the steps of testing the binding of a test antibody to human TPBG at pH 5.5 and at pH 7.2, and selecting the antibody that binds to human TPBG at both pH (pH 5.5 and pH 7.2).
- In one aspect the invention provides an antibody obtained by a method of screening of the invention.
- In one aspect the invention provides a method of generating an antibody that binds to human TPBG and to minipig TPBG, the method comprising the steps of (a) immunizing an animal with human TPBG or with human TBPG extracellular domain (ECD), (b) isolating B cells specific for human TPBG from the blood of the animal, (c) identifying the amino acid sequence of the variable domains (VH and VL) of the antibodies produced by the isolated B cells, (d) providing an antibody comprising the variable domains identified, (e) testing the binding of a the provided antibody to human TPBG and to minipig TPBG, and (f) selecting the antibody that binds to human TPBG and to minipig TPBG.
- In one embodiment the method is for generating an antibody for therapeutic application. In one embodiment the animal is a rodent. In one embodiment the animal is a rabbit.
- In one embodiment the method comprises the step of testing the binding of the provided antibody in monovalent form.
- In one embodiment the method comprises the steps of testing the binding of the provided antibody to human TPBG at pH 5.5 and at pH 7.2, and selecting the antibody that binds to human TPBG at both pH (pH 5.5 and pH 7.2).
- In one aspect the invention provides an antibody obtained by a method of generating an anti-TPBG antibody of the invention.
- The invention provides antibodies that bind to TPBG which are cross-reactive between TPBG of human and minipig species, and thereby are suitable for clinical development as they can be used for studies in minipig species (hence avoiding necessity of monkey studies). In addition the antibodies of the invention that bind to TPBG bind to their target, i.e. human TPBG, both at neutral as well as slightly acidic pH thereby assuring antigen binding in the slightly acidic microenvironment of a tumor, which is advantageous for a therapeutic application of the antibodies in cancer therapy. In addition, antibodies of the invention exhibit superior potency for treatment of several types of cancer, e.g. human non-small cell lung cancer.
-
FIG. 1 : mRNA expression profile of tissues from cynomolgus monkey and minipig (RPKM=reads assigned per kilobase of target per million mapped reads) (Example 1). -
FIG. 2 : Binding of different anti-TPBG antibodies (Fab fragments: Fab1=H8; Fab2=091; Fab3=051; Fab4=097) to cell surface expressed human TPBG at different pH values (Example 17). The human cell line SW620 clone 4, stably expressing TPBG, was incubated with different Fabs at varying pH. Upon incubation with a secondary antibody coupled to a fluorescent dye, signals were detected by flow cytometry. Baseline corrected mean fluorescent intensities (MFI) are shown. -
FIG. 3 : Internalization of anti-TPBG antibodies (Fab fragments: square=H8; triangle=097; diamond=051; circle=091) evaluated in the tumor cell line MCF7 (Example 18). The y-axis displays the loss of signal for cell surface bound Fabs as function of time. -
FIG. 4A : Cellular binding of anti-TPBG antibodies (Fab fragments: open circle=051; square=91; triangle=97; circle=H8) to minipig-TPBG expressing CHO cells (Example 19). Baseline corrected mean fluorescent intensities (MFI) are shown. -
FIG. 4B : Cellular binding of anti-TPBG antibodies (Fab-PE fusion proteins; Fab fragments: square=H8; triangle=097; diamond=051; circle=091) to human TPBG stably displayed on the cell surface of CHO-K1 (Example 20). A dilution series of Fab-PE was added to cells. Cellular binding was visualized with a secondary fluorescence labeled antibody and analysis in flow cytometry. Baseline corrected mean fluorescent intensities (MFI) are shown. -
FIG. 4C : Cellular binding of immunoconjugates comprising anti-TPBG antibodies (Fab-PE fusion proteins; Fab fragments derived from antibodies: square=H8; triangle=097; diamond=051; circle=091) to minipig TPBG stably displayed on the cell surface of CHO-K1 (Example 20). A dilution series of Fab-PE was added to cells. Cellular binding was visualized with a secondary fluorescence labeled antibody and analysis in flow cytometry. -
FIG. 5A : Cytotoxicity of immunoconjugates comprising anti-TPBG antibodies (Fabs coupled to PE via sortase coupling: square=H8; triangle=097; diamond=051; circle=091) on CHO-K1 cells transiently expressing human TPBG (Example 21). -
FIG. 5B : Cytotoxicity of immunoconjugates comprising anti-TPBG antibodies (Fabs coupled to PE via sortase coupling: square=H8; triangle=097; diamond=051; circle=091) on CHO-K1 cells transiently expressing minipig TPBG (Example 21). -
FIG. 6A-D : Cytotoxicity mediated by anti-TPBG antibodies (anti-TPBG Fab antibodies bound by anti-kappa chain antibody-PE fusion protein, prior art antibodies H8, A1, A2, A3 as well asantibodies FIG. 6A : CHO-K1 stably transfected with human TPBG. Figure legend: vertical dash=unspecific control; star=051; open triangle=091; cross=097; plus=H8.FIG. 6B : CHO-K1 stably transfected with human TPBG. Figure legend: plus=H8; open triangle=A1; open diamond=A2; open circle=A3.FIG. 6C : CHO-K1 stably transfected with minipig TPBG. Figure legend: triangle point left=unspecific control; star=051; triangle point down=091; cross=097; plus=H8.FIG. 6D : CHO-K1 stably transfected with minipig TPBG. Figure legend: plus=H8; open triangle=A1; open diamond=A2; open circle=A3. -
FIG. 7A-C : Cytotoxicity of immunoconjugates comprising anti-TPBG antibodies (Fab-PE fusion proteins: star=unspecific control; square=H8; diamond=051; circle=091; triangle=097) on human and minipig-TPBG expressing CHO-K1 cells (Example 23). Viability was determined by ATP-release assay (CellTiter-Glo).FIG. 7A : CHO-K1 cells stably transfected with full length human TPBG were incubated with immunoconjugates.FIG. 7B : CHO-K1 cells stably transfected with full length minipig TPBG were incubated with immunoconjugates.FIG. 7C : Parental CHO-K1 cells were incubated with immunoconjugates. -
FIG. 8 : Cellular binding of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) on human TPBG expressing MCF7 cells (Example 24). Binding was determined by flow cytometry (y-axis: mean fluorescence intensity=MFI). Baseline corrected mean fluorescent intensities (MFI) are shown. -
FIG. 9 : Cytotoxicity mediated by anti-TPBG antibodies of the invention (anti-TPBG Fab antibodies bound by anti-kappa chain antibody-PE fusion protein) on human TPBG expressing MCF7 cells (Example 25). Fab fragments were co-incubated with an anti-kappa-binding Fab-PE (pseudomonas exotoxin). The human breast cancer cell line MCF7 was incubated with the complex of Fab:Fab-PE constructs. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h. Figure legend: star=unspecific control; square=H8; diamond=051; circle=091; triangle=097. -
FIG. 10 : Cytotoxicity mediated by prior art anti-TPBG antibodies H8, A1, A2 and A3 (anti-TPBG Fab antibodies bound by anti-kappa chain antibody-PE fusion protein) on human TPBG expressing MCF7 cells (Example 25). Fab fragments were co-incubated with an anti-kappa-binding Fab-PE (pseudomonas exotoxin). The human breast cancer cell line MCF7 was incubated with the complex of Fab:Fab-PE constructs. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h. Figure legend: star=unspecific control; square=H8; triangle=A1; diamond=A2; circle=A3. -
FIG. 11 : Cytotoxicity of immunoconjugates comprising anti-TPBG antibodies (Fabs coupled to PE fragment via sortase coupling) on human TPBG expressing MCF7 cells (Example 26). The human breast cancer cell line MCF7 was incubated with sortase coupled Fab-PE constructs. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h. Figure legend: star=unspecific control; square=H8; diamond=051; circle=091; triangle=097. -
FIG. 12 : Cytotoxicity mediated by anti-TPBG antibodies (anti-TPBG Fab antibodies bound by anti-kappa chain antibody-PE fusion protein) on human TPBG expressing H1975 non-small cell lung cancer cells (Example 27). H1975 cells were incubated with the complex of Fab:Fab-PE constructs. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h. -
FIG. 13 : Cytotoxicity of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) on human TPBG expressing H1975 non-small cell lung cancer cells (Example 28). The human tumor cell line H1975 was incubated with Fab-PE fusion proteins. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h. Figure legend: star=unspecific control; square=H8; diamond=051; circle=091; triangle=097 -
FIG. 14A-D : Time course proliferation assay of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) applied to human TPBG expressing H1975 non-small cell lung cancer cells (Example 29). The human tumor cell line H1975 was incubated for different periods of time with the respective Fab-PE constructs. Viability was determined by ATP-release assay (CellTiter-Glo) after 72 h.FIG. 14A : Continuos incubation with Fab-PE.FIG. 14B : Incubation with Fab-PE for 60 min.FIG. 14C : Incubation with Fab-PE for 30 min.FIG. 14D : Incubation with Fab-PE for 10 min. Figure legend: star=unspecific control; square=H8; diamond=051; circle=091; triangle=097. -
FIG. 15 : In vivo anti-tumor efficacy of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) on human TPBG expressing human non-small cell lunger cancer H1975 cell xenografts (Example 30). Mean tumor growth is depicted on y-axis. Deviation is presented as standard error of the mean (SEM). Figure legend (anti-TPBG antibody): open diamonds=vehicle; dash=H8; triangle=051; square=091; circle=097. -
FIG. 16 : In vivo anti-tumor efficacy of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) on human TPBG expressing human gastric cancer NCI-N87 cell xenografts (Example 31) Mean tumor growth is depicted on y-axis. Deviation is presented as standard error of the mean (SEM). Figure legend (anti-TPBG antibody): open diamonds=vehicle; dash=H8; triangle=051; square=091; circle=097. -
FIG. 17A-B : Protein synthesis assay using BxPC3/luc cells contacted with immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) (Example 32). Viability was determined by luciferase assay and set in relation to buffer treated control cells. BxPC-3 stably transfected with a luciferase reporter were treated.FIG. 17A : Comparison of immunoconjugates comprising prior art antibody H8 with sandwichconstructs comprising antibodies FIG. 17B : Comparison of immunoconjugates comprising prior art antibodies. Figure legend: square=Fab(H8); triangle=Fab(A1); diamond=Fab(A2); circle=Fab(A3). -
FIG. 18 : Binding of immunoconjugates comprising anti-TPBG antibodies (anti-TPBG Fab-PE fusion proteins) to human TPBG at pH 5.5 and pH 7.4 (association-dissociation-plot, Example 35). Figure legend: Fab fragments comprised in immunoconjugates are indicated; circles indicate binding behaviour of respective immunoconjugate at pH 5.5, squares indicate binding behaviour of respective immunoconjugate at pH 7.4. -
FIG. 19 : Binding of anti-TPBG antibodies (Fab fragments) to minipig TPBG. - An “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
- An “affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.
- The terms “anti-TPBG antibody” and “an antibody that binds to TPBG” refer to an antibody that is capable of binding TPBG with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting TPBG. In certain embodiments, an antibody that binds to TPBG has a dissociation constant (Kd) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. 10−8 M or less, e.g. from 10−8 M to 10−13 M, e.g., from 10−9 M to 10−13 M). In certain embodiments, an anti-TPBG antibody binds to an epitope of TPBG that is conserved among TPBG from different species.
- A “test antibody” refers to an antibody with unknown characteristics with respect to its binding properties to TPBG.
- The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
- An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab′, Fab′-SH, F(ab′)2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.
- An “antibody that binds to the same epitope” as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. An exemplary competition assay is provided herein.
- The term “chimeric” antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
- The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
- The term “cytotoxic agent” as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and the various antitumor or anticancer agents disclosed below.
- “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
- An “effective amount” of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
- The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991), NIH Publication 91-3242.
- “Framework” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
- The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
- The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
- A “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
- A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, 5th ed., Bethesda Md. (1991), NIH Publication 91-3242, Vols. 1-3. In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., supra.
- A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.
- The term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence (“complementarity determining regions” or “CDRs”) and/or form structurally defined loops (“hypervariable loops”) and/or contain the antigen-contacting residues (“antigen contacts”). Generally, antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). Exemplary HVRs herein include:
- (a) hypervariable loops occurring at amino acid residues 26-32 (L), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987));
- (b) CDRs occurring at amino acid residues 24-34 (L), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991));
- (c) antigen contacts occurring at amino acid residues 27c-36 (L), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)); and
- (d) combinations of (a), (b), and/or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3), and 94-102 (H3).
- Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.
- An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
- An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.
- An “isolated” antibody is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman, S. et al., J. Chromatogr. B 848 (2007) 79-87.
- An “isolated” nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
- “Isolated nucleic acid encoding an anti-TPBG antibody” refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.
- The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
- “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.
- The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
- “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
- In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
-
100 times the fraction X/Y - where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.
- The term “pharmaceutical formulation” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
- A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
- The term “TPBG,” as used herein, refers to any native TPBG from any vertebrate source, including mammals such as primates (e.g. humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed TPBG as well as any form of TPBG that results from processing in the cell. The term also encompasses naturally occurring variants of TPBG, e.g., splice variants or allelic variants. The amino acid sequence of an exemplary human TPBG is shown in SEQ ID NO: 1. The amino acid sequence of an exemplary minipig TPBG is shown in SEQ ID NO: 2.
- As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.
- The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt, T. J. et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., N.Y. (2007), page 91) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano, S. et al., J. Immunol. 150 (1993) 880-887; Clackson, T. et al., Nature 352 (1991) 624-628).
- The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors”.
- “Cancer” as used herein include both solid and haematologic cancers, such as lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumours, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of the above cancers.
- Pseudomonas Exotoxin A:
- Native, wild-type Pseudomonas exotoxin A is a 66 kD bacterial toxin secreted by Pseudomonas aeruginosa, having the 613 amino acid sequence shown in SEQ ID NO:52 and also disclosed in U.S. Pat. No. 5,602,095. This sequence is shown without the native signal peptide, which is shown as the first 25 amino acids of UniProt accession number P11439.2 (gi: 12231043).
- The native protein has three major structural domains. The N-terminal domain I comprises two subdomains Ia (amino acids 1-252) and Ib (amino acids 365-399) that are structurally adjacent but separated in the primary amino acid sequence.
- Domain I and in particular domain Ia is the cell-binding domain. The function of domain Ib remains undefined. Domain I forms the major component of the B subunit. In the practice of the present invention, forms of PE in which the native domain Ia sequence is omitted or disrupted, and which consequently are unable to bind to LRP1 or LRP1B, are greatly preferred.
- Domain II (amino acids 253-364) has been reported to mediate translocation into the cytosol, but this remains controversial (Weldon & Pastan 2011 FEBS J 278(23):4683-4700).
- Domain III (amino acids 400-613) mediates ADP ribosylation of
elongation factor 2. The structural boundary between domain Ib and domain III is not fully settled. According to WO2013/040141 it lies betweenresidues 399 and 400, but Weldon and Pastan 2011 place it between residues 404 and 405. However, full catalytic activity requires a portion of domain Ib as well as domain III. Accordingly, the functional domain III of the native toxin is defined to start at residue 395. Amino acids 602-613 have been found to be inessential for NAD(+)-ribosyltransferase activity, but amino acids 609-613 of the native sequence are required for cytotoxic activity. These form an endoplasmic reticulum localisation sequence (WO 91/09948, Chaudhary et al 1991 Proc. Natl. Acad. Sci. USA 87: 308-312, Seetharam et al. 1991 J. Biol. Chem. 266: 17376-17381). Cytotoxicity can be maintained or enhanced by replacing the native ER localisation sequence with one or more other ER localisation sequences. Accordingly the functional domain III of native PE is considered to consist of residues 395-601. - An extensive body of work has been published disclosing variants and improvements of the native PE molecule for use in targeted cytotoxins. The terms “Pseudomonas exotoxin A”, “Pseudomonas exotoxin”, “exotoxin A chain (from Pseudomonas aeruginosa)” and “PE” as used herein are intended to encompass these and other variants and improvements of native PE that retain cytotoxic activity. In particular, the terms “Pseudomonas exotoxin A”, “Pseudomonas exotoxin” and “PE” are specifically intended to include the variants and improvements disclosed in WO88/02401A1, WO90/12592A1, WO91/09949, WO91/09965, WO93/25690, WO97/13529, WO98/20135, WO2005/052006, WO2007/016150, WO2007/031741, WO2009/32954, WO2011/32022, WO2012/154530, WO2012/170617, WO2013/40141, Mazor R, et al PNAS 111 (2014) 8571-8576, and Alewine C, et al, Mol Cancer Ther. (2014) 2653-61 and WO2015/051199. All these publications are incorporated herein in their entirety for the purpose of exemplifying variants and improvements of Pseudomonas exotoxin A/PE that are suitable for use in the present invention and that are included, without limitation, within the terms “Pseudomonas exotoxin A”, “Pseudomonas exotoxin” and “PE”, with those variants and improvements disclosed in WO2005/052006, WO2007/016150, WO2007/031741, WO2009/32954, WO2011/32022, WO2012/154530, WO2012/170617, and WO2013/40141 being preferred and those disclosed in WO2009/32954, WO2011/32022, WO2012/154530, WO2012/170617, WO2013/40141, Mazor R, et al PNAS 111 (2014) 8571-8576, and Alewine C, et al, Mol Cancer Ther. (2014) 2653-61 and WO2015/051199 being particularly preferred.
- It is anticipated that further variants and improvements of PE will be developed in future. Since the present invention relates to resistance against the cytotoxic effects of PE, it is anticipated that any such future variants and improvements of PE that retain cytotoxic activity may also be used in the practice of the invention and are therefore included within the terms “Pseudomonas exotoxin A” and “PE”.
- Generally, a PE toxin will have a polypeptide sequence comprising a PE functional domain III having at least 50% amino acid sequence identity over the full length of residues 395-601 of SEQ ID NO: 52, wherein the PE toxin has cytotoxic activity when introduced into a eukaryotic (preferably mammalian) cell. Preferred forms of PE comprise (1) a PE functional domain III having at least 50% amino acid sequence identity over the full length of residues 395-601 of SEQ ID NO: 52 and having NAD(+)-diphthamide ADP ribosyltransferase activity, and (2) at least one endoplasmic reticulum localisation sequence. In embodiments in which the PE is coupled to a cell-binding agent as a fusion polypeptide, the PE preferably also comprises (3) a cleavable linker sequence such as a furin-cleavable sequence (FCS) that permits cleavage of the PE functional domain III from the cell-binding agent following uptake into the target cell.
- The cleavable linker (such as an FCS) will generally be on the N-terminal side of the PE functional domain III.
- Other cleavable linkers may be used provided that they permit cleavage of the PE from the cell-binding agent following uptake into the target cell. Furthermore, other means of coupling the PE to the cell-binding agent are contemplated, provided again that they permit separation of the PE from the cell-binding agent following uptake into the target cell. For example, the cell-binding agent may be non-covalently linked to the PE, or linked by disulfide bonds which permit release of the PE moiety under reducing conditions, or linked by other conjugation chemistries that are known in the field of immunoconjugate production.
- The PE for use in accordance with the present invention will generally lack a functional cell-binding domain I.
- Much of the work on PE has focussed on eliminating portions of the native sequence that are unnecessary and/or disadvantageous for use in targeted therapies. For example, replacement of the B (receptor-binding) subunit with another cell-binding agent has reduced the non-specific toxicity of the molecule. Further removal of inessential sequences has reduced immunogenicity. This has led in particular to the development of the following truncated forms of PE: PE40, PE35, PE38, PE38QQR, PE-LR and PE24. PE40 is a truncated derivative of PE (Pai et al 1991 Proc. Natl. Acad. Sci. USA 88:3358-62 and Kondo et al. 1988 J. Biol. Chem. 263:9470-9475). PE35 is a 35 kD carboxyl-terminal fragment of PE in which amino acid residues 1-279 have been deleted and the molecule commences with a Met at position 280 followed by amino acids 281-364 and 381-613 of PE as defined by reference to SEQ ID NO: 52. PE35 and PE40 are disclosed, for example, in U.S. Pat. Nos. 5,602,095, 4,892,827, WO93/25690 and WO88/02401, each of which is incorporated herein by reference in its entirety.
- PE38 contains the translocating and ADP ribosylating domains of PE but not the cell-binding portion (Hwang et al. 1987 Cell 48:129-136). PE38 (SEQ ID NO: 53) is a truncated PE pro-protein composed of amino acids 253-364 and 381-613 of SEQ ID NO: 52 which is activated to its cytotoxic form upon processing within a cell (see U.S. Pat. No. 5,608,039, which is incorporated by reference in its entirety herein, and Pastan et al. 1997 Biochim. Biophys. Acta, 1333:C1-C6). PE38QR is a variant of PE38 having mutations of the lysines at positions 590, 606 and 613 of domain III, to permit conjugation to antibodies.
- PE-LR contains a deletion of domain II except for a furin-cleavable sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 52 (RHRQPRGWEQL (SEQ ID NO: 54)) and a deletion of amino acid residues 365-394 of domain 1b. Thus, PE-LR contains amino acid residues 274-284 and 395-613 of SEQ ID NO: 52. PE-LR is described in WO 2009/032954 and Weldon et al 2009 Blood 113:3792-3800, which are each incorporated herein by reference in their entirety.
- WO2012/154530 describes that the addition of a short, flexible linker of between 3 and 8 amino acids each independently selected from glycine and serine between the FCS and the PE functional domain III improves the cytotoxicity of the PE-LR molecule without disrupting binding by furin. Exemplary linkers are GGS and GGSGGS (SEQ ID NO: 55).
- Other work has sought to further reduce the immunogenicity of PE.
- WO2012/154530 reports that substitutions at the following amino acid residues within PE domain III reduce immunogenicity:
-
- D403, D406, R412, R427, E431, R432, R458, D461, R467, R490, R505, R513, E522, R538, E548, R551, R576, K590, Q592 and L597.
- Preferred substitutions are with a glycine, serine or alanine residue.
- WO2012/170617 reports that substitutions at these residues may reduce immunogenicity of B cell epitopes, and that substitutions at one or more of residues R427, R458, R467, R490, R505 and F538 are preferred, particularly with alanine.
- WO2013/040141 reports that substitutions at the following additional amino acid residues may reduce the immunogenicity of B cell epitopes within PE domain III:
-
- E420, D463, Y481, L516, R563, D581, D589 and K606.
- Preferred substitutions are with a glycine, serine, alanine or glutamine residue.
- WO2012/170617 reports that substitutions at the following residues can reduce the immunogenicity of T-cell epitopes within PE domain III:
-
- R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556 and W558.
- Preferred substitutions are at one or more of residues D463, Y481 and L516, which may also reduce the immunogenicity of B cell epitopes. Preferred substitutions are with a glycine, serine, alanine or glutamine residue.
- WO2012/170617 also reports that substitutions at the following amino acid residues can reduce the immunogenicity of T cell epitopes within PE domain II:
-
- L294, L297, Y298, L299 and R302.
- Preferred substitutions are with a glycine, serine, alanine or glutamine residue.
- WO2012/170617 also reports that substitutions at the following amino acid residues can reduce the immunogenicity of B cell epitopes within PE domain II:
-
- E282, E285, P290, R313, N314, P319, D324, E327, E331 and Q332.
- WO2012/170617 also reports that a particularly preferred combination of substitutions is D463A/R427A/R458A/R467A/R490A/R505A/R538A.
- Alewine et al. 2014 Mol. Cancer Ther. 13(11): 2653-61 discloses a similar combination of 7 point mutations within PE domain III that reduce B-cell immunogenicity, namely R427A/R456A/D463A/R467A/R490A/R505A/R538A (that is, with R456A instead of R458A).
- Mazor et al. Proc. Natl. Acad. Sci. USA 111(23): 8571-8576 discloses that a combination of 6 point mutations within PE domain III, together with deletion of most of PE domain II, reduced T cell responses by 93%. The mutations are R427A/F443A/L477H/R494A/R505A/L552E.
- Accordingly, the PE functional domain III may comprise mutations at any one or any combination of more than one of the following sites:
-
- D403, D406, R412, E420, R421, L422, L423, A425, R427, L429, E431, R432, Y439, H440, F443, L444, A446, A447, I450, R456, R458, D461, 463-519 (preferably D463, R467, L477, Y481, R490, R494, R505, R513 and/or L516), E522, R538, E548, R551, L552, T554, I555, L556, W558, R563, R576, D581, D589, K590, Q592, L597 and K606.
- Preferably the mutation(s) reduce(s) the immunogenicity compared to the unmutated sequence of the amino acids 395-613 of SEQ ID NO: 52.
- Insofar as the PE contains some or all of domain II, it may comprise mutations at any one or any combination of more than one of the following sites:
-
- E282, E285, P290, L294, L297, Y298, L299, R302, R313, N314, P319, D324, E327, E331 and Q332.
- Preferably the mutation(s) reduce(s) the immunogenicity compared to the unmutated sequence from domain II.
- In particular, in embodiments in which the FCS is derived from the native furin-cleavable sequence of PE consisting of amino acids 274-284 (RHRQPRGWEQL, SEQ ID NO: 54) may comprise a substitution of the E282 residue, especially if the adjacent sequence from the native PE sequence is included downstream of the FCS. In embodiments where the adjacent sequence from the native PE sequence is not included (such as PE-LR, in which the FCS is fused to domain III either directly or via a non-native linker sequence), the epitope from the native sequence may anyway be disrupted such that a mutation at the E282 residue may not be advantageous.
- Mazor et al. 2014 Proc. Natl. Acad. Sci. USA 111(23): 8571-8576, Liu et al. 2012 Proc. Natl. Acad. Sci. USA 109(29): 11782-7, Kreitman et al. 2012 J. Clin. Oncol. 30(15): 1822-8, Pastan et al. 2011 Leukemia & Lymphoma 52 Suppl 2:87-90, Onda et al. 2011 Proc. Natl. Acad. Sci. USA 108(14): 5742-7, Hansen et al. 2010 Journal of Immunotherapy 33(3): 297-304, Kreitman et al. 2009 Clin Cancer Res. 15:5274-5279, Onda et al. 2008 Proc. Natl. Acad. Sci. USA 105(32): 11311-6, Ho et al. 2005 Clin. Cancer Res. 11(10): 3814-20, Kreitman et al. 2000 J Clin Oncol. 18:1622-1636 and Roscoe et al. 1994 Infection and Immunity 62(11): 5055-65 are all directed towards reducing the immunogenicity of PE.
- Reduced immunogenicity in variant PE toxins may refer to a reduced ability of the variant sequence to induce a T cell response and/or a reduced ability of the variant sequence to induce a B cell (antibody) response, preferably both. Techniques for assessing the effect of mutations on T cell immunogenicity are well known in the art and described in the examples of WO 2012/170617. Techniques for assessing the effect of mutations on the B cell immunogenicity are likewise well known in the art and described in WO 2013/040141, for example. Human antibodies may be raised against the native PE sequence by phage display using a human antibody library. The ability of mutations in the PE sequence to disrupt binding of such antibodies to the variant PE molecule is indicative of reduced immunogenicity. Alternatively, the titre of PE-specific antibodies raised in transgenic mice carrying the human antibody repertoire may be compared for the native and mutated PE sequences.
- The C-terminal end of the PE functional domain III may contain the native sequence of residues 609-613, namely REDLK (SEQ ID NO: 55). Additionally or alternatively to any other modifications of the native PE sequence, the PE functional domain III may contain a variant of the REDLK sequence, or other sequences, that function to maintain the PR protein in the endoplasmic reticulum or to recycle proteins into the endoplasmic reticulum. Such sequences are referred to here as “endoplasmic reticulum localisation sequences” or “ER localisation sequences”. Preferred ER localisation sequences include such as KDEL (SEQ ID NO: 57), REDL (SEQ ID NO: 58), RDEL (SEQ ID NO: 59) or KEDLK (SEQ ID NO: 60). One or more additional ER localisation sequences, preferably independently selected from KDEL, REDL, REDLK, RDEL and KEDLK, may be added to the C-terminal end of the PE polypeptide sequence. The substitution of KDEL, or 2 or 3 tandem repeats of KDEL (KDELKDEL, SEQ ID NO 61; KDELKDELKDEL, SEQ ID NO: 62) for the native REDLK sequence, or the addition of KDEL after the native REDLK sequence is preferred. See for example WO91/099949, Chaudhary et al 1991 Seetharam et al 1991.
- WO91/09949 discloses that the C-terminal end of the PE functional domain III may lack some or all of residues 602-608, which are not essential for the NAD(+)-diphthamide ADP ribosyltransferase activity.
- Furin-Cleavable Sequence (FCS):
- As described in WO2012/154530, the furin-cleavable sequence can be any polypeptide sequence cleavable by furin. Duckert et al. 2004, Protein Engineering, Design & Selection 17(1):107-112 (hereafter, “Duckert et al.”) is incorporated herein by reference in its entirety and particularly with regard to the furin-cleavable sequences and motifs it discloses. Duckert et al. discloses that furin is an enzyme in a family of evolutionarily conserved dibasic- and monobasic-specific CA2+-dependent serine proteases called substilisin/kexin-like proprotein convertases. See page 107. Furin, also known as “paired basic amino acid cleaving enzyme”, “PACE”, or PCSK3, is one of several mammalian members of the PCSK family and is involved in processing several endogenous human proteins. See generally, Thomas 2002 Nat Rev Mol Cell Biol 10:753-66. It is a membrane-associated protein found mainly in the trans-Golgi network. The sequence of human furin has been known since the early 1990s. See for example Hatsuzawa et al. 1992 J Biol Chem 267: 16094-16099; and Molloy et al. 1992 J Biol Chem 267:16396-16402.
- The minimal furin-cleavable sequence typically is, in the single letter code for amino acid residues, R-X-X-R (SEQ ID NO: 63), with cleavage occurring after the second “R”. Duckert et al. summarizes the information available on the sequences of 38 proteins reported in the literature to have furin-cleavable sequences, including mammalian proteins, proteins of pathogenic bacteria, and viral proteins. It reports that 31, or 81%, of the cleavage motifs reviewed had the R-X-[R/K]-R (SEQ ID NO: 64, SEQ ID NO. 65) consensus sequence, of which 11, or 29%, had R-X-R-R (SEQ ID NO: 65), and 20, or 52%, were R-X-K-R (SEQ ID NO: 64). Three of the cleavage motifs contained only the minimal cleavage sequence. Duckert et al. further aligned the motifs and identified the residues found at each position in each furin both for the cleavage motif itself and in the surrounding residues.
FIG. 1A of Duckert et al. shows by relative size the residues most commonly found at each position. By convention, the residues surrounding the furin cleavage site are numbered from the scissile bond (which is typically indicated by a downward arrow). Counting toward the N terminus, the substrate residues are designated P1, P2, and so on, while counting towards the C-terminus, the residues are designated P1′, P2′, and so on. See Rockwell and Thorner 2004 Trends Biochem. Sci. 29:80-87; and Thomas 2002 Nat. Rev. Mol. Cell Biol 3:753-766. Thus, following the convention, the following sequence can be used to align and number the residues of the minimal cleavage sequence and the surrounding residues: -
- P6-P5-P4-P3-P2-P1-P1′-P2′-P3′-P4′-P5′,
- in which the minimal furin-cleavable sequence is numbered as P4-P1. Duckert et al.'s alignment of 38 sequences cleaved by furin identifies the variations permitted depending on the residues present at various positions. For example, if the residue at P4 is not an R, that can be compensated for by having arginine or lysine residues at P2 and P6. See page 109.
- In native PE, furin cleavage occurs between arginine 279 and glycine 280 in an arginine-rich loop located in domain II of the toxin. The native furin-cleavable sequence in domain II of PE is set forth below (with numbers indicating the positions of the residues in the 613-amino acid native PE sequence), and aligned to show its numbering under the convention noted above:
- 274-R H R Q P R G W E Q L-284 (SEQ ID NO: 66)
-
- P6--P5--P4--P3--P2--P1--P1′-P2′-P3′-P4′-P5′
- In studies underlying WO2012/154530, substitutions were made at positions P3 and P2 to form the following sequence, with the substitutions underlined:
-
- 274-R H R S K R G W E Q L-284 (SEQ ID NO: 67).
- This sequence has shown a cleavage rate faster than that of the native sequence, and when used in an exemplary immunotoxin resulted in cytotoxicity to target cells approximately the same as that of the native sequence.
- Based on this and previous studies, a furin-cleavable sequence used to attach the targeting molecule to PE domain III can be the minimal furin-cleavable sequence, R-X-X-R (wherein each X is independently any naturally occurring amino acid), preferably R-X-[R/K]-R (wherein X is any naturally occurring amino acid and [R/K] denotes either arginine or lysine), or any of the other furin-cleavable sequences known in the art or permitted by FIG. 1 A of Duckert et al., with the proviso that, if there is a residue present at the position identified as P2′, it should be tryptophan or, if not tryptophan, should not be valine or alanine. For example, in some embodiments, the sequence can be RKKR (SEQ ID NO: 68), RRRR (SEQ ID NO: 69), RKAR (SEQ ID NO: 70), SRVARS (SEQ ID NO: 71), TSSRKRRFW (SEQ ID NO: 72), or ASRRKARSW (SEQ ID NO: 73).
- As noted in Duckert et al., a less favorable residue than R (primarily valine) can be used position P4 if compensated for by arginine or lysine residues at positions P2 and P6, so that at least two of the three residues at P2, P4 and P6 are basic. Thus, in some embodiments, the furin-cleavable sequence is RRVKKRFW (SEQ ID NO: 74), RNVVRRDW (SEQ ID NO: 75), or TRAVRRRSW (SEQ ID NO: 76). The residue at position PI can be the arginine present in the native sequence, or lysine. Thus, a lysine can be substituted for the arginine at position PI in, for example, any the sequences set forth above.
- In some embodiments, the furin-cleavable sequence contains the native furin-cleavable sequence of PE: R-H-R-Q-P-R-G-W-E-Q-L (SEQ ID NO: 66) or a truncated version of the native sequence, so long as it contains the minimal furin-cleavable sequence and is cleavable by furin. Thus, in some embodiments, the furin-cleavable sequence can be RQPR (SEQ ID NO: 77), RHRQPRGW (SEQ ID NO: 78), RHRQPRGWE (SEQ ID NO: 79), HRQPRGWEQ (SEQ ID NO: 80), or RQPRGWE (SEQ ID NO: 81). In some embodiments, the sequence is RHRSKRGWEQL (SEQ ID NO: 67) or a truncated version of this sequence, so long as it contains the minimal furin-cleavable sequence and is cleavable by furin. Thus, in some embodiments, the furin-cleavable sequence can be RSKR (SEQ ID NO: 82), RHRSKRGW (SEQ ID NO: 83), HRSKRGWE (SEQ ID NO: 84), RSKRGWEQL (SEQ ID NO: 85), HRSKRGWEQL (SEQ ID NO: 86), or RHRSKR (SEQ ID NO: 87).
- As mentioned above, the E282 residue at the P3′ position of FCS sequences derived from PE may be replaced by another amino acid to reduce B cell immunogenicity. Where the sequence lacks native PE residues downstream of this residue, or where the FCS contains other mutations relative to the native PE sequence, such replacement may not be necessary.
- Whether or not any particular sequence is cleavable by furin can be determined by methods known in the art. For example, whether or not a sequence is cleavable by furin can be tested by incubating the sequence with furin in furin buffer (0.2 M NaOAc (pH 5.5), 5 mM CaCl2) at a 1:10 enzyme:substrate molar ratio at 25° C. for 16 hours. These conditions have previously been established as optimal for furin cleavage of PE. Preferably, the furin used is human furin. Recombinant truncated human furin is commercially available, for example, from New England Biolabs (Beverly, Mass.). See also, Bravo et al. 1994 J Biol Chem 269(14):25830-25837.
- Alternatively, a furin-cleavable sequence can be tested by making it into an immunotoxin with an antibody against a cell surface protein and testing the resulting immunotoxin on a cell line expressing that cell surface protein. Suitable antibody sequences are disclosed in, for example, WO2012/154530 and WO2009/032954.
- General Formula for Preferred PE Toxins
- Preferred PE toxins for use in accordance with the present invention have the following structure:
-
- FCSl-R1 m-R2 n-R3 p-PE functional domain III-R4 q
- wherein:
- l, m, n, p and q are each, independently, 0 or 1;
- FCS is a furin-cleavable sequence, preferably (i) R-H-R-Q-P-R-G-W-E-Q-L or a truncated version thereof containing R-Q-P-R, optionally R-Q-P-R, R-H-R-Q-P-R-G-W, R-H-R-Q-P-R-G-W-E, H-R-Q-P-R-G-W-E-Q, or R-Q-P-R-G-W-E; or (ii) R-H-R-S-K-R-G-W-E-Q-L or a truncated version thereof containing R-S-K-R, optionally R-S-K-R, R-H-R-S-K-R-G-W, H-R-S-K-R-G-W-E, R-S-K-R-G-W-E-Q-L, H-R-S-K-R-G-W-E-Q-L, or R-H-R-S-K-R, wherein the glutamic acid residue corresponding to position 282 of the native PE sequence (where present) is optionally replaced by another residue, preferably glycine, serine, alanine or glutamine;
- R1 is a linker sequence of 1 to 10 amino acids, preferably GGS or GGSGGS;
- R2 is one or more consecutive amino acid residues of residues 285-364 of SEQ ID NO:52, in which any one or more of residues E285, P290, L294, L297, Y298, L299, R302, R313, N314, P319, D324, E327, E331 and Q332, where present, is/are optionally independently replaced by another amino acid, preferably glycine, serine, alanine or glutamine;
- R3 is one or more consecutive amino acid residues of residues 365-394 of SEQ ID NO:52;
- PE functional domain III comprises residues 395-613 of SEQ ID NO:52 in which:
- (a) some or all of residues 602-608 are optionally deleted, and
- (b) residues 609-613 are optionally replaced by another ER localisation sequence, preferably KDEL, REDL, RDEL or KEDLK, and
- (c) any one or more of residues D403, D406, R412, E420, R421, L422, L423, A425, R427, L429, E431, R432, Y439, H440, F443, L444, A446, A447, I450, R456, R458, D461, 463-519 (preferably D463, R467, L477, Y481, R490, R494, R505, R513 and/or L516), E522, R538, E548, R551, L552, T554, I555, L556, W558, R563, R576, D581, D589, K590, Q592, L597 and (where present) K606 is/are optionally independently replaced by another amino acid, preferably glycine, serine, alanine or glutamine, or histidine in the case of L477;
- R4 is one or more (preferably 1 or 2) additional ER localisation sequences, preferably REDLK, KDEL, REDL, RDEL or KEDLK.
- Within the formula above:
-
- l is preferably 1; that is, an FCS is preferably present;
- m is preferably 1; that is, a linker is preferably present especially in the case that 1 is 1;
- n is preferably 0; that is, residues 285-364 of SEQ ID NO:1 are preferably absent;
- p is preferably 0; that is residues 365-394 of SEQ ID NO:1 are preferably absent;
- PE functional domain III preferably includes the combination of mutations R427A/F443A/L477H/R494A/R505A/L552E, or the combination of mutations R427A/R456A/D463A/R467A/R490A/R505A/R538A, or the combination of mutations R427A/F443A/R456A/D463A/R467A/L477H/R490A/R494A/R505A/R538A/L552E.
- Particularly preferred PE toxins for use in accordance with the present invention comprise the amino acid sequence corresponding to amino acid residues 395-613 of SEQ ID NO: 52 with Ala substitutions at positions 427, 456, 463, 467, 490, 505 and 538 (as disclosed in WO2015/51199 as LO10R-456A and SEQ ID NO:37) or the amino acid sequence corresponding to amino acid residues 395-613 of SEQ ID NO: 52 with Ala substitutions at positions 427, 443, 477, 494, 505 and 552 (as is disclosed in WO2015/051199 as T18/T20 and SEQ ID NO:289).
- In one aspect, the invention is based, in part, on antibodies that are crossreactive with human and minipig TPGF. In certain embodiments, antibodies that bind to human TPBG at neutral as well as at slightly acidic pH are provided. Antibodies of the invention are useful, e.g., for the diagnosis or treatment of cancer.
- A. Exemplary Anti-TPBG Antibodies
- In one aspect, the invention provides isolated antibodies that bind to TPBG. In certain embodiments, an anti-TPBG antibody of the invention binds to human TPBG according to SEQ ID NO: 1 and binds to to minipig TPBG according to SEQ ID NO: 2. In certain embodiments, an anti-TPBG antibody of the invention binds to human TPBG at a pH of 5.5 and at a pH of 7.2.
- In one aspect, the invention provides an anti-TPBG antibody comprising at least one, two, three, four, five, or six CDRs selected from (a) CDR1 of the heavy chain of SEQ ID NO: 3, (b) CDR2 of the heavy chain of SEQ ID NO: 4, (c) CDR3 of the heavy chain of SEQ ID NO: 5, (d) CDR1 of the light chain of SEQ ID NO: 6, (e) CDR2 of the light chain of SEQ ID NO: 7, and (f) CDR3 of the light chain of SEQ ID NO: 8 (corresponding to the aforementioned CDRs of the antibody “051” as disclosed herein).
- In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR1 of the heavy chain of SEQ ID NO: 3, (b) CDR2 of the heavy chain of SEQ ID NO: 4, (c) CDR3 of the heavy chain of SEQ ID NO: 5 (corresponding to the aforementioned CDRs of the antibody “051” as disclosed herein). In one embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 5. In another embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 5 and CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8. In a further embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 5, CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 5, and CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 4. In a further embodiment, the antibody comprises (a) CDR3 of the heavy chain of SEQ ID NO: 5, (b) CDR3 of the light chain of SEQ ID NO: 8, and (c) CDR2 of the heavy chain of SEQ ID NO: 4.
- In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8. In one embodiment, the antibody comprises (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 4, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 5; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- In another aspect, the invention provides an antibody comprising (a) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, (b) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 4, and (c) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 5, (d) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6, (e) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7, and (f) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8. In one embodiment, the anti-TPBG antibody is a humanized antibody derived from an antibody comprising the aforementioned CDRs.
- In one aspect, the invention provides an anti-TPBG antibody comprising at least one, two, three, four, five, or six CDRs selected from (a) CDR1 of the heavy chain of SEQ ID NO: 11, (b) CDR2 of the heavy chain of SEQ ID NO: 12, (c) CDR3 of the heavy chain of SEQ ID NO: 13, (d) CDR1 of the light chain of SEQ ID NO: 14, (e) CDR2 of the light chain of SEQ ID NO: 15, and (f) CDR3 of the light chain of SEQ ID NO: 16 (corresponding to the aforementioned CDRs of the antibody “091” as disclosed herein).
- In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR1 of the heavy chain of SEQ ID NO: 11, (b) CDR2 of the heavy chain of SEQ ID NO: 12, (c) CDR3 of the heavy chain of SEQ ID NO: 13 (corresponding to the aforementioned CDRs of the antibody “091” as disclosed herein). In one embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 13. In another embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 13 and CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16. In a further embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 13, CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 13, and CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 12. In a further embodiment, the antibody comprises (a) CDR3 of the heavy chain of SEQ ID NO: 13, (b) CDR3 of the light chain of SEQ ID NO: 16, and (c) CDR2 of the heavy chain of SEQ ID NO: 12.
- In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16. In one embodiment, the antibody comprises (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 11, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 13; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- In another aspect, the invention provides an antibody comprising (a) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 11, (b) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and (c) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 13, (d) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14, (e) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15, and (f) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16. In one embodiment, the anti-TPBG antibody is a humanized antibody derived from an antibody comprising the aforementioned CDRs.
- In one aspect, the invention provides an anti-TPBG antibody comprising at least one, two, three, four, five, or six CDRs selected from (a) CDR1 of the heavy chain of SEQ ID NO: 19, (b) CDR2 of the heavy chain of SEQ ID NO: 20, (c) CDR3 of the heavy chain of SEQ ID NO: 21, (d) CDR1 of the light chain of SEQ ID NO: 22, (e) CDR2 of the light chain of SEQ ID NO: 23, and (f) CDR3 of the light chain of SEQ ID NO: 24 (corresponding to the aforementioned CDRs of the antibody “097” as disclosed herein).
- In one aspect, the invention provides an antibody comprising at least one, at least two, or all three VH CDR sequences selected from (a) CDR1 of the heavy chain of SEQ ID NO: 19, (b) CDR2 of the heavy chain of SEQ ID NO: 20, (c) CDR3 of the heavy chain of SEQ ID NO: 21 (corresponding to the aforementioned CDRs of the antibody “097” as disclosed herein). In one embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 21. In another embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 21 and CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24. In a further embodiment, the antibody comprises CDR3 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 21, CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 21, and CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 20. In a further embodiment, the antibody comprises (a) CDR3 of the heavy chain of SEQ ID NO: 21, (b) CDR3 of the light chain of SEQ ID NO: 24, and (c) CDR2 of the heavy chain of SEQ ID NO: 20.
- In another aspect, the invention provides an antibody comprising at least one, at least two, or all three VL CDR sequences selected from (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24. In one embodiment, the antibody comprises (a) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22; (b) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23; and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- In another aspect, an antibody of the invention comprises (a) a VH domain comprising at least one, at least two, or all three VH CDR sequences selected from (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 19, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 21; and (b) a VL domain comprising at least one, at least two, or all three VL HVR sequences selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- In another aspect, the invention provides an antibody comprising (a) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 19, (b) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and (c) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 21, (d) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22, (e) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23, and (f) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24. In one embodiment, the anti-TPBG antibody is a humanized antibody derived from an antibody comprising the aforementioned CDRs.
- In any of the above embodiments, an anti-TPBG antibody is humanized. In one embodiment, an anti-TPBG antibody comprises CDRs as in any of the above embodiments, and further comprises an acceptor human framework, e.g. a human immunoglobulin framework or a human consensus framework.
- In another aspect, an anti-TPBG antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 9 (corresponding to the variable heavy chain domain of the antibody “051” as disclosed herein). In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to TPBG. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 9. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-TPBG antibody comprises the VH sequence in SEQ ID NO: 9, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three CDRs selected from: (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 3, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 4, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 5.
- In another aspect, an anti-TPBG antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 10. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to PRO. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 10. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-TPBG antibody comprises the VL sequence in SEQ ID NO: 10, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 6, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 7, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 8.
- In another aspect, an anti-TPBG antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 9 and SEQ ID NO: 10, respectively, including post-translational modifications of those sequences.
- In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-TPBG antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-TPBG antibody comprising a VH sequence of SEQ ID NO: 9 and a VL sequence of SEQ ID NO: 10.
- In another aspect, an anti-TPBG antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 17 (corresponding to the variable heavy chain domain of the antibody “091” as disclosed herein). In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to TPBG. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 17. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-TPBG antibody comprises the VH sequence in SEQ ID NO: 17, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three CDRs selected from: (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 11, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 13.
- In another aspect, an anti-TPBG antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 18. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to PRO. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 10. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-TPBG antibody comprises the VL sequence in SEQ ID NO: 18, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 14, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 15, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 16.
- In another aspect, an anti-TPBG antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 17 and SEQ ID NO: 18, respectively, including post-translational modifications of those sequences.
- In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-TPBG antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-TPBG antibody comprising a VH sequence of SEQ ID NO: 17 and a VL sequence of SEQ ID NO: 18.
- In another aspect, an anti-TPBG antibody comprises a heavy chain variable domain (VH) sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 25 (corresponding to the variable heavy chain domain of the antibody “097” as disclosed herein). In certain embodiments, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to TPBG. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 25. In certain embodiments, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-TPBG antibody comprises the VH sequence in SEQ ID NO: 25, including post-translational modifications of that sequence. In a particular embodiment, the VH comprises one, two or three CDRs selected from: (i) CDR1 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 19, (ii) CDR2 of the heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and (iii) CDR3 of the heavy chain comprising an amino acid sequence selected from SEQ ID NO: 21.
- In another aspect, an anti-TPBG antibody is provided, wherein the antibody comprises a light chain variable domain (VL) having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 26. In certain embodiments, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-TPBG antibody comprising that sequence retains the ability to bind to PRO. In certain embodiments, a total of 1 to 10 amino acids have been substituted, inserted and/or deleted in SEQ ID NO: 10. In certain embodiments, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). Optionally, the anti-TPBG antibody comprises the VL sequence in SEQ ID NO: 26, including post-translational modifications of that sequence. In a particular embodiment, the VL comprises one, two or three HVRs selected from (i) CDR1 of the light chain comprising the amino acid sequence of SEQ ID NO: 22, (ii) CDR2 of the light chain comprising the amino acid sequence of SEQ ID NO: 23, and (c) CDR3 of the light chain comprising the amino acid sequence of SEQ ID NO: 24.
- In another aspect, an anti-TPBG antibody is provided, wherein the antibody comprises a VH as in any of the embodiments provided above, and a VL as in any of the embodiments provided above. In one embodiment, the antibody comprises the VH and VL sequences in SEQ ID NO: 25 and SEQ ID NO: 26, respectively, including post-translational modifications of those sequences.
- In a further aspect, the invention provides an antibody that binds to the same epitope as an anti-TPBG antibody provided herein. For example, in certain embodiments, an antibody is provided that binds to the same epitope as an anti-TPBG antibody comprising a VH sequence of SEQ ID NO: 17 and a VL sequence of SEQ ID NO: 18.
- In a further aspect of the invention, an anti-TPBG antibody according to any of the above embodiments is a monoclonal antibody, including a chimeric, humanized or human antibody. In one embodiment, an anti-TPBG antibody is an antibody fragment, e.g., a Fv, Fab, Fab′, scFv, diabody, or F(ab′)2 fragment. In another embodiment, the antibody is a full length antibody, e.g., an intact IgG1 antibody or other antibody class or isotype as defined herein.
- In one embodiment, the invention relates to an isolated antibody that binds to TPBG, wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2.
- The binding of human TPBG at those different pH values may be defined by a “binding ratio”, which is herein defined as the ratio of the mean fluorescence intensity detected by flow cytometry in a cell surface binding assay (in one embodiment an assay as described in Example 18) at pH 7.2 to the mean fluorescence intensity detected by flow cytometry at pH 5.5 (in one embodiment an assay as described in Example 18).
- In one embodiment of the invention, the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2, wherein the binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2. In one embodiment the binding is detected via flow cytometry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2, wherein the binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2. In one embodiment the binding is detected via flow cytometry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2, wherein a binding ratio, which is defined as the ratio of the mean fluorescence intensity detected by flow cytometry in a cell surface binding assay (in one embodiment an assay as described in Example 18) at pH 7.2 to the mean fluorescence intensity detected by flow cytometry at pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2, wherein binding ratio at pH 7.2 to pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2. In one embodiment the binding is detected via flow cytometry and the binding ratio is determined by comparing mean fluorescence intensities as described in Example 18.
- In one embodiment of the invention, the antibody specifically binds to cell surface expressed TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2, wherein a binding ratio, which is defined as the ratio of the mean fluorescence intensity detected by flow cytometry in a cell surface binding assay (in one embodiment an assay as described in Example 18) at pH 7.2 to the mean fluorescence intensity detected by flow cytometry at pH 5.5 is less than 1.5, in one preferred embodiment between 0.8 and 1.5, in another preferred embodiment between 0.9 and 1.2.
- In a further aspect, an anti-TPBG antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below:
- 1. Antibody Affinity
- In certain embodiments, an antibody provided herein has a dissociation constant (Kd) of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g. 10−8 M or less, e.g. from 10−8 M to 10−13 M, e.g., from 10−9 M to 10−13 M).
- In one embodiment, Kd is measured by a radiolabeled antigen binding assay (RIA) performed with the Fab version of an antibody of interest and its antigen as described by the following assay. Solution binding affinity of FABs for antigen is measured by equilibrating Fab with a minimal concentration of (125I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen, Y. et al., J. Mol. Biol. 293 (1999) 865-881). To establish conditions for the assay, MICROTITER® multi-well plates (Thermo Scientific) are coated overnight with 5 μg/ml of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23° C.). In a non-adsorbent plate (Nunc #269620), 100 pM or 26 pM [125I]-antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta, L. G. et al., Cancer Res. 57 (1997) 4593-4599). The Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room temperature (e.g., for one hour). The solution is then removed and the plate washed eight times with 0.1% polysorbate 20 (TWEEN-20®) in PBS. When the plates have dried, 150 μl/well of scintillant (MICROSCINT-20™; Packard) is added, and the plates are counted on a TOPCOUNT™ gamma counter (Packard) for ten minutes. Concentrations of each Fab that give less than or equal to 20% of maximal binding are chosen for use in competitive binding assays.
- According to another embodiment, Kd is measured using surface plasmon resonance assays using a BIACORE®-2000 or a BIACORE®-3000 (BIAcore, Inc., Piscataway, N.J.) at 25° C. with immobilized antigen CM5 chips at ˜10 response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) are activated with N-ethyl-N′-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 μg/ml (˜0.2 μM) before injection at a flow rate of 5 μl/minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20™) surfactant (PBST) at 25° C. at a flow rate of approximately 25 μl/min. Association rates (kon) and dissociation rates (koff) are calculated using a simple one-to-one Langmuir binding model (BIACORE® Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant (Kd) is calculated as the ratio koff/kon. See, e.g., Chen, Y. et al., J. Mol. Biol. 293 (1999) 865-881. If the on-rate exceeds 106 M−1 s−1 by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation=295 nm; emission=340 nm, 16 nm band-pass) at 25° C. of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000-series SLM-AMINCO™ spectrophotometer (ThermoSpectronic) with a stirred cuvette.
- 2. Antibody Fragments
- In certain embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to Fab, Fab′, Fab′-SH, F(ab′)2, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson, P. J. et al., Nat. Med. 9 (2003) 129-134. For a review of scFv fragments, see, e.g., Plueckthun, A., In; The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore (eds.), Springer-Verlag, New York (1994), pp. 269-315; see also WO 93/16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab′)2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Pat. No. 5,869,046.
- Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example,
EP 0 404 097; WO 1993/01161; Hudson, P. J. et al., Nat. Med. 9 (2003) 129-134; and Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448. Triabodies and tetrabodies are also described in Hudson, P. J. et al., Nat. Med. 9 (20039 129-134). - Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, Mass.; see, e.g., U.S. Pat. No. 6,248,516 BI).
- Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.
- 3. Chimeric and Humanized Antibodies
- In certain embodiments, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Pat. No. 4,816,567; and Morrison, S. L. et al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
- In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
- Humanized antibodies and methods of making them are reviewed, e.g., in Almagro, J. C. and Fransson, J., Front. Biosci. 13 (2008) 1619-1633, and are further described, e.g., in Riechmann, I. et al., Nature 332 (1988) 323-329; Queen, C. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033; U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri, S. V. et al., Methods 36 (2005) 25-34 (describing SDR (a-CDR) grafting); Padlan, E. A., Mol. Immunol. 28 (1991) 489-498 (describing “resurfacing”); Dall'Acqua, W. F. et al., Methods 36 (2005) 43-60 (describing “FR shuffling”); and Osbourn, J. et al., Methods 36 (2005) 61-68 and Klimka, A. et al., Br. J. Cancer 83 (2000) 252-260 (describing the “guided selection” approach to FR shuffling).
- Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the “best-fit” method (see, e.g., Sims, M. J. et al., J. Immunol. 151 (1993) 2296-2308; framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter, P. et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; and Presta, L. G. et al., J. Immunol. 151 (1993) 2623-2632); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro, J. C. and Fransson, J., Front. Biosci. 13 (2008) 1619-1633); and framework regions derived from screening FR libraries (see, e.g., Baca, M. et al., J. Biol. Chem. 272 (1997) 10678-10684 and Rosok, M. J. et al., J. Biol. Chem. 271 (19969 22611-22618).
- 4. Human Antibodies
- In certain embodiments, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk, M. A. and van de Winkel, J. G., Curr. Opin. Pharmacol. 5 (2001) 368-374 and Lonberg, N., Curr. Opin. Immunol. 20 (2008) 450-459.
- Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, N., Nat. Biotech. 23 (2005) 1117-1125. See also, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Pat. No. 5,770,429 describing HUMAB® technology; U.S. Pat. No. 7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application Publication No. US 2007/0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.
- Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor, D., J. Immunol. 133 (1984) 3001-3005; Brodeur, B. R. et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York (1987), pp. 51-63; and Boerner, P. et al., J. Immunol. 147 (1991) 86-95) Human antibodies generated via human B-cell hybridoma technology are also described in Li, J. et al., Proc. Natl. Acad. Sci. USA 103 (2006) 3557-3562 Additional methods include those described, for example, in U.S. Pat. No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, J., Xiandai Mianyixue 26 (2006) 265-268 (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers, H. P. and Brandlein, S., Histology and Histopathology 20 (2005) 927-937 and Vollmers, H. P. and Brandlein, S., Methods and Findings in Experimental and Clinical Pharmacology 27 (2005) 185-191.
- Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.
- 5. Library-Derived Antibodies
- Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom, H. R. et al., Methods in Molecular Biology 178 (2001) 1-37 and further described, e.g., in the McCafferty, J. et al., Nature 348 (1990) 552-554; Clackson, T. et al., Nature 352 (1991) 624-628; Marks, J. D. et al., J. Mol. Biol. 222 (1992) 581-597; Marks, J. D. and Bradbury, A., Methods in Molecular Biology 248 (2003) 161-175; Sidhu, S. S. et al., J. Mol. Biol. 338 (2004) 299-310; Lee, C. V. et al., J. Mol. Biol. 340 (2004) 1073-1093; Fellouse, F. A., Proc. Natl. Acad. Sci. USA 101 (2004) 12467-12472; and Lee, C. V. et al., J. Immunol. Methods 284 (2004) 119-132.
- In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter, G. et al., Ann. Rev. Immunol. 12 (1994) 433-455. Phage typically display antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths, A. D. et al., EMBO J. 12 (1993) 725-734. Finally, naive libraries can also be made synthetically by cloning non-rearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom, H. R. and Winter, G., J. Mol. Biol. 227 (1992) 381-388. Patent publications describing human antibody phage libraries include, for example: U.S. Pat. No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.
- Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
- 6. Multispecific Antibodies
- In certain embodiments, an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for TPBG and the other is for any other antigen. In certain embodiments, bispecific antibodies may bind to two different epitopes of TPBG. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express TPBG. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
- Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein, C. and Cuello, A. C., Nature 305 (1983) 537-540, WO 93/08829, and Traunecker, A. et al., EMBO J. 10 (1991) 3655-3659), and “knob-in-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168).
- Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan, M. et al., Science 229 (1985) 81-83); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny, S. A. et al., J. Immunol. 148 (1992) 1547-1553; using “diabody” technology for making bispecific antibody fragments (see, e.g., Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448); and using single-chain Fv (sFv) dimers (see, e.g. Gruber, M et al., J. Immunol. 152 (1994) 5368-5374); and preparing trispecific antibodies as described, e.g., in Tutt, A. et al., J. Immunol. 147 (1991) 60-69).
- Engineered antibodies with three or more functional antigen binding sites, including “Octopus antibodies,” are also included herein (see, e.g. US 2006/0025576).
- The antibody or fragment herein also includes a “Dual Acting Fab” or “DAF” comprising an antigen binding site that binds to TPBG as well as another, different antigen (see, US 2008/0069820, for example).
- The antibody or fragment herein also includes multispecific antibodies described in WO 2009/080251, WO 2009/080252, WO 2009/080253, WO 2009/080254, WO 2010/112193, WO 2010/115589, WO 2010/136172, WO 2010/145792, and WO 2010/145793.
- 7. Antibody Variants
- In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.
- a) Substitution, Insertion, and Deletion Variants
- In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Exemplary changes are provided in the following Table under the heading of “exemplary substitutions”, and as further described below in reference to amino acid side chain classes. Conservative substitutions are shown in Table 1 under the heading of “preferred substitutions”. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.
-
TABLE Original Exemplary Preferred Residue Substitutions Substitutions Ala (A) Val; Leu; Ile Val Arg (R) Lys; Gln; Asn Lys Asn (N) Gln; His; Asp, Lys; Arg Gln Asp (D) Glu; Asn Glu Cys (C) Ser; Ala Ser Gln (Q) Asn; Glu Asn Glu (E) Asp; Gln Asp Gly (G) Ala Ala His (H) Asn; Gln; Lys; Arg Arg Ile (I) Leu; Val; Met; Ala; Phe; Norleucine Leu Leu (L) Norleucine; Ile; Val; Met; Ala; Phe Ile Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe; Ile Leu Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro (P) Ala Ala Ser (S) Thr Thr Thr (T) Val; Ser Ser Trp (W) Tyr; Phe Tyr Tyr (Y) Trp; Phe; Thr; Ser Phe Val (V) Ile; Leu; Met; Phe; Ala; Norleucine Leu - Amino acids may be grouped according to common side-chain properties:
-
- (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
- (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- (3) acidic: Asp, Glu;
- (4) basic: His, Lys, Arg;
- (5) residues that influence chain orientation: Gly, Pro;
- (6) aromatic: Trp, Tyr, Phe.
- Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
- One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).
- Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR “hotspots,” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, P. S., Methods Mol. Biol. 207 (2008) 179-196), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom, H. R. et al. in Methods in Molecular Biology 178 (2002) 1-37. In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.
- In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may be outside of HVR “hotspots” or SDRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.
- A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham, B. C. and Wells, J. A., Science 244 (1989) 1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.
- Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.
- b) Glycosylation Variants
- In certain embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
- Where the antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright, A. and Morrison, S. L., TIBTECH 15 (1997) 26-32. The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an antibody of the invention may be made in order to create antibody variants with certain improved properties.
- In one embodiment, antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ±3 amino acids upstream or downstream of position 297, i.e., between
positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US 2003/0157108; US 2004/0093621. Examples of publications related to “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO 2005/053742; WO 2002/031140; Okazaki, A. et al., J. Mol. Biol. 336 (2004) 1239-1249; Yamane-Ohnuki, N. et al., Biotech. Bioeng. 87 (2004) 614-622. Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka, J. et al., Arch. Biochem. Biophys. 249 (1986) 533-545; US 2003/0157108; and WO 2004/056312, especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki, N. et al., Biotech. Bioeng. 87 (2004) 614-622; Kanda, Y. et al., Biotechnol. Bioeng. 94 (2006) 680-688; and WO 2003/085107). - Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878; U.S. Pat. No. 6,602,684; and US 2005/0123546. Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087; WO 1998/58964; and WO 1999/22764.
- c) Fe Region Variants
- In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.
- In certain embodiments, the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcγR binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express Fc(RIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch, J. V. and Kinet, J. P., Annu. Rev. Immunol. 9 (1991) 457-492. Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Pat. No. 5,500,362 (see, e.g. Hellstrom, I. et al., Proc. Natl. Acad. Sci. USA 83 (1986) 7059-7063; and Hellstrom, I. et al., Proc. Natl. Acad. Sci. USA 82 (1985) 1499-1502); U.S. Pat. No. 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166 (1987) 1351-1361). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTI™ non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, Calif.; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, Wis.). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes, R. et al., Proc. Natl. Acad. Sci. USA 95 (1998) 652-656. C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro, H. et al., J. Immunol. Methods 202 (1996) 163-171; Cragg, M. S. et al., Blood 101 (2003) 1045-1052; and Cragg, M. S. and M. J. Glennie, Blood 103 (2004) 2738-2743). FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S. B. et al., Int. Immunol. 18 (2006: 1759-1769).
- Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA” Fc mutant with substitution of residues 265 and 297 to alanine (U.S. Pat. No. 7,332,581).
- Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Pat. No. 6,737,056; WO 2004/056312, and Shields, R. L. et al., J. Biol. Chem. 276 (2001) 6591-6604)
- In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
- In some embodiments, alterations are made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99/51642, and Idusogie, E. E. et al., J. Immunol. 164 (2000) 4178-4184.
- Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer, R. L. et al., J. Immunol. 117 (1976) 587-593, and Kim, J. K. et al., J. Immunol. 24 (1994) 2429-2434), are described in US 2005/0014934. Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (U.S. Pat. No. 7,371,826).
- See also Duncan, A. R. and Winter, G., Nature 322 (1988) 738-740; U.S. Pat. Nos. 5,648,260; 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.
- d) Cysteine Engineered Antibody Variants
- In certain embodiments, it may be desirable to create cysteine engineered antibodies, e.g., “thioMAbs,” in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, e.g., in U.S. Pat. No. 7,521,541.
- e) Antibody Derivatives
- In certain embodiments, an antibody provided herein may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
- In another embodiment, conjugates of an antibody and non-proteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, N. W. et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.
- B. Recombinant Methods and Compositions
- Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Pat. No. 4,816,567. In one embodiment, isolated nucleic acid encoding an anti-TPBG antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an anti-TPBG antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
- For recombinant production of an anti-TPBG antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
- Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Pat. Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, K. A., In: Methods in Molecular Biology, Vol. 248, Lo, B. K. C. (ed.), Humana Press, Totowa, N.J. (2003), pp. 245-254, describing expression of antibody fragments in E. coli.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
- In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, T. U., Nat. Biotech. 22 (2004) 1409-1414; and Li, H. et al., Nat. Biotech. 24 (2006) 210-215.
- Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
- Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).
- Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham, F. L. et al., J. Gen Virol. 36 (1977) 59-74); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, J. P., Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather, J. P. et al., Annals N.Y. Acad. Sci. 383 (1982) 44-68; MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR− CHO cells (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA 77 (1980) 4216-4220); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, A. M., Methods in Molecular Biology, Vol. 248, Lo, B. K. C. (ed.), Humana Press, Totowa, N.J. (2004), pp. 255-268.
- C. Assays
- Anti-TPBG antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.
- 1. Binding Assays and Other Assays
- In one aspect, an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, Western blot, etc.
- In another aspect, competition assays may be used to identify an antibody that competes with an antibody selected from the group of
antibodies antibodies - In an exemplary competition assay, immobilized TPBG is incubated in a solution comprising a first labeled antibody that binds to TPBG (e.g., an antibody selected from the group of
antibodies - 2. Activity Assays
- In one aspect, assays are provided for identifying anti-TPBG antibodies thereof having biological activity. Biological activity may include, e.g., binding to TPBG-expressing tumor cells. Antibodies having such biological activity in vivo and/or in vitro are also provided.
- In certain embodiments, an antibody of the invention is tested for such biological activity.
- D. Immunoconjugates
- The invention also provides immunoconjugates comprising an anti-TPBG antibody herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes.
- In one embodiment, an immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more drugs, including but not limited to a maytansinoid (see U.S. Pat. Nos. 5,208,020, 5,416,064 and
EP 0 425 235 BI); an auristatin such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see U.S. Pat. Nos. 5,635,483, 5,780,588, and 7,498,298); a dolastatin; a calicheamicin or derivative thereof (see U.S. Pat. Nos. 5,712,374, 5,714,586, 5,739,116, 5,767,285, 5,770,701, 5,770,710, 5,773,001, and 5,877,296; Hinman, L. M. et al., Cancer Res. 53 (1993) 3336-3342; and Lode, H. N. et al., Cancer Res. 58 (1998) 2925-2928); an anthracycline such as daunomycin or doxorubicin (see Kratz, F. et al., Curr. Med. Chem. 13 (2006) 477-523; Jeffrey, S. C. et al., Bioorg. Med. Chem. Lett. 16 (2006) 358-362; Torgov, M. Y. et al., Bioconjug. Chem. 16 (2005) 717-721; Nagy, A. et al., Proc. Natl. Acad. Sci. USA 97 (2000) 829-834; Dubowchik, G. M. et al., Bioorg. & Med. Chem. Letters 12 (2002) 1529-1532; King, H. D. et al., J. Med. Chem. 45 (20029 4336-4343; and U.S. Pat. No. 6,630,579); methotrexate; vindesine; a taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; a trichothecene; and CC1065. - In another embodiment, an immunoconjugate comprises an antibody as described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, nonbinding active fragments of exotoxin A chain (from Pseudomonas aeruginosa), diphtheria toxin, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. In one embodiment the enzymatically active toxin is Pseudomonas exotoxin A or a variant thereof.
- In another embodiment, an immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioactive isotopes are available for the production of radioconjugates. Examples include At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive isotopes of Lu. When the radioconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example TC99m or I123, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.
- Conjugates of an antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as
toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta, E. S. et al., Science 238 (1987) 1098-1104. Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triamine pentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO 94/11026. The linker may be a “cleavable linker” facilitating release of a cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari, R. V. et al., Cancer Res. 52 (1992) 127-131; U.S. Pat. No. 5,208,020) may be used. - The immunuoconjugates or ADCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Ill., U.S.A).
- Conjugates of the antibody and cytotoxic agents, which are polypeptides, may also be provided as recombinant fusion proteins, e.g. by direct expression of said fusion protein within a host cell, thereby not requiring an additional coupling step for provision.
- E. Methods and Compositions for Diagnostics and Detection
- In certain embodiments, any of the anti-TPBG antibodies provided herein is useful for detecting the presence of TPBG in a biological sample. The term “detecting” as used herein encompasses quantitative or qualitative detection. In certain embodiments, a biological sample comprises a cell or tissue, such as tumor cells.
- In one embodiment, an anti-TPBG antibody for use in a method of diagnosis or detection is provided. In a further aspect, a method of detecting the presence of TPBG in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-TPBG antibody as described herein under conditions permissive for binding of the anti-TPBG antibody to TPBG, and detecting whether a complex is formed between the anti-TPBG antibody and TPBG. Such method may be an in vitro or in vivo method. In one embodiment, an anti-TPBG antibody is used to select subjects eligible for therapy with an anti-TPBG antibody, e.g. where TPBG is a biomarker for selection of patients.
- Exemplary disorders that may be diagnosed using an antibody of the invention include cancer, e.g. lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumours, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of the above cancers.
- In certain embodiments, labeled anti-TPBG antibodies are provided. Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes 32P, 14C, 125I, 3H, and 131I, fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, e.g., firefly luciferase and bacterial luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β-galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like.
- F. Pharmaceutical Formulations
- Pharmaceutical formulations of an anti-TPBG antibody as described herein are prepared by mixing such antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyl dimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as poly(vinylpyrrolidone); amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rhuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rhuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
- Exemplary lyophilized antibody formulations are described in U.S. Pat. No. 6,267,958. Aqueous antibody formulations include those described in U.S. Pat. No. 6,171,586 and WO 2006/044908, the latter formulations including a histidine-acetate buffer.
- The formulation herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide a chemotherapeutic agent, preferably a chemotherapeutic agent listed below. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
- Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980).
- Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules.
- The formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
- G. Therapeutic Methods and Compositions
- Any of the anti-TPBG antibodies provided herein, or the recombinant fusion proteins or immunoconjugates comprising the anti-TPBG antibodies provided herein, may be used in therapeutic methods.
- In one aspect, an anti-TPBG antibody for use as a medicament is provided. In further aspects, an anti-TPBG antibody for use in treating cancer is provided. In certain embodiments, an anti-TPBG antibody for use in a method of treatment is provided. In certain embodiments, the invention provides an anti-TPBG antibody for use in a method of treating an individual having cancer comprising administering to the individual an effective amount of the anti-TPBG antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below. An “individual” according to any of the above embodiments is preferably a human.
- In a further aspect, the invention provides for the use of an anti-TPBG antibody in the manufacture or preparation of a medicament. In one embodiment, the medicament is for treatment of cancer. In a further embodiment, the medicament is for use in a method of treating cancer comprising administering to an individual having cancer an effective amount of the medicament. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g., as described below. An “individual” according to any of the above embodiments may be a human.
- In a further aspect, the invention provides a method for treating cancer. In one embodiment, the method comprises administering to an individual having cancer an effective amount of an anti-TPBG antibody. In one such embodiment, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described below. An “individual” according to any of the above embodiments may be a human.
- In a further aspect, the invention provides pharmaceutical formulations comprising any of the anti-TPBG antibodies provided herein, e.g., for use in any of the above therapeutic methods. In one embodiment, a pharmaceutical formulation comprises any of the anti-TPBG antibodies provided herein and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutical formulation comprises any of the anti-TPBG antibodies provided herein and at least one additional therapeutic agent, e.g., as described below.
- Antibodies of the invention can be used either alone or in combination with other agents in a therapy. For instance, an antibody of the invention may be co-administered with at least one additional therapeutic agent. In certain embodiments, an additional therapeutic agent is a chemotherapeutic agent.
- In one embodiment such chemotherapeutic agents include, but are not limited to, anti-neoplastic agents including alkylating agents including: nitrogen mustards, such as mechlorethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU); Temodal™ (temozolamide), ethylenimines/methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil (5FU), fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, 2,2′-difluorodeoxycytidine, purine analogs such as 6-merca.rho.topurine, 6-thioguamne, azathioprine, T-deoxycoformycin (pentostatin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA); natural products including antimitotic drugs such as paclitaxel, vinca alkaloids including vinblastine (VLB), vincristine, and vinorelbine, taxotere, estramustine, and estramustine phosphate; pipodophylotoxins such as etoposide and teniposide; antibiotics such as actinomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleomycins, plicamycin (mithramycin), mitomycin C, and actinomycin; enzymes such as L-asparaginase; biological response modifiers such as interferon-alpha, IL-2, G-CSF and GM-CSF; miscellaneous agents including platinum coordination complexes such as oxaliplatin, cisplatin and carboplatin, anthracenediones such as mitoxantrone, substituted urea such as hydroxyurea, methylhydrazine derivatives including N-methylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as mitotane (o, p-DDD) and aminoglutethimide; hormones and antagonists including adrenocorticosteroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide; Gemzar™ (gemcitabine), progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogen such as diethylstilbestrol and ethinyl estradiol equivalents; antiestrogen such as tamoxifen; androgens including testosterone propionate and fluoxymesterone/equivalents; antiandrogens such as flutamide, gonadotropin-releasing hormone analogs and leuprolide; and non-steroidal antiandrogens such as flutamide. Therapies targeting epigenetic mechanism including, but not limited to, histone deacetylase inhibitors, demethylating agents (e.g., Vidaza) and release of transcriptional repression (ATRA) therapies can also be combined with antibodies of the invention.
- In one embodiment the chemotherapeutic agent is selected from the group consisting of taxanes (like e.g. paclitaxel (Taxol), docetaxel (Taxotere), modified paclitaxel (e.g., Abraxane and Opaxio), doxorubicin, sunitinib (Sutent), sorafenib (Nexavar), and other multikinase inhibitors, oxaliplatin, cisplatin and carboplatin, etoposide, gemcitabine, and vinblastine. In one embodiment the chemotherapeutic agent is selected from the group consisting of taxanes (like e.g. taxol (paclitaxel), docetaxel (Taxotere), modified paclitaxel (e.g. Abraxane and Opaxio)). In one embodiment, the additional chemotherapeutic agent is selected from 5-fluorouracil (5-FU), leucovorin, irinotecan, or oxaliplatin. In one embodiment the chemotherapeutic agent is 5-fluorouracil, leucovorin and irinotecan (FOLFIRI). In one embodiment the chemotherapeutic agent is 5-fluorouracil, and oxaliplatin (FOLFOX).
- Specific examples of therapeutic appliacations of antibodies of the invention with additional chemotherapeutic agents include, for instance,
-
- therapies with taxanes (e.g., docetaxel or paclitaxel) or a modified paclitaxel (e.g., Abraxane or Opaxio), doxorubicin), capecitabine and/or bevacizumab (Avastin) for the treatment of breast cancer;
- therapies with carboplatin, oxaliplatin, cisplatin, paclitaxel, doxorubicin (or modified doxorubicin (Caelyx or Doxil)), or topotecan (Hycamtin) for the treatment of ovarian cancer,
- therapies with a multi-kinase inhibitor, MKI, (Sutent, Nexavar, or 706) and/or doxorubicin for the treatment of kidney cancer;
- therapies with oxaliplatin, cisplatin and/or radiation for the treatment of squamous cell carcinoma; and
- therapies with taxol and/or carboplatin for the treatment of lung cancer.
- Therefore, in one embodiment the additional chemotherapeutic agent is selected from the group of taxanes (docetaxel or paclitaxel or a modified paclitaxel (Abraxane or Opaxio), doxorubicin, capecitabine and/or bevacizumab for the treatment of breast cancer.
- In one embodiment the antibodies of the invention are administered in absence of an additional chemotherapeutic agent.
- Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant. Antibodies of the invention can also be used in combination with radiation therapy.
- An antibody of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
- Antibodies of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
- For the prevention or treatment of disease, the appropriate dosage of an antibody of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 μg/kg to 15 mg/kg (e.g. 0.5 mg/kg-10 mg/kg) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody would be in the range from about 0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody). However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
- It is understood that any of the above formulations or therapeutic methods may be carried out using an immunoconjugate of the invention or a recombinant fusion protein of the invention in place of or in addition to an anti-TPBG antibody.
- In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody of the invention. The label or package insert indicates that the composition is used for treating the condition of choice.
- Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
- It is understood that any of the above articles of manufacture may include an immunoconjugate of the invention or a recombinant fusion protein of the invention in place of or in addition to an anti-TPBG antibody.
- In the following specific embodiments of the invention are listed.
- 1. An isolated antibody that binds to trophoblast glycoprotein (TPBG), wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2).
- 2. An isolated antibody that binds to trophoblast glycoprotein (TPBG), wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to cell surface expressed minipig TPBG (SEQ ID NO: 2).
- 3. An isolated antibody that binds to trophoblast glycoprotein (TPBG), wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.4.
- 4. An isolated antibody that binds to trophoblast glycoprotein (TPBG), wherein the antibody binds to human TPBG (SEQ ID NO: 1) and to minipig TPBG (SEQ ID NO: 2), and wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.2.
- 5. The antibody of any one of
embodiments 1 to 4, wherein the antibody specifically binds to human and minipig TPBG with a KD of 10−8 M or less, respectively. - 6. The antibody of any one of
embodiments 1 to 4, wherein the antibody specifically binds to human and minipig TPBG with a KD of 10−8 M to 10−13 M, respectively. - 7. The antibody of any one of embodiments 4 to 6, wherein the antibody specifically binds to cell surface expressed human TPBG at a pH of 5.5 and a pH of 7.2.
- 8. The antibody of any one of embodiments 4 to 6, wherein the antibody specifically binds to cell surface expressed human TPBG on SW620 cells at a pH of 5.5 and a pH of 7.2.
- 9. The antibody of any one of
embodiments 3 to 8, wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.4 with a KD of 10−8 M or less. - 10. The antibody of any one of
embodiments 3 to 9, wherein the antibody specifically binds to human TPBG at a pH of 5.5 and a pH of 7.4 with a KD of 10-8 M to 10-13 M. - 11. The antibody according to any one of
embodiments 1 to 10, wherein the antibody is internalized into a TPBG-expressing cell upon binding. - 12. The antibody of any one of
embodiments 1 to 11, wherein the antibody comprises- (a) a CDR3 of the heavy chain of SEQ ID NO: 5, a CDR3 of the light chain of SEQ ID NO: 8, and a CDR2 of the heavy chain of SEQ ID NO: 4; or [antibody 051]
- (b) a CDR3 of the heavy chain of SEQ ID NO: 13, a CDR3 of the light chain of SEQ ID NO: 16, and a CDR2 of the heavy chain of SEQ ID NO: 12; or [antibody 091]
- (c) a CDR3 of the heavy chain of SEQ ID NO: 21, a CDR3 of the light chain of SEQ ID NO: 24, and a CDR2 of the heavy chain of SEQ ID NO: 20, [antibody 097]
- or wherein the antibody is a humanized antibody derived from the antibody indicated in (a), (b) or (c).
- 13. The antibody of embodiment of any one of
embodiments 1 to 11, wherein the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 5, a CDR3 of the light chain of SEQ ID NO: 8, and a CDR2 of the heavy chain of SEQ ID NO: 4. [antibody 051] - 14. The antibody of embodiment of any one of
embodiments 1 to 11, wherein the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 13, a CDR3 of the light chain of SEQ ID NO: 16, and a CDR2 of the heavy chain of SEQ ID NO: 12. [antibody 091] - 15. The antibody of embodiment of any one of
embodiments 1 to 11, wherein the antibody comprises a CDR3 of the heavy chain of SEQ ID NO: 21, a CDR3 of the light chain of SEQ ID NO: 24, and a CDR2 of the heavy chain of SEQ ID NO: 20. [antibody 097] - 16. A humanized antibody derived from the antibody of any one of embodiments 13 to 15.
- 17. The antibody of any one of
embodiments 1 to 11, wherein the antibody comprises- (a) a CDR1 of the heavy chain of SEQ ID NO: 3, a CDR2 of the heavy chain of SEQ ID NO: 4, a CDR3 of the heavy chain of SEQ ID NO: 5, a CDR1 of the light chain of SEQ ID NO: 6, a CDR2 of the light chain of SEQ ID NO: 7, and a CDR3 of the light chain of SEQ ID NO: 8; or [antibody 051]
- (b) a CDR1 of the heavy chain of SEQ ID NO: 11, a CDR2 of the heavy chain of SEQ ID NO: 12, and a CDR3 of the heavy chain of SEQ ID NO: 13, a CDR1 of the light chain of SEQ ID NO: 14, a CDR2 of the light chain of SEQ ID NO: 15, and a CDR3 of the light chain of SEQ ID NO: 16; or [antibody 091]
- (c) a CDR1 of the heavy chain of SEQ ID NO: 19, a CDR2 of the heavy chain of SEQ ID NO: 20, and a CDR3 of the heavy chain of SEQ ID NO: 21, a CDR1 of the light chain of SEQ ID NO: 22, a CDR2 of the light chain of SEQ ID NO: 23, and a CDR3 of the light chain of SEQ ID NO: 24; [antibody 097]
- or wherein the antibody is a humanized antibody derived from the antibody indicated in (a), (b) or (c).
- 18. The antibody of embodiment of any one of
embodiments 1 to 11, wherein the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 3, a CDR2 of the heavy chain of SEQ ID NO: 4, a CDR3 of the heavy chain of SEQ ID NO: 5, a CDR1 of the light chain of SEQ ID NO: 6, a CDR2 of the light chain of SEQ ID NO: 7, and a CDR3 of the light chain of SEQ ID NO: 8. [antibody 051] - 19. The antibody of embodiment of any one of
embodiments 1 to 11, wherein the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 11, a CDR2 of the heavy chain of SEQ ID NO: 12, and a CDR3 of the heavy chain of SEQ ID NO: 13, a CDR1 of the light chain of SEQ ID NO: 14, a CDR2 of the light chain of SEQ ID NO: 15, and a CDR3 of the light chain of SEQ ID NO: 16. [antibody 091] - 20. The antibody of embodiment of any one of
embodiments 1 to 11, wherein the antibody comprises a CDR1 of the heavy chain of SEQ ID NO: 19, a CDR2 of the heavy chain of SEQ ID NO: 20, and a CDR3 of the heavy chain of SEQ ID NO: 21, a CDR1 of the light chain of SEQ ID NO: 22, a CDR2 of the light chain of SEQ ID NO: 23, and a CDR3 of the light chain of SEQ ID NO: 24. [antibody 097] - 21. A humanized antibody derived from the antibody of any one of embodiments 18 to 20.
- 22. The antibody of any one of
embodiments 1 to 11, comprising- (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9;
- (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10; or
- (c) a VH sequence as in (a) and a VL sequence as in (b). [antibody 051]
- 23. The antibody of embodiment 22, comprising a VH sequence of SEQ ID NO: 9. [antibody 051]
- 24. The antibody of
embodiment 22 or 23, comprising a VL sequence of SEQ ID NO: 10. [antibody 051] - 25. An antibody comprising a VH sequence of SEQ ID NO: 9 and a VL sequence of SEQ ID NO: 10. [antibody 051]
- 26. A humanized antibody that binds to TPBG derived from the antibody of
embodiment 25. - 27. The antibody of any one of
embodiments 1 to 11, comprising- (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17;
- (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 18; or
- (c) a VH sequence as in (a) and a VL sequence as in (b). [antibody 091]
- 28. The antibody of
embodiment 27, comprising a VH sequence of SEQ ID NO: 17. [antibody 091] - 29. The antibody of
embodiment 27 or 28, comprising a VL sequence of SEQ ID NO: 18. [antibody 091] - 30. An antibody comprising a VH sequence of SEQ ID NO: 17 and a VL sequence of SEQ ID NO: 18. [antibody 091]
- 31. A humanized antibody that binds to TPBG derived from the antibody of embodiment 30.
- 32. The antibody of any one of
embodiments 1 to 11, comprising- (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 25;
- (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 26; or
- (c) a VH sequence as in (a) and a VL sequence as in (b). [antibody 097]
- 33. The antibody of embodiment 32, comprising a VH sequence of SEQ ID NO: 25. [antibody 097]
- 34. The antibody of
embodiment 32 or 33, comprising a VL sequence of SEQ ID NO: 26. [antibody 097] - 35. An antibody comprising a VH sequence of SEQ ID NO: 25 and a VL sequence of SEQ ID NO: 26. [antibody 097]
- 36. A humanized antibody that binds to TPBG derived from the antibody of
embodiment 35. - 37. The antibody of any one of
embodiments 1 to 36, which is a monoclonal antibody. - 38. The antibody of any one of
embodiments 1 to 37, which is a human, humanized, or chimeric antibody. - 39. The antibody of any one of
embodiments 1 to 38, which is an antibody fragment that binds TPBG. - 40. The antibody of any one of
embodiments 1 to 39, which is a Fab fragment that binds TPBG. - 41. The antibody of any one of
embodiments 1 to 38, which is of IgG isotype. - 42. The antibody of any one of
embodiments 1 to 38, which is a full length IgG antibody. - 43. The antibody of any one of
embodiments 1 to 38, which is of IgG1 isotype. - 44. The antibody of any one of
embodiments 1 to 38, which is a full length IgG1 antibody. - 45. An isolated nucleic acid encoding the antibody of any one of
embodiments 1 to 44. - 46. A host cell comprising the nucleic acid of
embodiment 45. - 47. A method of producing an antibody comprising culturing the host cell of embodiment 46 so that the antibody is produced.
- 48. The method of
embodiment 47, further comprising recovering the antibody from the host cell. - 49. An immunoconjugate comprising the antibody of any one of
embodiments 1 to 44 and a cytotoxic agent. - 50. The immunoconjugate of embodiment 49, wherein the cytotoxic agent is an enzymatically active toxin or fragment thereof.
- 51. The immunoconjugate of embodiment 50, wherein the cytotoxic agent is selected from the group consisting of exotoxin A chain (from Pseudomonas aeruginosa), diphtheria toxin, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
- 52. An immunoconjugate of any one of embodiments 49 to 51, wherein the cytotoxic agent is Pseudomonas exotoxin A or a variant thereof.
- 53. A method of producing an immunoconjugate according to any one of embodiments 49 to 52, including the step of coupling the antibody to the cytotoxic agent.
- 54. The method of embodiment 53, wherein the antibody is coupled to the cytotoxic agent via sortase mediated coupling.
- 55. The method of any one of embodiments 53 to 54, including the step of providing the antibody before the step of coupling.
- 56. The method of embodiment 55, wherein the antibody is provided by culturing the host cell of embodiment 46 so that the antibody is produced.
- 57. The method of embodiment 56, further including the step of recovering the antibody from the host cell before the step of coupling.
- 58. A recombinant fusion protein comprising an antibody of any one of
embodiments 1 to 44 and any other polypeptide. - 59. The recombinant fusion protein of embodiment 58, wherein the other polypeptide is fused to at least one of the heavy chains of the antibody.
- 60. The recombinant fusion protein of embodiment 59, wherein the other polypeptide is fused to the C-terminus of at least one of the heavy chains of the antibody.
- 61. The recombinant fusion protein of any one of embodiments 58 to 60, wherein the polypeptide is a cytotoxic agent.
- 62. The recombinant fusion protein of any one of embodiments 58 to 61, wherein the polypeptide is an enzymatically active toxin or fragment thereof.
- 63. The recombinant fusion protein of any one of embodiments 58 to 62, wherein the cytotoxic agent is selected from the group of exotoxin A chain (from Pseudomonas aeruginosa), diphtheria toxin, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
- 64. The recombinant fusion protein of any one of embodiments 58 to 63, wherein the cytotoxic agent is Pseudomonas exotoxin A or a variant thereof.
- 65. An isolated nucleic acid encoding the recombinant fusion protein of any one of the embodiments 58 to 64.
- 66. A host cell comprising the nucleic acid of embodiment 65.
- 67. A method of producing a recombinant fusion protein comprising culturing the host cell of embodiment 66 so that the recombinant fusion protein is produced.
- 68. The method of embodiment 67, further comprising recovering the recombinant fusion protein from the host cell.
- 69. The method of embodiment 67 or 68, wherein the recombinant fusion protein is an immunoconjugate comprising the antibody of any one of
embodiments 1 to 44 and a cytotoxic agent. - 70. The method of any of embodiments 67 to 69, comprising isolating inclusion bodies of the host cell and solubilizing the inclusion bodies.
- 71. The method of embodiment 70, further comprising the step of renaturation of the material from the solubilized inclusion bodies.
- 72. The method of any of embodiments 67 to 71, wherein the host cell is a bacterial cell.
- 73. The method of any of embodiments 67 to 72, wherein the host cell is E. coli.
- 74. A pharmaceutical formulation comprising the antibody of any one of
embodiments 1 to 44 and a pharmaceutically acceptable carrier. - 75. The pharmaceutical formulation of embodiment 74, further comprising an additional therapeutic agent.
- 76. The pharmaceutical formulation of embodiment 75, wherein the additional therapeutic agent is a chemotherapeutic agent.
- 77. A pharmaceutical formulation comprising the immunoconjugate of any one of embodiments 49 to 52 and a pharmaceutically acceptable carrier.
- 78. The pharmaceutical formulation of embodiment 77, further comprising an additional therapeutic agent.
- 79. The pharmaceutical formulation of embodiment 78, wherein the additional therapeutic agent is a chemotherapeutic agent.
- 80. A pharmaceutical formulation comprising the recombinant fusion protein of any one of embodiments 58 to 64 and a pharmaceutically acceptable carrier.
- 81. The pharmaceutical formulation of
embodiment 80 further comprising an additional therapeutic agent. - 82. The pharmaceutical formulation of embodiment 81, wherein the additional therapeutic agent is a chemotherapeutic agent.
- 83. The pharmaceutical formulation of
embodiment 80 for administration in combination with radiation therapy. - 84. The antibody of any one of
embodiments 1 to 44 for use as a medicament. - 85. The antibody of any one of
embodiments 1 to 44 for use in the treatment of cancer. - 86. The antibody for use of embodiment 85, wherein the cancer is selected from lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumours, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of said cancers.
- 87. The antibody for use of embodiment 85 or 86, wherein the cancer is non-small cell lung cancer.
- 88. Use of the antibody of any one of
embodiments 1 to 44 in the manufacture of a medicament. - 89. The use of embodiment 88, wherein the medicament is for treatment of cancer.
- 90. The use of embodiment 89, wheren the cancer is selected from lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumours, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of said cancers.
- 91. The use of embodiment 89 or 90, wherein the cancer is non-small cell lung cancer.
- 92. The use of one of embodiments 89 to 91, wherein the medicament is for administration in combination with one or more chemotherapeutic agents and/or raditotherapy.
- 93. A method of treating an individual having cancer comprising administering to the individual an effective amount of the antibody of any of
embodiments 1 to 44. - 94. The method of embodiment 93, further comprising administering an additional therapeutic agent to the individual.
- 95. The method of embodiment 94, wherein the additional therapeutic agent is a chemotherapeutic agent.
- 96. The method of embodiment 93, further comprising administering radiation therapy to the individual.
- 97. The immunoconjugate of any one of embodiments 49 to 52 for use as a medicament.
- 98. The immunoconjugate of any one of embodiments 49 to 52 for use in treating cancer.
- 99. The immunoconjugate for use of embodiment 98, wherein the cancer is selected from lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumours, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of said cancers.
- 100. The immunoconjugate for use of embodiment 98 or 99, wherein the cancer is non-small cell lung cancer.
- 101. The immunoconjugate for use of one of embodiments 98 to 100, wherein the immunoconjugate is for administration in combination with a chemotherapeutic agent and/or radiotherapy.
- 102. Use of the immunoconjugate of any one of embodiments 49 to 52 in the manufacture of a medicament.
- 103. The use of embodiment 102, wherein the medicament is for treatment of cancer.
- 104. The use of embodiment 103, wherein the cancer is selected from lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumours, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of said cancers.
- 105. The use of embodiment 103 or 104, wherein the cancer is non-small cell lung cancer.
- 106. The use of one of embodiments 102 to 105, wherein the immunoconjugate is for administration in combination with one or more chemotherapeutic agents and/or radiotherapy.
- 107. A method of treating an individual having cancer comprising administering to the individual an effective amount of the immunoconjugate of any one of embodiments 49 to 52.
- 108. The method of embodiment 107, further comprising administering an additional therapeutic agent to the individual.
- 109. The method of embodiment 108, wherein the additional therapeutic agent is a chemotherapeutic agent.
- 110. The method of one of embodiments 107 to 109, further comprising administering radiation therapy.
- 111. The recombinant fusion protein of any one of embodiments 58 to 64 for use as a medicament.
- 112. The recombinant fusion protein of any one of embodiments 58 to 64 for use in treating cancer.
- 113. The recombinant fusion protein for use of embodiment 112, wherein the cancer is selected from lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumours, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of said cancers.
- 114. The recombinant fusion protein for use of embodiment 112 or 113, wherein the cancer is non-small cell lung cancer.
- 115. The recombinant fusion protein for use of one of embodiments 112 to 114, wherein the recombinant fusion protein is for administration in combination with a chemotherapeutic agent and/or raditotherapy.
- 116. Use of the recombinant fusion protein of any one of embodiments 58 to 64 in the manufacture of a medicament.
- 117. The use of embodiment 116, wherein the medicament is for treatment of cancer.
- 118. The use of embodiment 117, wherein the cancer is selected from lymphomas, lymphocytic leukemias, lung cancer, non-small cell lung (NSCL) cancer, bronchioloalviolar cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, gastric cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, mesothelioma, hepatocellular cancer, biliary cancer, neoplasms of the central nervous system (CNS), spinal axis tumours, brain stem glioma, glioblastoma multiforme, astrocytomas, schwanomas, ependymomas, medulloblastomas, meningiomas, squamous cell carcinomas, pituitary adenoma and Ewings sarcoma, including refractory versions of any of the above cancers, or a combination of one or more of said cancers.
- 119. The use of embodiment 117 or 118, wherein the cancer is non-small cell lung cancer.
- 120. The use of one of embodiments 117 to 119, wherein the recombinant fusion protein is for administration in combination with one or more chemotherapeutic agents and/or radiotherapy.
- 121. A method of treating an individual having cancer comprising administering to the individual an effective amount of the recombinant fusion protein of any one of embodiments 58 to 64.
- 122. The method of embodiment 121, further comprising administering an additional therapeutic agent to the individual.
- 123. The method of embodiment 122, wherein the additional therapeutic agent is a chemotherapeutic agent.
- 124. The method of one of embodiments 121 to 123, further comprising administering radiation therapy.
- 125. A method of screening for an antibody that binds to TPBG, wherein the antibody binds to human and to minipig TPBG, the method comprising the steps of testing the binding of a test antibody to human TPBG and to minipig TPBG, and selecting the antibody that binds to human TPBG and to minipig TPBG.
- 126. The method of embodiment 125, including the step of selecting the antibody that binds to human TPBG and to minipig TPBG with a a KD of 10−8 M or less.
- 127. The method of embodiment 125 or 126, wherein the method is for screening of an antibody for therapeutic application.
- 128. The method of any one of embodiments 125 to 127, wherein the method is for screening of an antibody of
embodiments 1 to 44. - 129. The method of any one of embodiments 125 to 128, wherein the method comprises the step of testing the binding of a test antibody in monovalent form.
- 130. The method of any one of embodiments 125 to 129, wherein the method comprises the steps of testing the binding of a test antibody to human TPBG at pH 5.5 and at pH 7.2, and selecting the antibody that binds to human TPBG at pH 5.5 and at pH 7.2.
- 131. The method of any one of embodiments 125 to 130, wherein the method comprises the steps of testing the binding of a test antibody to human TPBG at pH 5.5 and at pH 7.4, and selecting the antibody that binds to human TPBG at pH 5.5 and at pH 7.4.
- 132. The method of embodiment 131, including the step of selecting the antibody that binds to human TPBG at pH 5.5 and at pH 7.4 with a KD of 10−8 M or less.
- 133. An antibody obtained by the method according to any one of embodiments 125 to 132.
- 134. A method of generating an antibody that binds to TPBG, wherein the antibody binds to human and to minipig TPBG, the method comprising the steps of (a) immunizing an animal with human TPBG or with human TBPG extracellular domain (ECD), (b) isolating B cells specific for human TPBG from the blood of the animal, (c) identifying the amino acid sequence of the variable domains (VH and VL) of the antibodies produced by the isolated B cells, (d) providing an antibody comprising the variable domains identified, (e) testing the binding of a the provided antibody to human TPBG and to minipig TPBG, and (f) selecting the antibody that binds to human TPBG and to minipig TPBG.
- 135. The method of embodiment 134, including the step of selecting the antibody that binds to human TPBG and to minipig TPBG with a a KD of 10−8 M or less.
- 136. The method of embodiment 134 or 135, wherein the method is for generating an antibody for therapeutic application.
- 137. The method of any one of embodiments 134 to 136, wherein the method is for screening of an antibody of
embodiments 1 to 44. - 138. The method of any one of embodiments 134 to 137, wherein the animal is a rodent.
- 139. The method of any one of embodiments 134 to 138, wherein the animal is a rabbit.
- 140. The method of any one of embodiments 134 to 139, wherein the method comprises the step of testing the binding of the provided antibody in monovalent form.
- 141. The method of any one of embodiments 134 to 140, wherein the method comprises the steps of testing the binding of the provided antibody to human TPBG at pH 5.5 and at pH 7.2, and selecting the antibody that binds to human TPBG at pH 5.5 and at pH 7.2.
- 142. The method of any one of embodiments 134 to 141, wherein the method comprises the steps of testing the binding of a test antibody to human TPBG at pH 5.5 and at pH 7.4, and selecting the antibody that binds to human TPBG at pH 5.5 and at pH 7.4.
- 143. The method of embodiment 142, including the step of selecting the antibody that binds to human TPBG at pH 5.5 and at pH 7.4 with a KD of 10−8 M or less.
- 144. An antibody obtained by the method according to any one of embodiments 134 to 143.
-
-
SEQ ID NO: 1 human TPBG (mature form, without signal peptide) SSPTSSASSFSSSAPFLASAVSAQPPLPDQCPALCECSEAARTVKCVNR NLTEVPTDLPAYVRNLFLTGNQLAVLPAGAFARRPPLAELAALNLSGSR LDEVRAGAFEHLPSLRQLDLSHNPLADLSPFAFSGSNASVSAPSPLVEL ILNHIVPPEDERQNRSFEGMVVAALLAGRALQGLRRLELASNHFLYLPR DVLAQLPSLRHLDLSNNSLVSLTYVSFRNLTHLESLHLEDNALKVLHNG TLAELQGLPHIRVFLDNNPWVCDCHMADMVTWLKETEVVQGKDRLTCAY PEKMRNRVLLELNSADLDCDPILPPSLQTSYVFLGIVLALIGAIFLLVL YLNRKGIKKWMHNIRDACRDHMEGYHYRYEINADPRLTNLSSNSDV SEQ ID NO: 2 minipig TPBG (mature form, without signal peptide) SSLTSSASSTSSASFPASAASALPPLPGRCPQPCECSEAARTVKCVGRN LTEVPADLPPYVRTLFLTGNQLAVLPTGAFARRPPLAELSALNLSGSRL TEVQAGAFEHLPSLRLLDLSHNPLANLSAFAFSGSNASVAAPSPLVDLI LNHIVTSAAQRQNRSFEGMVAAALRAGHALRGLRRLELASNHLLYLPLD VLAQLPDLRHLDLRNNSLVSLTYVFFRNLTHLESFHLEDNALKVLHNGT LAELQSLPHVRVFLDDNPWVCDCHLADMVAWLKETEVVQDKARLTCAFP EKMRHRVLLELNSSDLDCDPDLPPSLQTSYVFLGIVLALIGAIFLLVLY LNRKGIKKWMHNIRDACRDHMEGYHYRYEINADPRLTNLSSNSDV SEQ ID NO: 3 heavy chain CDR1 of antibody 051 IYWMT SEQ ID NO: 4 heavy chain CDR2 of antibody 051 AISGSGGSTYYADSVKG SEQ ID NO: 5 heavy chain CDR3 of antibody 051 DYYSNVY SEQ ID NO: 6 light chain CDR1 of antibody 051 RASQGIYSWLA SEQ ID NO: 7 light chain CDR2 of antibody 051 AASSLQS SEQ ID NO: 8 light chain CDR3 of antibody 051 QQSDSPPYT SEQ ID NO: 9 variable heavy chain domain VH of antibody 051 EVQLLESGGGLLQPGGSLRLSCAASGFTFSIYWMTWVRQAPGKG LEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRA EDTAVYYCAKDYYSNVYWGQGTLVTVSS SEQ ID NO: 10 variable light chain domain VL of antibody 051 DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAP KLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSDSPPYTFGQGTKLEIK SEQ ID NO: 11 heavy chain CDR1 of antibody 091 SDAMH SEQ ID NO: 12 heavy chain CDR2 of antibody 091 GVSGSGGSPYYADSVKG SEQ ID NO: 13 heavy chain CDR3 of antibody 091 GGSIAGSYYYYPMDV SEQ ID NO: 14 light chain CDR1 of antibody 091 QASQDISNYLN SEQ ID NO: 15 light chain CDR2 of antibody 091 AASTLQI SEQ ID NO: 16 light chain CDR3 of antibody 091 QQANSFPLT SEQ ID NO: 17 variable heavy chain domain VH of antibody 091 EVHLLESGGGLVHPGGSLRLSCAASGFTFRSDAMHWVRQAPGKG LEWVSGVSGSGGSPYYADSVKGRFTISRDDSKTTLYLQMNSLRA EDTAVYYCATGGSIAGSYYYYPMDVWGQGTTVTVSS SEQ ID NO: 18 variable light chain domain VL of antibody 091 DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAP KLLIYAASTLQIGVPSRFSGSGSGTDFTFTISSLQPEDFATYYC QQANSFPLTFGGGTKVEIK SEQ ID NO: 19 heavy chain CDR1 of antibody 097 NDAMT SEQ ID NO: 20 heavy chain CDR2 of antibody 097 AISGSGGSTYYADSVKG SEQ ID NO: 21 heavy chain CDR3 of antibody 097 GGSWGDWYYYFYPMDV SEQ ID NO: 22 light chain CDR1 of antibody 097 RASQSISSYLN SEQ ID NO: 23 light chain CDR2 of antibody 097 AASSLQS SEQ ID NO: 24 light chain CDR3 of antibody 097 QQSDSFPLT SEQ ID NO: 25 variable heavy chain domain VH of antibody 097 EVQLLESGGGLAQPGGSLRLSCAASGFTFNNDAMTWVRQAPGKG LEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRA EDTAVYYCAKGGSWGDWYYYFYPMDVWGQGTTVTVSS SEQ ID NO: 26 variable light chain domain VL of antibody 097 DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAP KLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSDSFPLTFGGGTKVEIK SEQ ID NO: 27 human TPBG extracellular domain, His6Avi MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSPTSSASSFSSS APFLASAVSAQPPLPDQCPALCECSEAARTVKCVNRNLTEVPTD LPAYVRNLFLTGNQLAVLPAGAFARRPPLAELAALNLSGSRLDE VRAGAFEHLPSLRQLDLSHNPLADLSPFAFSGSNASVSAPSPLV ELILNHIVPPEDERQNRSFEGMVVAALLAGRALQGLRRLELASN HFLYLPRDVLAQLPSLRHLDLSNNSLVSLTYVSFRNLTHLESLH LEDNALKVLHNGTLAELQGLPHIRVFLDNNPWVCDCHMADMVTW LKETEVVQGKDRLTCAYPEKMRNRVLLELNSADLDCDPILPPSL QTSAAALEVLFQGPGTHHHHHHHHHHIGLNDIFEAQKIEWHE SEQ ID NO: 28 human TPBG extracellular domain, huIgG1-Fc-His6 MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSPTSSASSFSSS APFLASAVSAQPPLPDQCPALCECSEAARTVKCVNRNLTEVPTD LPAYVRNLFLTGNQLAVLPAGAFARRPPLAELAALNLSGSRLDE VRAGAFEHLPSLRQLDLSHNPLADLSPFAFSGSNASVSAPSPLV ELILNHIVPPEDERQNRSFEGMVVAALLAGRALQGLRRLELASN HFLYLPRDVLAQLPSLRHLDLSNNSLVSLTYVSFRNLTHLESLH LEDNALKVLHNGTLAELQGLPHIRVFLDNNPWVCDCHMADMVTW LKETEVVQGKDRLTCAYPEKMRNRVLLELNSADLDCDPILPPSL QTSAAALEVLFQGPGTIEGRMDPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSGHHHHHH SEQ ID NO: 29 minipig TPBG extracellular domain, His6Avi MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSLTSSASSTSSA SFPASAASALPPLPGRCPQPCECSEAARTVKCVGRNLTEVPADL PPYVRTLFLTGNQLAVLPTGAFARRPPLAELSALNLSGSRLTEV QAGAFEHLPSLRLLDLSHNPLANLSAFAFSGSNASVAAPSPLVD LILNHIVTSAAQRQNRSFEGMVAAALRAGHALRGLRRLELASNH LLYLPLDVLAQLPDLRHLDLRNNSLVSLTYVFFRNLTHLESFHL EDNALKVLHNGTLAELQSLPHVRVFLDDNPWVCDCHLADMVAWL KETEVVQDKARLTCAFPEKMRHRVLLELNSSDLDCDPDLPPSLQ TSAAALEVLFQGPGTHHHHHHHHHHIGLNDIFEAQKIEWHE SEQ ID NO: 30 minipig TPBG extracellular domain, huIgG1-Fc-His MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSLTSSASSTSSA SFPASAASALPPLPGRCPQPCECSEAARTVKCVGRNLTEVPADL PPYVRTLFLTGNQLAVLPTGAFARRPPLAELSALNLSGSRLTEV QAGAFEHLPSLRLLDLSHNPLANLSAFAFSGSNASVAAPSPLVD LILNHIVTSAAQRQNRSFEGMVAAALRAGHALRGLRRLELASNH LLYLPLDVLAQLPDLRHLDLRNNSLVSLTYVFFRNLTHLESFHL EDNALKVLHNGTLAELQSLPHVRVFLDDNPWVCDCHLADMVAWL KETEVVQDKARLTCAFPEKMRHRVLLELNSSDLDCDPDLPPSLQ TSAAALEVLFQGPGTIEGRMDPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA LPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKG FYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSGHHHHHH SEQ ID NO: 31 cynomolgus TPBG extracellular domain, His6Avi MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSPTSSASSFSSS APFLASAASAQPPLPDQCPALCECSEAARTVKCVNRNLTEVPTD LPLYVRNLFLTGNQLAVLPAGAFARRPPLAELAALNLSGSRLDE VRAGAFEHLPSLRQLDLSHNPLAYLSPFAFSGSNASISAPSPLV ELILNHIVPPDDKRQNRSFEGMVAAALVAGRALQGLHLLELASN HFLYLPRDVLAQLPSLRYLDLSNNSLVSLTYVSFRNLTHLESLH LEDNALKVLHNGTLAELQGLPHVRVFLDNNPWVCDCHMADMVTW LKQTEVVQGKDRLTCAFPEKMRNRVLLELNSADLDCDPILPPSL QTSAAALEVLFQGPGTHHHHHHHHHHIGLNDIFEAQKIEWHE SEQ ID NO: 32 cynomolgus TPBG extracellular domain, huIgG1-Fc-His6 MPGGCSRGPAAGDGRLRLARLALVLLGWVSSSSPTSSASSFSSS APFLASAASAQPPLPDQCPALCECSEAARTVKCVNRNLTEVPTD LPLYVRNLFLTGNQLAVLPAGAFARRPPLAELAALNLSGSRLDE VRAGAFEHLPSLRQLDLSHNPLAYLSPFAFSGSNASISAPSPLV ELILNHIVPPDDKRQNRSFEGMVAAALVAGRALQGLHLLELASN HFLYLPRDVLAQLPSLRYLDLSNNSLVSLTYVSFRNLTHLESLH LEDNALKVLHNGTLAELQGLPHVRVFLDNNPWVCDCHMADMVTW LKQTEVVQGKDRLTCAFPEKMRNRVLLELNSADLDCDPILPPSL QTSAAALEVLFQGPGTIEGRMDPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNK ALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSGHHHHHH SEQ ID NO: 33 murine TPBG extracellular domain, His6Avi MPGAGSRGPSAGDGRLRLARLALVLLGWVSASAPSSSVPSSSTS PAAFLASGSAQPPPAERCPAACECSEAARTVKCVNRNLLEVPAD LPPYVRNLFLTGNQMTVLPAGAFARQPPLADLEALNLSGNHLKE VCAGAFEHLPGLRRLDLSHNPLTNLSAFAFAGSNASVSAPSPLE ELILNHIVPPEDQRQNGSFEGMVAFEGMVAAALRSGLALRGLTR LELASNHFLFLPRDLLAQLPSLRYLDLRNNSLVSLTYASFRNLT HLESLHLEDNALKVLHNSTLAEWHGLAHVKVFLDNNPWVCDCYM ADMVAWLKETEVVPDKARLTCAFPEKMRNRGLLDLNSSDLDCDA VLPQSLQTSAAALEVLFQGPGTHHHHHHHHHHIGLNDIFEAQKI EWHE SEQ ID NO: 34 murine TPBG extracellular domain, huIgG1-Fc-His6 MPGAGSRGPSAGDGRLRLARLALVLLGWVSASAPSSSVPSSSTS PAAFLASGSAQPPPAERCPAACECSEAARTVKCVNRNLLEVPAD LPPYVRNLFLTGNQMTVLPAGAFARQPPLADLEALNLSGNHLKE VCAGAFEHLPGLRRLDLSHNPLTNLSAFAFAGSNASVSAPSPLE ELILNHIVPPEDQRQNGSFEGMVAFEGMVAAALRSGLALRGLTR LELASNHFLFLPRDLLAQLPSLRYLDLRNNSLVSLTYASFRNLT HLESLHLEDNALKVLHNSTLAEWHGLAHVKVFLDNNPWVCDCYM ADMVAWLKETEVVPDKARLTCAFPEKMRNRGLLDLNSSDLDCDA VLPQSLQTSAAALEVLFQGPGTIEGRMDPKSCDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSGHHH HHH SEQ ID NO: 35 rat TPBG extracellular domain, His6Avi MPGAGSRGPSAGDGRLRLARLALVLLGWVSASAPSSSLPSSSTS PAAFLASGSAQPPPAERCPAACECSEAARTVKCVNRNLLEVPAD LPPYVRNLFLTGNQMTVLPAGAFARQPPLADLAVLNLSGNHLKE VGAGAFEHLPGLRRLDLSHNPLTNLSAFTFAGSNVSVSTPSPLL ELILNHIVPPEDQRQNGSFEGMVAFEGMVAAALRSGLALRGLHH LELASNHFLYLPRDLLDQLPSLKHLDLRNNSLVSLTYASFRNLT HLESLHLEDNALKVLHNSTLAEWQGLAHVRVFLDNNPWVCDCYM ADMVSWLKETEVVPDKARLTCAFPEKMRNRGLLDLTSSDLDCDA TLPQSLQTSAAALEVLFQGPGTHHHHHHHHHHIGLNDIFEAQKI EWHE SEQ ID NO: 36 rat TPBG extracellular domain, huIgG1-Fc-His6 MPGAGSRGPSAGDGRLRLARLALVLLGWVSASAPSSSLPSSSTS PAAFLASGSAQPPPAERCPAACECSEAARTVKCVNRNLLEVPAD LPPYVRNLFLTGNQMTVLPAGAFARQPPLADLAVLNLSGNHLKE VGAGAFEHLPGLRRLDLSHNPLTNLSAFTFAGSNVSVSTPSPLL ELILNHIVPPEDQRQNGSFEGMVAFEGMVAAALRSGLALRGLHH LELASNHFLYLPRDLLDQLPSLKHLDLRNNSLVSLTYASFRNLT HLESLHLEDNALKVLHNSTLAEWQGLAHVRVFLDNNPWVCDCYM ADMVSWLKETEVVPDKARLTCAFPEKMRNRGLLDLTSSDLDCDA TLPQSLQTSAAALEVLFQGPGTIEGRMDPKSCDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS KLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSGHHH HHH SEQ ID NO: 37 H8 heavy chain for sortase coupling without signal peptide EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQSHGKS LEWIGRINPNNGVTLYNQKFKDKAILTVDKSSTTAYMELRSLTS EDSAVYYCARSTMITNYVMDYWGQVTSVTVSSASTKGPSVFPLA PSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCGGGSLPETGGSGSHHHHHH SEQ ID NO: 38 H8 light chain for sortase coupling without signal peptide SIVMTQTPTFLLVSAGDRVTITCKASQSVSNDVAWYQQKPGQSP TLLISYTSSRYAGVPDRFIGSGYGTDFTFTISTLQAEDLAVYFC QQDYNSPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 39 051 heavy chain for sortase coupling without signal peptide EVQLLESGGGLLQPGGSLRLSCAASGFTFSIYWMTWVRQAPGKG LEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRA EDTAVYYCAKDYYSNVYWGQGTLVTVSSASTKGPSVFPLAPSSK STSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCG GGSLPETGGSGSEQKLISEEDLHHHHHHGAAEPEA SEQ ID NO: 40 051 light chain for sortase coupling without signal peptide DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKAP KLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSDSPPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 41 091 heavy chain for sortase coupling without signal peptide EVHLLESGGGLVHPGGSLRLSCAASGFTFRSDAMHWVRQAPGKG LEWVSGVSGSGGSPYYADSVKGRFTISRDDSKTTLYLQMNSLRA EDTAVYYCATGGSIAGSYYYYPMDVWGQGTTVTVSSASTKGPSV FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDK KVEPKSCGGGSLPETGGSGSEQKLISEEDLHHHHHHGAAEPEA SEQ ID NO: 42 091 light chain for sortase coupling without signal peptide DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAP KLLIYAASTLQIGVPSRFSGSGSGTDFTFTISSLQPEDFATYYC QQANSFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 43 097 heavy chain for sortase coupling without signal peptide EVQLLESGGGLAQPGGSLRLSCAASGFTFNNDAMTWVRQAPGKG LEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRA EDTAVYYCAKGGSWGDWYYYFYPMDVWGQGTTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD KKVEPKSCGGGSLPETGGSGSEQKLISEEDLHHHHHHGAAEPEA SEQ ID NO: 44 097 light chain for sortase coupling without signal peptide DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAP KLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSDSFPLTFGGGTKVEIKGTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 45 Pseudomonas exotoxin for sortase coupling GGGRHRQPRGWEQLYPTGAEFLGDGGAVSFSTRGTQNWTVERLL QAHRQLEEGGYVFVGYHGTFLEAAQSIVFGGVRARSQDLDAIWA GFYIAGDPALAYGYAQDQEPDAAGRIRNGALLRVYVPRSSLPGF YATSLTLAAPEAAGEVERLIGHPLPLRLDAITGPEESGGRLETI LGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIPDSEAAISALPD YASQPGKPPREDL SEQ ID NO: 46 heavy chain of anti-TPBG 051 Fab-PE fusion protein MEVQLLESGGGLLQPGGSLRLSCAASGFTFSIYWMTWVRQAPGK GLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLR AEDTAVYYCAKDYYSNVYWGQGTLVTVSSASTKGPSVFPLAPSS KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKTHKASGGRHRQPRGWEQLGGGGGSPTGAEFLGDGGDVSFSTR GTQNWTVERLLQAHAQLEERGYVFVGYHGTFLEAAQSIVFGGVA ARSQDLAAIWAGFYIAGDPALAYGYAQDQEPDAAGRIRNGALLR VYVPASSLPGFYRTSLTLAAPEAAGEVERLIGHPLPLALDAITG PEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGGDLDPSSIP DKEQAISALPDYASQPGKPPREDLK SEQ ID NO: 47 light chain of anti-TPBG 051 Fab-PE fusion protein MDIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQKPGKA PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQSDSPPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 48 heavy chain of anti-TPBG 091 Fab-PE fusion protein MEVHLLESGGGLVHPGGSLRLSCAASGFTFRSDAMHWVRQAPGK GLEWVSGVSGSGGSPYYADSVKGRFTISRDDSKTTLYLQMNSLR AEDTAVYYCATGGSIAGSYYYYPMDVWGQGTTVTVSSASTKGPS VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVD KKVEPKSCDKTHKASGGRHRQPRGWEQLGGGGGSPTGAEFLGDG GDVSFSTRGTQNWTVERLLQAHAQLEERGYVFVGYHGTFLEAAQ SIVFGGVAARSQDLAAIWAGFYIAGDPALAYGYAQDQEPDAAGR IRNGALLRVYVPASSLPGFYRTSLTLAAPEAAGEVERLIGHPLP LALDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVGG DLDPSSIPDKEQAISALPDYASQPGKPPREDLK SEQ ID NO: 49 light chain of anti-TPBG 091 Fab-PE fusion protein MDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKA PKLLIYAASTLQIGVPSRFSGSGSGTDFTFTISSLQPEDFATYY CQQANSFPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 50 heavy chain of anti-TPBG 097 Fab-PE fusion protein MEVQLLESGGGLAQPGGSLRLSCAASGFTFNNDAMTWVRQAPGK GLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLR AEDTAVYYCAKGGSWGDWYYYFYPMDVWGQGTTVTVSSASTKGP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKKVEPKSCDKTHKASGGRHRQPRGWEQLGGGGGSPTGAEFLGD GGDVSFSTRGTQNWTVERLLQAHAQLEERGYVFVGYHGTFLEAA QSIVFGGVAARSQDLAAIWAGFYIAGDPALAYGYAQDQEPDAAG RIRNGALLRVYVPASSLPGFYRTSLTLAAPEAAGEVERLIGHPL PLALDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRNVG GDLDPSSIPDKEQAISALPDYASQPGKPPREDLK SEQ ID NO: 51 light chain of anti-TPBG 097 Fab-PE fusion protein MDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKA PKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYY CQQSDSFPLTFGGGTKVEIKGTVAAPSVFIFPPSDEQLKSGTAS VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO: 52 Pseudomonas exotoxin A wild type AEEAFDLWNECAKACVLDLKDGVRSSRMSVDPAIADTNGQGVLH YSMVLEGGNDALKLAIDNALSITSDGLTIRLEGGVEPNKPVRYS YTRQARGSWSLNWLVPIGHEKPSNIKVFIHELNAGNQLSHMSPI YTIEMGDELLAKLARDATFFVRAHESNEMQPTLAISHAGVSVVM AQTQPRREKRWSEWASGKVLCLLDPLDGVYNYLAQQRCNLDDTW EGKIYRVLAGNPAKHDLDIKPTVISHRLHFPEGGSLAALTAHQA CHLPLETFTRHRQPRGWEQLEQCGYPVQRLVALYLAARLSWNQV DQVIRNALASPGSGGDLGEAIREQPEQARLALTLAAAESERFVR QGTGNDEAGAANADVVSLTCPVAAGECAGPADSGDALLERNYPT GAEFLGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYH GTFLEAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQD QEPDARGRIRNGALLRVYVPRSSLPGFYRTSLTLAAPEAAGEVE RLIGHPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIP TDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPPREDLK SEQ ID NO: 53 Pseudomonas exotoxin A synthetic variant PE38 GGSLAALTAHQACHLPLETFTRHRQPRGWEQLEQCGYPVQRLVA LYLAARLSWNQVDQVIRNALASPGSGGDLGEAIREQPEQARLAL TLAAAESERFVRQGTGNDEAGAANGPADSGDALLERNYPTGAEF LGDGGDVSFSTRGTQNWTVERLLQAHRQLEERGYVFVGYHGTFL EAAQSIVFGGVRARSQDLDAIWRGFYIAGDPALAYGYAQDQEPD ARGRIRNGALLRVYVPRSSLPGFYRTSLTLAAPEAAGEVERLIG HPLPLRLDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPR NVGGDLDPSSIPDKEQAISALPDYASQPGKPPREDLK SEQ ID NO: 54 Pseudomonas exotoxin A variant PE-LR RHRQPRGWEQL SEQ ID NO: 55 flexible glycin serine linker GGSGGS SEQ ID NO: 56 C-terminal end of the PE functional domain III native REDLK SEQ ID NO: 57 C-terminal end of the PE functional domain III with endoplasmic reticulum localisation sequences KDEL SEQ ID NO: 58 C-terminal end of the PE functional domain III with endoplasmic reticulum localisation sequences REDL SEQ ID NO: 59 C-terminal end of the PE functional domain III with endoplasmic reticulum localisation sequences RDEL SEQ ID NO: 60 C-terminal end of the PE functional domain III with endoplasmic reticulum localisation sequences KEDLK SEQ ID NO: 61 C-terminal end of the PE functional domain III with endoplasmic reticulum localisation sequences KDELKDEL SEQ ID NO: 62 C-terminal end of the PE functional domain III with endoplasmic reticulum localisation sequences KDELKDELKDEL SEQ ID NO: 63 furin cleavage site RXXR SEQ ID NO: 64 furin cleavage site RXKR SEQ ID NO: 65 furin cleavage site RXRR SEQ ID NO: 66 native furin-cleavable sequence in domain II of Pseudomonas exotoxin A RHRQPRGWEQL SEQ ID NO: 67 furin-cleavable sequence in domain II of modified Pseudomonas exotoxin A RHRSKRGWEQL SEQ ID NO: 68 furin-cleavable sequence RKKR SEQ ID NO: 69 furin-cleavable sequence RRRR SEQ ID NO: 70 furin-cleavable sequence RKAR SEQ ID NO: 71 furin-cleavable sequence SRVARS SEQ ID NO: 72 furin-cleavable sequence TSSRKRRFW SEQ ID NO: 73 furin-cleavable sequence ASRRKARSW SEQ ID NO: 74 furin-cleavable sequence RRVKKRFW SEQ ID NO: 75 furin-cleavable sequence RNVVRRDW SEQ ID NO: 76 furin-cleavable sequence TRAVRRRSW SEQ ID NO: 77 truncated version of native furin- cleavable sequence in domain II of Pseudomonas exotoxin A RQPR SEQ ID NO: 78 truncated version of native furin- cleavable sequence in domain II of Pseudomonas exotoxin A RHRQPRGW SEQ ID NO: 79 truncated version of native furin- cleavable sequence in domain II of Pseudomonas exotoxin A RHRQPRGWE SEQ ID NO: 80 truncated version of native furin- cleavable sequence in domain II of Pseudomonas exotoxin A HRQPRGWEQ SEQ ID NO: 81 truncated version of native furin- cleavable sequence in domain II of Pseudomonas exotoxin A RQPRGWE SEQ ID NO: 82 truncated version of furin-cleavable sequence in domain II of modified Pseudomonas exotoxin A RSKR SEQ ID NO: 83 truncated version of furin-cleavable sequence in domain II of modified Pseudomonas exotoxin A RHRSKRGW SEQ ID NO: 84 truncated version of furin-cleavable sequence in domain II of modified Pseudomonas exotoxin A HRSKRGWE SEQ ID NO: 85 truncated version of furin-cleavable sequence in domain II of modified Pseudomonas exotoxin A RSKRGWEQL SEQ ID NO: 86 truncated version of furin-cleavable sequence in domain II of modified Pseudomonas exotoxin A HRSKRGWEQL SEQ ID NO: 87 truncated version of furin-cleavable sequence in domain II of modified Pseudomonas exotoxin A RHRSKR - The following are examples of methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.
- Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.
- Materials & General Methods
- Recombinant DNA Techniques
- Standard methods were used to manipulate DNA as described in Sambrook, J. et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. The molecular biological reagents were used according to the manufacturer's instructions.
- DNA and Protein Sequence Analysis and Sequence Data Management
- General information regarding the nucleotide sequences of human immunoglobulins light and heavy chains is given in: Kabat, E. A. et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Ed., NIH Publication No 91-3242. Amino acids of antibody chains are numbered according to EU numbering (Edelman, G. M., et al., PNAS 63 (1969) 78-85; Kabat, E. A., et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Ed., NIH Publication No 91-3242). Vector NTI Advance suite version 11.5 (Invitrogen) was used for sequence creation, mapping, analysis, annotation and illustration.
- DNA Sequencing
- DNA sequences were determined by double strand sequencing performed at SequiServe (Vaterstetten, Germany) and Geneart AG (Regensburg, Germany).
- Gene Synthesis
- Desired gene segments were prepared by Geneart AG (Regensburg, Germany) from synthetic oligonucleotides and PCR products by automated gene synthesis. The gene segments which are flanked by singular restriction endonuclease cleavage sites were cloned into pGA18 (ampR) plasmids. The plasmid DNA was purified from transformed bacteria and concentration determined by UV spectroscopy. The DNA sequence of the sub-cloned gene fragments was confirmed by DNA sequencing.
- Expression of TPBG-RNA in Minipig and Cynomolgus
- Cynomolgus monkey was previously used to evaluate TPBG-specific antibodies or conjugates thereof for their tolerability (Sapra et al. (2013) Mol Canc Ther 12: 38-47). 14 different tissues of cynomolgus monkey and minipig were prepared and the mRNA expression profile evaluated. Transcription profiling by sequencing of tissue RNAs coming from Roche cynomolgus monkey and minipig RNAseq-projects was evaluated on Illumina NextSeq500 as indexed, 75 bp, paired-end run with an average depth of 30 million reads pairs. Gene expression signals are indicated as unique reads per kilobase exon model per million reads (rpkm) in log scale indicating median expression levels and standard deviation.
- Obtained signals were compared to each other. The results imply that the RNA expression profile of minipig and cynomolgus monkey are largely comparable. Thus, minipig is a suitable toxicology species to evaluate novel minipig cross-reactive anti-TPBG antibodies and Fab-PE constructs (
FIG. 1 ). - Cloning and Transient Expression of Extracellular Domains of TPBG
- The cDNA of either full length TPBG, thus comprising extracellular domain, transmembrane domain and intracellular domain or fragments thereof was cloned in eukaryotic expression vectors. Cloning was performed by standard restriction digest. For plasmids containing a C-terminal PreScission site followed by a HIS6-Avi epitope tag or a C-terminal PreScission site followed by a huIgG1-Fc-HIS6 epitope tag, site-directed cloning was performed with BamHI and NotI restriction enzymes. Plasmids were sequence verified and amplified according to standard molecular biology techniques.
- Plasmids containing the extracellular domain of TPBG or fragments thereof were transiently transfected in HEK293F (Life Technologies) cells. Briefly, cells were cultured in FreeStyle 293-F (Life Technologies) expression medium. The day before transfection cells were seeded at a density of 1×106/ml culture medium. The following
day 1 μg of plasmid DNA was used per ml culture medium. 293Free (Life Technologies) transfection reagent was used for transient transfection. Transfected cells were incubated at 37° C. and 8% CO2 for 7 d while shaking at 125-130 rpm in Erlenmeyer flasks. Supernatant was harvested and either frozen at −80° C. or directly processed for protein purification. - Purification of Recombinant TPBG
- Recombinant TPBG containing a huIgG1-Fc-HIS6 epitope tag (human TPBG: SEQ ID NO: 28; minipig TPGB: SEQ ID NO: 30; cynomolgus TPBG: SEQ ID NO: 32; murine TPBG: SEQ ID NO: 34, rat TPBG: SEQ ID NO: 36; the listed sequences all include signal peptides) was purified from cell culture supernatant using a HiTrap MabSelect Xtra protein A column (GE Healthcare). Elution occurred under acidic conditions (100 mM citrate buffer, pH3.0). Eluates were pH neutralized by addition of small amounts of Tris-Cl, pH9.0. Recombinant TPBG containing a HIS6-Avi epitope tag (human TPBG: SEQ ID NO: 27; minipig TPGB: SEQ ID NO: 29; cynomolgus TPBG: SEQ ID NO: 31; murine TPBG: SEQ ID NO: 33, rat TPBG: SEQ ID NO: 35, the listed sequences all include signal peptides) was purified from cell culture supernatant using a HisTrap HP (GE Healthcare) column. Elution occurred with an imidazole step gradient. Affinity purified protein was subsequently loaded on a
HiLoad 16/60Superdex 200 prep grade (GE Healthcare) size exclusion column. The product peak was collected and volume adjusted by ultracentrifugation with Amicon Ultra Filters (Merck Millipore). The final storage buffer consisted of 20 mM Histidine, 140 mM NaCl, pH 5.5. - Immunization of Rabbits Against TPBG
- Roche proprietary transgenic rabbits expressing a humanized antibody repertoire were immunized either with recombinant TPBG protein or genetically.
- One set of 3 rabbits was immunized with 400 μg of recombinant human TPBG extracellular domain (ECD) coupled to huFc, emulsified with complete Freund's adjuvant, at
day 0 by intradermal application, and with 200 μg each of TPBG-huFc, emulsified with complete Freund's adjuvant, atdays 7, 14, 28, 56 and 84, by alternating intramuscular and subcutaneous applications. Blood (10% of estimated total blood volume) was taken atdays 20, 34, 62 and 90. Serum was prepared, which was used for titer determination by ELISA (see below), and peripheral mononuclear cells were isolated, which were used as a source of antigen-specific B cells in the B cell cloning process. - Another set of 3 rabbits was immunized genetically, using a plasmid expression vector coding for full-length human TPBG, by intradermal application of 400 μg vector DNA, followed by electroporation (5 square pulses of 750 V/cm,
duration 10 ms, interval 1 s). Rabbits received 7 consecutive immunizations atdays 0, 14, 28, 49, 70, 98 and 126. Blood (10% of estimated total blood volume) was taken atdays 35, 77, 105 and 133. Serum was prepared, which was used for titer determination by ELISA (see below), and peripheral mononuclear cells were isolated, which were used as a source of antigen-specific B cells in the B cell cloning process. - Determination of Serum Titers (ELISA) from Immunized Rabbits
- Human recombinant soluble TPBG extracellular domain was immobilized on a 96-well NUNC Maxisorp plate at 2 μg/ml, 100 μl/well, in PBS, followed by: blocking of the plate with 2% Crotein C in PBS, 200 μl/well; application of serial dilutions of antisera, in duplicates, in 0.5% Crotein C in PBS, 100 μl/well; detection with either (1) HRP-conjugated donkey anti-rabbit IgG antibody (Jackson Immunoresearch/Dianova), or (2) HRP-conjugated rabbit anti-human IgG antibody (Pierce/Thermo Scientific; 1/5000), or (3) biotinylated goat anti-human kappa antibody (Southern Biotech/Biozol; 1/5000) and streptavidin-HRP; each diluted in 0.5% Crotein C in PBS, 100 μl/well. For all steps, plates were incubated for 1 h at 37° C. Between all steps plates were washed 3 times with 0.05
% Tween 20 in PBS. Signal was developed by addition of BM Blue POD Substrate soluble (Roche), 100 μl/well; and stopped by addition of 1 M HCl, 100 μl/well. Absorbance was read out at 450 nm, against 690 nm as reference. Titer was defined as dilution of antisera resulting in half-maximal signal. - Isolation of TPBG-Specific B Cells
- Blood samples were taken of immunized rabbits. EDTA-containing whole blood was diluted twofold with 1×PBS (PAA, Pasching, Austria) before density centrifugation using lympholyte mammal (Cedarlane Laboratories, Burlington, Ontario, Canada) according to the specifications of the manufacturer. PBMCs were washed twice with 1×PBS. Sterile streptavidin coated 6-well plates (Microcoat, Bernried, Germany) were coated with 2 μg/ml of the biotinylated extracellular domain of human TPBG protein in PBS for 3 h at room temperature. Prior to the panning step these 6-well plates were washed three times with sterile PBS. The PBMCs were seeded on sterile 6-well plates (cell culture grade) to deplete macrophages and monocytes through unspecific adhesion. Each well was filled at maximum with 4 ml medium and up to 6×10e6 PBMCs from the immunized rabbit and were allowed to bind for 1 h at 37° C. and 5% CO2. The cells in the supernatant (peripheral blood lymphocytes (PBLs)) were used for the antigen panning step. 6-well plates coated with TPBG protein were seeded with up to 6×10e6 PBLs per 4 ml medium and allowed to bind for 1 h at 37° C. and 5% CO2 to enrich TPBG-specific B cells. Non-adherent cells were removed by carefully washing the wells 1-2 times with 1×PBS. The remaining sticky cells were detached by trypsin for 10 min at 37° C. and 5% CO2. Trypsination was stopped with EL-4 B5 medium (EL-4 B5: RPMI 1640 (Pan Biotech, Aidenbach, Germany) supplemented with 10% fetal calf serum (Hyclone, Logan, Utah, USA), 2 mM Glutamin, 1% penicillin/streptomycin solution (PAA, Pasching, Austria), 2 mM sodium pyruvate, 10 mM HEPES (PAN Biotech, Aidenbach, Germany) and 0.05 mM b-mercaptoethanole (Gibco, Paisley, Scotland). The cells were kept on ice until the immune fluorescence staining. Anti-IgG FITC (AbD Serotec, Dusseldorf, Germany) was used for single cell sorting. For surface staining, cells from the depletion and enrichment step were incubated with anti-IgG FITC antibody in PBS and incubated for 45 min in the dark at 4° C. After staining the PBLs were washed two times with ice cold PBS. Finally the PBLs were resuspended in ice cold PBS and immediately subjected to the FACS analyses. Propidium iodide at a concentration of 5 μg/ml (BD Pharmingen, San Diego, Calif., USA) was added prior to FACS analyses to discriminate between dead and live cells. A Becton Dickinson FACSAria equipped with a computer and the FACSDiva software (BD Biosciences, USA) was used for single cell sort. The cultivation of the rabbit B cells was done by a method described by Seeber S. et al., PLoS One. 2014 Feb. 4; 9(2):e86184. Briefly, single sorted rabbit B cells were incubated in 96-well plates with 200 μl/well EL-4 B5 medium containing Pansorbin cells (1:100000) (Calbiochem (Merck), Darmstadt, Deutschland), 5% rabbit thymocyte supernatant (MicroCoat, Bernried, Germany) and gamma-irradiated murine EL-4 B5 thymoma cells (2.5×10e4 cells/well) for 7 days at 37° C. in the incubator. The supernatants of the B-cell cultivation were removed for screening and the remaining cells were harvested immediately and were frozen at −80° C. in 100 μl RLT buffer (Qiagen, Hilden, Germany).
- B Cell PCR
- Total RNA was prepared from B cells lysate (resuspended in RLT buffer—Qiagen) using the NucleoSpin 8/96 RNA kit (Macherey & Nagel) according to manufacturer's protocol. RNA was eluted with 60 μl RNase free water. 6 μl of RNA was used to generate cDNA by reverse transcriptase reaction using the Superscript III First-Strand Synthesis SuperMix (Invitrogen) and an oligo dT-primer according to the manufatures's instructions. All steps were performed on a Hamilton ML Star System. 41 μl of cDNA were used to amplify the immunoglobulin heavy and light chain variable regions (VH and VL) with the AccuPrime Supermix (Invitrogen) in a final volume of 50 μl using the primers rbHC.up and rbHC.do for the heavy chain and BcPCR_FHLC_leader.fw and BcPCR_huCkappa.rev for the light chain. All forward primers were specific for the signal peptide (of respectively VH and VL) whereas the reverse primers were specific for the constant regions (of respectively VH and VL). The PCR conditions for the RbVH+RbVL were as follows: Hot start at 94° C. for 5 min; 35 cycles of 20 s at 94° C., 20 s at 70° C., 45 s at 68° C., and a final extension at 68° C. for 7 min. The PCR conditions for the HuVL were as follows: Hot start at 94° C. for 5 min; 40 cycles of 20 s at 94° C., 20 s at 52° C., 45 s at 68° C., and a final extension at 68° C. for 7 min.
- Primer Sequences:
-
rbHC.up AAGCTTGCCACCATGGAGACTGGGCTGCGCTGGCTTC rbHCf.do CCATTGGTGAGGGTGCCCGAG BcPCR_FHLC_ ATGGACATGAGGGTCCCCGC leader.fw BcPCR_ GATTTCAACTGCTCATCAGATGGC huCkappa.rev - 81 μl of 50 μl PCR solution were loaded on a 48 E-Gel 2% (Invitrogen G8008-02). Positive PCR reactions were cleaned using the NucleoSpin Extract II kit (Macherey & Nagel; 740609250) according to manufacturer's protocol and eluted in 50 μl elution buffer. All cleaning steps were performed on a Hamilton ML Starlet System.
- Binding of TPBG-Specific Fab Fragments to TPBG of Different Species
- To assess binding of recombinant TPBG of different species, Nunc maxisorp streptavidin coated plates (MicroCoat #11974998001) were coated with 25 μl/well biotinylated TPBG-AviHis of the relevant species (hu=human; mu=murine; rt=rat; cy=cynomolgus; mp=minipig) at a concentration of 100 ng/ml for human, cyno, and minipig TPBG and at a concentration of 500 ng/ml for mouse and rat TPBG. Plates were incubated at 4° C. over night. After washing (3×90 μl/well with PBST-buffer) anti-TPBG samples were added in a 1:2 dilution series starting at 2 μg/ml and incubated 1 h at RT. After washing (3×90 l/well with PBST-buffer) 25 μl/well goat anti c-myc HRP (Bethyl, # A190-104P) or goat anti hu kappa HRP (Millipore, # AP502P) was added in a 1:7000 or 1:4000 dilution, respectively and incubated at RT for 1 h on a shaker. After washing (3×90 μl/well with PBST-buffer) 25 μl/well TMB substrate (Calbiochem, # CL07) was added and incubated 2 min for human and minipig TPBG, 3 min for cyno TPBG and 4 min for mouse and rat TPBG. Measurement took place at 370/492 nm on a Safire2 reader (Tecan).
- To assess cellular binding of human TPBG, the human breast cancer tumor cell line MFC7 endogenously expressing TPBG was seeded at a concentration of 21000 cells/well in 384-well cellcoat Poly-D-Lysine plates (Greiner, #781940). Cells were allowed to attach over night at 37° C. After removing the supernatant, 25 μl/well of supernatant containing anti-TPBG antibodies were added in a 1:2 dilution series starting at 5 μg/ml and incubated 1 h at 4° C. Upon washing (2×50 μl/well PBST) cells were fixed by adding 50 μl/well 0.05% Glutaraldehyde (Sigma, 25%) diluted in 1×PBS-buffer and incubated for 10 min at RT. After washing (3 times; 90 μl/well PBS-T), 25 μl/well secondary antibody was added for detection: goat anti c-myc HRP (1:5000, Bethyl) followed by 1 h incubation at room temperature on a shaker. After washing (3 times; 90 μl/well PBS-T) 25 μl/well TMB substrate solution (Calbiochem) was added. After 10 min at room temperature, measurement took place at 370/492 nm on a Safire2 reader (Tecan).
-
TABLE 1 Binding of anti-TPBG Fab fragments to TPBG of different species EC50 [ng/ml] recombinant TPBG MCF7 sample: huTPBG muTPBG rtTPBG cyTPBG mpTPBG huTPBG 051 18.1 — — >2000 175.0 57.5 091 27.7 — — 1229.8 61.8 14.0 097 15.2 — — — 43.6 451.3 - Fab fragments of 051, 091, and 097 were found to be crossreactive between human and minipig TPBG. Cell binding of human TPBG expressed on cells of a human breast cancer cell line was confirmed.
- Binding of Purified Antibodies (mAbs) to TPBG of Different Species [Comparison with Prior Art]
- Nunc maxisorp plates (Nunc, 464718) were coated with 25 μl/well Fc-TPBG at a concentration of 1 μg/ml for rat, minipig, mouse, cyno and at a concentration of 500 ng/ml for human TPBG. Plates were incubated at 4° C. overnight. After washing (3×90 μl/well; PBS-T buffer) plates were blocked with 90 μl blocking buffer (PBS with 2% BSA and 0.05% Tween-20) for 1 h at room temperature. After washing (3×90 μl/well with PBST-buffer) anti-TPBG antibodies were added in a 1:2 dilution series starting at 1 μg/ml and incubated 1 h at RT. After washing (3×90 μl/well with PBST-buffer) 25 μl/well, goat anti kappa antibody-POD conjugate (Millipore, AP502P) or donkey anti rabbit Fc antibody-POD conjugate (Amersham, NA9310V) was added in a 1:4000 dilution or a 1:1000 dilution, respectively and incubated at RT for 1 h on a shaker. After washing (3×90 μl/well with PBST-buffer) 25 al/well TMB substrate (Roche Diagnostics GmbH, Cat. No.: 11835033001) was added and incubated for 5 min. Measurement took place at 370/492 nm on a Safire2 reader (Tecan).
- For comparison, prior art antibodies as disclosed in WO 2006/031653 (antibody H8, as defined by its VH and VL domain amino acid sequences as indicated in SEQ ID NO: 2 and 1 of WO 2006/031653) and WO 2007/106744 A2 (antibodies A1, A2, A3; as defined by their VH and VL domain amino acid sequences as indicated in table 2 of WO 2007/106744) were assessed in parallel.
-
TABLE 2 Binding of anti-TPBG antibodies (mAbs) to TPBG of different species antibody TPBG*: 051 091 097 A1 A2 A3 H8 hu + + + + + + + rt − + − +/− − − − mp + + + − − − + mo +/− − − − − − − cy + + − + + + +/− (+) . . . binding, (−) . . . no binding, (+/−) partial binding; hu . . . human, mp . . . minipig, rt . . . rat, mo . . . mouse, cy . . . cynomolgus - Binding Competition of Antibodies (mAbs) 051, 091, and 097 with Prior Art Antibodies A1, A2, and A3
- 384-well TRSA-SA Maxisorp (MicroCoat) plates were coated with 25 μl/well biotinylated human TPBG-AviHis at a concentration of 200 ng/ml followed by an incubation at 4° C. overnight. After washing 3 times with 90 μl/well PBS-T, antibodies A1, A2, A3 were added at a concentration of 4 μg/ml followed by an incubation for 1 h at room temperature. Wells were washed 3 times with 90 μl/well PBS-T. Anti-TPBG antibodies were added at a concentration of 0.1 μg/ml and incubated for 1 h at room temperature on a shaker. After washing 3 times with 90 μl/well PBST, 25 μl/well goat anti c-myc HRP (1:6000, Bethyl) was added followed by 1 h incubation at room temperature on a shaker. After washing (3 times; 90 μl/well PBST) 25 μl/well TMB substrate solution (Calbiochem) was added. After 10 min at room temperature, measurement took place at 370/492 nm on a Safire2 reader (Tecan).
-
TABLE 3 Binding competition between anti-TPBG antibodies (mAbs) 051, 097, and 097 and antibodies (mAbs) A1, A2, and A3 as disclosed in WO 2007/106744 A1 A2 A3 051 − − − 091 − − +/− − 097 − − +/− − +/− = very weak competition (was confirmed to be equal or less than 15% in a BiaCore assay) - The results indicate that
anti-TPBG antibodies - Cloning and Expression of TPBG-Specific Fabs
- Recombinant Expression of Rabbit Monoclonal Bivalent Antibodies
- For recombinant expression of rabbit monoclonal bivalent antibodies, PCR-products coding for VH or VL were cloned as cDNA into expression vectors by the overhang cloning method (R S Haun et al., Biotechniques (1992) 13, 515-518; MZ Li et al., Nature Methods (2007) 4, 251-256). The expression vectors contained an expression cassette consisting of a 5′ CMV promoter including intron A, and a 3′ BGH poly adenylation sequence. In addition to the expression cassette, the plasmids contained a pUC18-derived origin of replication and a beta-lactamase gene conferring ampicillin resistance for plasmid amplification in E. coli. Three variants of the basic plasmid were used: one plasmid containing the rabbit IgG constant region designed to accept the VH regions while two additional plasmids containing rabbit or human kappa LC constant region to accept the VL regions.
- Linearized expression plasmids coding for the kappa or gamma constant region and VL/VH inserts were amplified by PCR using overlapping primers.
- Purified PCR products were incubated with T4 DNA-polymerase which generated single-strand overhangs. The reaction was stopped by dCTP addition.
- In the next step, plasmid and insert were combined and incubated with recA which induced site specific recombination. The recombined plasmids were transformed into E. coli. The next day the grown colonies were picked and tested for correct recombined plasmid by plasmid preparation, restriction analysis and DNA-sequencing.
- For antibody expression, the isolated HC and LC plasmids were transiently co-transfected into HEK293 cells and the supernatants were harvested after 1 week.
- Recombinant Expression of Rabbit Monoclonal Monovalent Antibodies
- For recombinant expression of selected candidates as monoclonal monovalent antibodies rabbit constant regions of all VH chains were converted into human constant regions enclosing the Knob-mutation in the CH3 segment. For VL chains derived from rabbit wild type B cells, rabbit C kappa constant regions were converted into human. 4 μl of cDNA of the selected candidates were used to amplify the immunoglobulin heavy and light chain variable regions with the AccuPrime Supermix (Invitrogen 12344-040) in a final volume of 50 μl with forward primers specific for the signal peptide and reverse primers specific for the CDR3-J region with (at the 3′ end) overlap sequence (20 bp) homologous to the human constant regions (respectively of VH and VL). The PCR conditions for the VH and VL chain amplification were as follows: Hot start at 94° C. for 5 min; 35 cycles of 20 s at 94° C., 20 s at 68° C., 45 s at 68° C., and a final extension at 68° C. for 7 min.
- PCR-products coding for VH or VL were cloned as cDNA into expression vectors by the overhang cloning method (R S Haun et al., Biotechniques (1992) 13, 515-518; MZ Li et al., Nature Methods (2007) 4, 251-256). The expression vectors contained an expression cassette consisting of a 5′ CMV promoter including intron A, and a 3′ BGH poly adenylation sequence. In addition to the expression cassette, the plasmids contained a pUC18-derived origin of replication and a beta-lactamase gene conferring ampicillin resistance for plasmid amplification in E. coli. Two variants of the basic plasmid were used: one plasmid containing the human IgG constant region designed to accept the new amplified VH chain and a second plasmid containing the human kappa LC constant region to accept the VL chain.
- Linearized expression plasmids coding for the kappa or gamma constant region and VL/VH inserts were amplified by PCR using overlapping primers.
- Purified PCR products were incubated with T4 DNA-polymerase which generated single-strand overhangs. The reaction was stopped by dCTP addition.
- In the next step, plasmid and insert were combined and incubated with recA which induced site specific recombination. The recombined plasmids were transformed into E. coli. The next day the grown colonies were picked and tested for correct recombined plasmid by plasmid preparation, restriction analysis and DNA-sequencing.
- The following polypeptides were generated:
-
TABLE 4 Amino acid sequences of Fabs and PE for sortase coupling SEQ ID Amino acid sequences NO: 051 VH EVQLLESGGGLLQPGGSLRLSCAASGFTFSIYWMTWVRQ 9 ok APGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCAKDYYSNVYWGQGTLVTVSS ok VL DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQK 10 PGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL QPEDFATYYCQQSDSPPYTFGQGTKLEIK 091 VH EVHLLESGGGLVHPGGSLRLSCAASGFTFRSDAMHWVRQ 17 ok APGKGLEWVSGVSGSGGSPYYADSVKGRFTISRDDSKTT LYLQMNSLRAEDTAVYYCATGGSIAGSYYYYPMDVWGQG TTVTVSS ok VL DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQK 18 PGKAPKLLIYAASTLQIGVPSRFSGSGSGTDFTFTISSL QPEDFATYYCQQANSFPLTFGGGTKVEIK 097 VH EVQLLESGGGLAQPGGSLRLSCAASGFTFNNDAMTWVRQ 25 ok APGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCAKGGSWGDWYYYFYPMDVWGQ GTTVTVSS ok VL DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQK 26 PGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL QPEDFATYYCQQSDSFPLTFGGGTKVEIK -
TABLE 5 CDRs according to Kabat of anti-TPBG antibodies (HC . . . heavy chain, LC . . . light chain) SEQ ID Amino acid sequences NO: 051 HC- CDR1 IYWMT 3 ok HC-CDR2 AISGSGGSTYYADSVKG 4 HC-CDR3 DYYSNVY 5 LC-CDR1 RASQGIYSWLA 6 LC- CDR2 AASSLQS 7 LC-CDR3 QQSDSPPYT 8 091 HC-CDR1 SDAMH 11 ok HC-CDR2 GVSGSGGSPYYADSVKG 12 HC-CDR3 GGSIAGSYYYYPMDV 13 LC-CDR1 QASQDISNYLN 14 LC- CDR2 AASTLQI 15 LC- CDR3 QQANSFPLT 16 097 HC- CDR1 NDAMT 19 ok HC- CDR2 AISGSGGSTYYADSVKG 20 HC- CDR3 GGSWGDWYYYFYPMDV 21 LC-CDR1 RASQSISSYLN 22 LC- CDR2 AASSLQS 23 LC-CDR3 QQSDSFPLT 24 - Sortase Coupling of Fab Fragment to a Truncated GGG-PE24 Variant (LR8M)
- An immunoconjugate of an anti-TPBG antibody Fab fragment and a truncated variant of exotoxin A chain of P. aeruginosa was generated via enzymatic coupling with sortase.
- The following polypeptides were used:
-
TABLE 6 Amino acid sequences of Fabs and PE for sortase coupling (HC . . . heavy chain, LC . . . light chain) SEQ ID Amino acid sequences NO: H8 HC EVQLQQSGPDLVKPGASVKISCKASGYSFTGYYMHWVKQ 37 ok SHGKSLEWIGRINPNNGVTLYNQKFKDKAILTVDKSSTT AYMELRSLTSEDSAVYYCARSTMITNYVMDYWGQVTSVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSS LGTQTYICNVNHKPSNTKVDKKVEPKSCGGGSLPETGGS GSHHHHHH ok LC SIVMTQTPTFLLVSAGDRVTITCKASQSVSNDVAWYQQK 38 PGQSPTLLISYTSSRYAGVPDRFIGSGYGTDFTFTISTL QAEDLAVYFCQQDYNSPPTFGGGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC 051 HC EVQLLESGGGLLQPGGSLRLSCAASGFTFSIYWMTWVRQ 39 ok APGEGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCAKDYYSNVYWGQGTLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDEKVEPESCGGGSLPETGGSGSEQ KLISEEDLHHHHHHGAAEPEA ok LC DIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQK 40 PGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL QPEDFATYYCQQSDSPPYTFGQGTKLEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC 091 HC EVHLLESGGGLVHPGGSLRLSCAASGFTFRSDAMHWVRQ 41 ok APGEGLEWVSGVSGSGGSPYYADSVEGRFTISRDDSKTT LYLQMNSLRAEDTAVYYCATGGSIAGSYYYYPMDVWGQG TTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV PSSSLGTQTYICNVNHKPSNTKVDEKVEPESCGGGSLPE TGGSGSEQKLISEEDLHHHHHHGAAEPEA ok LC DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQK 42 PGKAPKLLIYAASTLQIGVPSRFSGSGSGTDFTFTISSL QPEDFATYYCQQANSFPLTFGGGTKVEIKRTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC 097 HC EVQLLESGGGLAQPGGSLRLSCAASGFTFNNDAMTWVRQ 43 ok APGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYYCAKGGSWGDWYYYFYPMDVWGQ GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCGGGSLP ETGGSGSEQKLISEEDLHHHHHHGAAEPEA ok LC DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQK 44 PGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSL QPEDFATYYCQQSDSFPLTFGGGTKVEIKGTVAAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE VTHQGLSSPVTKSFNRGEC PE GGGRHRQPRGWEQLYPTGAEFLGDGGAVSFSTRGTQNWT 45 (LR VERLLQAHRQLEEGGYVFVGYHGTFLEAAQSIVFGGVRA 8M) RSQDLDAIWAGFYIAGDPALAYGYAQDQEPDAAGRIRNG ALLRVYVPRSSLPGFYATSLTLAAPEAAGEVERLIGHPL PLRLDAITGPEESGGRLETILGWPLAERTVVIPSAIPTD PRNVGGDLDPSSIPDSEAAISALPDYASQPGKPPREDL - Purified Fab fragments transiently expressed in HEK293-F (with LPETG-HIS6 motif at the C-terminus) and GGG-PE24 LR8M (purified from E. coli extract as published in the literature) were concentrated to 7-8 mg/ml in 20 mM Tris, 150 mM NaCl, 5 mM CaCl2, pH 7.5. Both proteins were combined in a 1:1 molar ratio. Coupling reaction was started by adding HIS-tagged Sortase (0.8 molar equivalent). After incubation for 1 h at 37° C. the reaction mixture was chromatographed on a Ni HiTrap column (GE Healthcare) to remove uncoupled Fab and Sortase. Coupled Fab-PE24 eluted in the flow through and was further purified on a Superdex200 gel filtration column in 20 mM His, 140 mM NaCl, pH 6.0. The final product was concentrated to 1 mg/ml and frozen in aliquots at −80° C.
- Expression of Fab-PE and Inclusion Body Isolation
- An immunoconjugate of an anti-TPBG antibody Fab fragment and a truncated variant of exotoxin A chain of P. aeruginosa was generated via expression of the immunoconjugate as recombinant fusion protein in E. coli cells. The toxin was fused to the C-terminus of the heavy chain of the anti-TPBG antibody.
- The following polypeptides were used:
-
TABLE 7 Amino acid sequences of anti-TPBG Fab-PE fusion proteins SEQ ID Amino acid sequences NO: 051 HC- MEVQLLESGGGLLQPGGSLRLSCAASGFTFSIYWMTWVR 46 PE QAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKN TLYLQMNSLRAEDTAVYYCAKDYYSNVYWGQGTLVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKVEPKSCDKTHKASGGRHRQP RGWEQLGGGGGSPTGAEFLGDGGDVSFSTRGTQNWTVER LLQAHAQLEERGYVFVGYHGTFLEAAQSIVFGGVAARSQ DLAAIWAGFYIAGDPALAYGYAQDQEPDAAGRIRNGALL RVYVPASSLPGFYRTSLTLAAPEAAGEVERLIGHPLPLA LDAITGPEEEGGRLETILGWPLAERTVVIPSAIPTDPRN VGGDLDPSSIPDKEQAISALPDYASQPGKPPREDLK 051 LC MDIQMTQSPSSVSASVGDRVTITCRASQGIYSWLAWYQQ 47 KPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISS LQPEDFATYYCQQSDSPPYTFGQGTKLEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRGEC 091 HC- MEVHLLESGGGLVHPGGSLRLSCAASGFTFRSDAMHWVR 48 PE QAPGKGLEWVSGVSGSGGSPYYADSVKGRFTISRDDSKT TLYLQMNSLRAEDTAVYYCATGGSIAGSYYYYPMDVWGQ GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKD YFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHKA SGGRHRQPRGWEQLGGGGGSPTGAEFLGDGGDVSFSTRG TQNWTVERLLQAHAQLEERGYVFVGYHGTFLEAAQSIVF GGVAARSQDLAAIWAGFYIAGDPALAYGYAQDQEPDAAG RIRNGALLRVYVPASSLPGFYRTSLTLAAPEAAGEVERL IGHPLPLALDAITGPEEEGGRLETILGWPLAERTVVIPS AIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKPP REDLK 091 LC MDIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQ 49 KPGKAPKLLIYAASTLQIGVPSRFSGSGSGTDFTFTISS LQPEDFATYYCQQANSFPLTFGGGTKVEIKRTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRGEC 097 HC- MEVQLLESGGGLAQPGGSLRLSCAASGFTFNNDAMTWVR 50 PE QAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKN TLYLQMNSLRAEDTAVYYCAKGGSWGDWYYYFYPMDVWG QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHK ASGGRHRQPRGWEQLGGGGGSPTGAEFLGDGGDVSFSTR GTQNWTVERLLQAHAQLEERGYVFVGYHGTFLEAAQSIV FGGVAARSQDLAAIWAGFYIAGDPALAYGYAQDQEPDAA GRIRNGALLRVYVPASSLPGFYRTSLTLAAPEAAGEVER LIGHPLPLALDAITGPEEEGGRLETILGWPLAERTVVIP SAIPTDPRNVGGDLDPSSIPDKEQAISALPDYASQPGKP PREDLK 097 LC MDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQ 51 KPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISS LQPEDFATYYCQQSDSFPLTFGGGTKVEIKNTVAAPSVF IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYAC EVTHQGLSSPVTKSFNRGEC - The variable light chain constructs (LC) and the variable heavy chain constructs (HC-PE) were produced in E. coli cells applying the Roche in-house antibiotic free expression system (
EP 0 972 838 and U.S. Pat. No. 6,291,245) and a fermentation process on chemical defined medium with alkaline feeding (WO2012/028522). In all fermentations the product was located in the insoluble fraction of the cytoplasm as inclusion bodies which were isolated and solubilized. The solubilized IB material was then combined during the renaturation process with its respective partner to form the TPBG binding Fab-PE fusion molecules. In brief, the E. coli K12 strain CSPZ-25 (thi-1, ΔompT, ΔpyrF, Δlon, ΔgalE) was transformed by electroporation with the relevant expression plasmids. The transformed E. coli cells were first grown at 37° C. on agar plates. For each transformation a colony picked from this plate was transferred to a 3 mL roller culture and grown at 37° C. to an optical density of 1-2 (measured at 578 nm). Then 1000 μl culture were mixed with 1000 μl sterile 86%-glycerol and immediately frozen at −80° C. for long time storage. The correct product expression of these clones was verified in small scale shake flask experiments and analyzed with SDS-Page. - For pre-cultivation one 1000 mL shake-flask with four baffles was inoculated with 1.0 mL out of a research seed bank ampoule. The cultivation was performed on a rotary shaker for 8-11 hours at 37° C. and 170 rpm until an optical density (578 nm) of 4 to 8 was obtained. 100 ml of the pre cultivation was used to inoculate a 10 L bioreactor. After 24 hours of cultivation the whole broth is cooled down to 4-8° C. and stored overnight in the fermenter vessel. The bacteria were harvested via centrifugation with a flow-through centrifuge (13,000 rpm, 13 l/h) and the obtained biomass was immediately processed in an inclusion body isolation process or stored at −20° C. until further processing.
- Inclusion body preparations (IBP) of the 10 L fermentations were routinely started directly after the harvest of the bacteria with the re-suspension of the cell pellet in buffer containing 12.1 g/l Tris, 0.246 g/l MgSO4*7H2O and 12 ml/
l 25%-HCl. The buffer volume was calculated in dependence of the dry matter content of the biomass. Lysozyme (100 kU/mg) and a small amount of Benzonase™ were added. Then the suspension was homogenized at 900 bar (APV Rannie 5, 1 pass) to disrupt the bacteria cells followed by further addition of Benzonase and an incubation for 30 min at 30-37° C. Then the first wash buffer (60 g/l Brij, 87.6 g/l NaCl, 22.5 g/1 EDTA, 6 ml/l 10N NaOH) was added and again the suspension was incubated for 30 minutes. The following centrifugation step (BP12, Sorvall) lead to the inclusion body slurry which was re-suspended in the second wash buffer (12.1 μg/l Tris, 7.4 g/l EDTA, 1 ml/l 25%-HCl) and incubated for 20 min. A further separation step yielded the inclusion bodies which are stored frozen at −20° C. or immediately transferred to the DSP department. - Renaturation and Purification of Anti-TPBG Fab-PE Fusion Proteins
- Inclusion bodies of HC-PE and LC (HC=heavy chain; LC=light chain) were solubilized separately in 6.7 M Guanidinium-Hydrochloride, 100 mM Tris/HCl, 5 mM acetate, 1 mM EDTA pH 8.0+100 mM Dithiothreitol (DTT) 2 h at room temperature. Solubilized material was adjusted to pH 5 and microfiltrated (6.7 M Guanidinium-HCl, 100 mM Tris, 1 mM EDTA, 5 mM acetate, 100 mM DTT pH 5.0) using a 1000 kDa membrane. After diafiltration against 6.7 M Guanidinium-HCl, 100 mM Tris, 10 mM EDTA, 5 mM acetate, pH 5.0 in order to remove DTT and for concentration, the total protein concentration was determined using Biuret method. The purity of HC and LC content was estimated using a Bioanalyzer (Agilent Technologies). Solubilisates were diluted at a 1:1 molar ratio in renaturation buffer containing 0.5 M arginine, 2 mM EDTA,
pH 10+1 mM GSH/GSSG, respectively, at 2-10° C. The target protein concentration was increased in four steps to 0.5 g/L, with an incubation time of 2 h between the two doses. Afterwards the renaturation solution was kept at 2-10° C. overnight. The renaturate was diafiltrated against 20 mM Tris/HCl, 40 mM NaCl pH7.4 (pH 8.0 for TPBG-0199) and pumped onto an anion exchange column (AIEX) equilibrated in 20 mM Tris/HCl, 40 mM NaCl pH 7.4 (pH 8.0 for TPBG-0199). After washing the column with equilibration buffer the protein was eluted with a gradient up to 20 mM Tris/HCl, 320 mM NaCl, pH 7.4 (pH 8.0 for TPBG-0199). Peak fractions containing Fab-PE were pooled, concentrated and applied onto a preparative Size Exclusion Column (SEC) in 20 mM Tris, 150 mM NaCl, pH 7.4 to remove aggregates, fragments and E. coli proteins. The final protein pool was adjusted to the required protein concentration and analyzed via Bioanalyzer (Agilent Technologies), analytical SEC and UV280, identity was confirmed by mass spectrometry - MS Analysis and Identity Confirmation of Proteins
- The correct molecular mass (identity) and integrity of the amino acid backbones of the Fab fragments were verified by Electrospray ionization (ESI) mass spectrometry with and without prior reduction. Reduction was performed using TCEP (Thermo Scientific). Desalting was performed on self-packed G25-Sephadex-Superfine (GE Healthcare) columns using an isocratic formic acid gradient. ESI mass spectra (+ve) were recorded on a Q-TOF instrument (maXis, Bruker) equipped with a nano ESI source (TriVersa NanoMate, Advion). MS parameter settings were as follows: Transfer: Funnel RF, 400 Vpp; ISCID Energy, 0 or 85 eV; Multipole RF, 400 Vpp; Quadrupole: Ion Energy, 3.0 eV; Low Mass, 850 m/z; Source: Dry Gas, 8 L/min; Dry Gas Temperature, 160° C.; Collision Cell: Collision Energy, 8 eV; Collision RF: 3800 Vpp; Ion Cooler: Ion Cooler RF, 800 Vpp; Transfer Time: 140 s; Pre Puls Storage, 20 s; scan ranges m/
z 600 to 2000 and m/z 1000 to 4000. The MassAnalyzer software (developed in-house) was used for data evaluation. - Generation of Stable TPBG Expressing CHO Cell Lines
- CHO-K1 cells were stably transfected with full length TPBG from different species, namely human, or minipig, to evaluate cellular binding properties and potency of novel TPBG-specific antibodies. CHO-K1 cells (ATCC) were cultivated in DMEM/F12 medium (no phenol red) supplemented with 10% fetal calf serum and 2 mM L-Glutamine. Upon reaching 80-90% confluency lipid/DNA complexes were prepared with TPBG expression vectors using Roche's XtremeGeneHP transfection reagent. After pre-incubation, lipid/DNA complexes were added to 2×105 CHO-K1 cells in suspension at a total volume of 2 ml of selection medium (DMEM/F12, 10% fetal calf serum, 400 μg/ml (3418). Cells were cultivated for 14 days under selection pressure and then stained with in-house TPBG antibodies. Briefly, 2×105 cells were stained with 2 μg/ml primary anti-TPBG antibody for 30 min on ice, washed and counterstained with PE-labelled anti-human kappa antibody (1:50 in PBS containing 2% fetal calf serum, 30 min on ice). Single cell sorting of high or medium to low expressing clones was performed on a FacsARIA (BD) and single cells were deposited into 96--well flat bottom cell culture plates. After 12 days a variety of clones for each species (human, cynomolgus, minipig TPBG) were transferred to 24-well plates and cultivated for three more days. Clones were stained with above mentioned internal reference TPBG antibodies as formerly described and analyzed on a FacsCanto (BD). Selected clones were cultivated for one more week and stored in FCS containing 7.5% DMSO in liquid nitrogen. For stability testing, cells were further cultivated for two more weeks, then stained and analyzed on a FacsCanto (BD) resulting in the final selection of TPBG--expressing CHO cells that were stable over the observed time period.
- pH Dependent Binding of Anti-TPBG Antibodies to Cell Surface Expressed Human TPBG
- pH-dependent binding of anti-TPBG Fabs as expressed in Example 11 to human TPBG was assessed. To this end, a SW620 clone (clone 4), stably expressing high level of TPBG, was chosen as cellular model. Cells growing in the logarithmic growth phase were detached using Accutase (Sigma) and a cell suspension was prepared in a PBS buffer (bufferA) containing 1% fetal calf serum and pH adjusted to pH 7.2, 6.0, and 5.5. Respective Fabs were added to cell suspension and binding occurred for 30 min on ice. Cells were subsequently washed twice with buffer of the same pH (buffer A). Cells were then resuspended in PBS containing 2% fetal calf serum, pH 7.4 (buffer B) and a secondary anti-kappa mouse anti-human mAb coupled to PE (phyoerythrin) (Life Technologies) was added for 30 min on ice. Cells were then again washed twice with buffer B and finally resuspended in onetime CellFix buffer (BD). To discriminate life from dead cells Hoechst 33258 stain was applied. Signals were detected on a FACS Canto II (BD). Data evaluation was done with FACS Diva software and Microsoft Excel. Experiments were done in biological replicates.
- While the applied pH range does not closely reflect physiological values it was used to evaluate the pH-dependent binding of different Fabs using a maximal window. From the analysis it is obvious that the Fab(H8) prior art antibody displays a much higher pH-dependent binding than the antibodies of the invention (
FIG. 2 ). This would indicate that the binding of Fab(H8) in comparison to the antibodies of the invention has likely a much higher contribution of hydrogen-bonds. In biological replicates, comparing pH 5.5 and pH 7.2 this factor was between 4.2 and 6.8 calculated from the mean fluorescence intensity (MFI) while it was for the Fabs of the invention in the range of 0.9-1.2 (Table 8). -
TABLE 8 Comparison of anti-TPBG Fab binding to cell surface TPBG at different pH values SW620 cl.4 Fold change pH 7.2 vs pH 5.5 Fab replicate 1 replicate 2 H8 4.2 6.8 051 1.1 1.1 091 0.9 1.0 097 1.2 1.2 - Internalization of Anti-TPBG Antibodies (Fab Fragments) in Human TPBG-Expressing MCF7 Cells
- Internalization upon target binding of TPBG-specific Fabs as expressed in Example 11 was evaluated in MCF7 cells.
- Cells in the logarithmic growth phase were detached using Accutase (Sigma). 2.5×10e5 cells per sample were resuspended in ice-cold buffer (PBS containing 2% fetal calf serum) and 10 μg/mL of the respective Fabs and kept for 15 min on ice. Cells were spun down at 300 g for 5 min at 4° C. and washed twice with 150 L ice-cold buffer. Cells were resuspended in 100 μL buffer and incubated for 30, 60 or 180 min at 37° C. Samples for time point zero remained on ice. Plates for time course at 37° C. were pre-warmed prior sample addition. Cells were resuspended in 50 μL ice-cold buffer containing 10 μg/mL anti-kappa light chain RE-PE (phycoerythrin) labeled secondary antibody (Life Technologies). The suspension was incubated for 45 min on ice. Cells were then washed twice as described and resuspended in 200 μL ice-cold fixation buffer (BD CellFix). Samples were measured on a FACSCanto II (BD). Data processing was done using the FlowJo Software. Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. The GeoMean fluorescence signal of each Fab sample was corrected by the mean fluorescence intensity (MFI) of the corresponding isotype control. The MFI for each time point was set in relation to time point zero and calculated as percentage value. The percentage of internalization was calculated by subtracting the percentage of detected antibody from 100%.
- All Fabs did internalize within the given time frame (
FIG. 3 ). -
TABLE 9 Internalization of anti-TPBG antibodies (Fab fragments) in human TPBG-expressing MCF7 cells time [h] Fab 0.5 1.0 2.0 H8 39% 61% 79% 051 31% 55% 72% 091 16% 33% 42% 097 28% 42% 61% - Cellular Binding of Anti-TPBG Antibodies (Fab Fragments) to Minipig-TPBG Expressing CHO Cells
- Binding of TPBG-specific Fabs as expressed in Example 11 to cell surface expressed minipig TPBG was assessed using stably transfected CHO cells (Example 16) and a flow cytometry based assay.
- Stable transfectants expressing cell surface levels of TPBG in a similar range were used for the flow cytometry based analysis of cellular binding. Dilution series of antibodies were prepared spanning a concentration range from 0.01-20 μg/ml. In brief, cell suspensions were prepared in ice cold PBS (Gibco) containing 2% fetal calf serum (PAN Biotech). 2.5×10e5 cells were dispensed per well in a v-shaped 96well-MTP. Antibody dilution series prepared in the same buffer were added as twofold concentrated solution. Samples were incubated on ice for 45 min upon which they were washed twice with 150 μL ice cold PBS containing 2% fetal calf serum. In between, cells were spun down at 300 g for 5 min at 4° C. Cells were resuspended in 50 μL ice-cold buffer containing 10 μg/mL anti-kappa light chain RE-PE (phycoerythrin) labeled secondary antibody (Life Technologies). The suspension was incubated for 45 min on ice. Cells were washed twice as described and resuspended in 50 μL ice-cold buffer containing 1 μg/mL Hoechst 33258. After 10 min cells were washed once more and finally resuspended in 200 μL ice-cold fixation buffer (BD CellFix). Samples were measured on a FACSCanto II (BD). Data processing was done using the FlowJo Software. Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in.
-
Antibodies FIG. 4A ). - Cellular Binding of Immunoconjugates Comprising Anti-TPBG Antibodies (Fab-PE Fragments) to Human and Minipig-TPBG Expressing CHO Cells
- Binding of TPBG-specific antibodies to either human (hu) or minipig (pg) TPBG was evaluated using CHO-K1 cells stably transfected with the respective full length antigen (Example 16). Stable transfectants expressing cell surface levels of TPBG in a similar range were used for flow cytometry based analysis of cellular binding. Dilution series of Fab-PEs (anti-TPBG Fab-PE fusion proteins as expressed in Examples 13 and 14) were prepared spanning a concentration range from 400-0.002 nM. In brief, cell suspensions were prepared in ice cold PBS (Gibco) containing 2% fetal calf serum (PAN Biotech). 2.5×10e5 cells were dispensed per well in a v-shaped 96well-MTP. Fab-PE dilution series prepared in the same buffer were added as twofold concentrated solution. Samples were incubated on ice for 45 min upon which they were washed twice with 150 μL ice cold PBS containing 2% fetal calf serum. In between, cells were spun down at 300 g for 5 min at 4° C. Cells were resuspended in 50 μL ice-cold buffer containing 10 μg/mL anti-kappa light chain RE-PE (phycoerythrin) labeled secondary antibody (Life Technologies). The suspension was incubated for 45 min on ice. Cells were washed twice as described and resuspended in 50 μL ice-cold buffer containing 1 μg/mL Hoechst 33258. After 10 min cells were washed once more and finally resuspended in 200 μL ice-cold fixation buffer (BD CellFix). Samples were measured on a FACSCanto II (BD). Data processing was done using the FlowJo Software. Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in.
- All Fab-PE bound to a similar degree to CHO-K1 expressing human TPBG with at most a twofold difference in the EC50 (
FIG. 4B ). - Only Fab-
PEs comprising antibodies FIG. 4C ). -
TABLE 10 Cellular binding to human and minipig TPBG Fab-PE comprising stable CHO-K1 transfectants antibody huTPBG pgTPBG EC50 H8 13.6 — [nM] 051 12.4 16.9 091 8.5 10.8 097 5.6 15.4 - Cytotoxicity of Immunoconjugates Comprising Anti-TPBG Antibodies (Fabs Coupled to PE Fragment Via Sortase Coupling) on Human and Minipig-TPBG Expressing CHO Cells
- A surrogate assay to evaluate the potency of Fab-PE constructs (Fabs coupled to PE fragment via sortase coupling as provided in Example 12) on cells expressing human (hu) or minipig (pg) TPBG was established. To this end, CHO-K1 cells were transiently transfected with full length TPBG from the respective species. In addition a luciferase reporter plasmid was co-transfected. Upon treatment with test compound potency was determined by measuring luciferase activity.
- CHO-K1 cells were transiently transfected with TPBG and luciferase containing plasmids in a ratio of 2:1 in
suspension using Lipofectamine 3000 at a ratio of 3:1 and 3 μg total DNA per 1×10e6 cells. 30.000 cells per well were then seeded in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 21 h prior addition of compounds. Dilution series of Fab-PEs were prepared in medium spanning a concentration range from 15 to 0.0003 nM. Individual data points were measured as triplicates. 24 h after compound addition luciferase reporter activity as a surrogate marker for cellular protein synthesis capacity was quantified using Steady Glo (Promega). Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates. - All immunoconjugates comprising antibodies of the invention (i.e.
antibodies FIG. 5 A). On the other hand, activity on minipig expressing CHO cells was clearly better for the antibodies of the invention while prior art antibody H8 displayed much lower activity (FIG. 5 B). It is noteworthy that also the negative control, an immunoconjugate which does not bind to a cell surface target, displays potency between 1-10 nM. This is due to the transient transfection procedure which exerts additional stress on the cells. For this reason CHO-K1 clones stably expressing the respective TPBG antigens were generated (cf. example 16 and 21). - Cytotoxicity Mediated by Anti-TPBG Antibodies (Anti-TPBG Fab Antibodies Bound by Anti-Kappa Chain Antibody-PE Fusion Protein) on Human and Minipig-TPBG Expressing CHO Cells
- To evaluate the suitability of anti-TPBG Fab fragments for payload delivery a surrogate assay was performed. In this assay, TPBG-specific Fabs were co-incubated in a 1:3 molar ratio for 30 min prior addition to cells with a second Fab binding to the kappa-light chain of the TPBG-specific Fab. The kappa binding Fab carried in addition a pseudomonas exotoxin (PE) moiety. The so formed complex was added to CHO-K1 cells stably expressing either human or minipig TPBG. CHO-K1 cells were stably transfected with full length TPBG from the respective species (Example 16). Single clones were selected and expanded. Clones expressing cell surface TPBG in a similar range were selected for subsequent proliferation assays. While the clones were maintained under selection pressure, the actual proliferation assays were performed in medium without selection pressure.
- 10.000 cells were seeded per well in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series of Fab-PE sandwich constructs were prepared in medium spanning a concentration range from 133 to 0.002 nM. Individual data points were measured as triplicates. 72 h after compound addition CellTiterGlo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- On CHO-K1 stably transfected with human TPBG all candidates showed potency to some degree.
- Fabs derived vom antibodies A1, A2, and A3 do not display significant potency on CHO-K1 stably transfected with minipig TPBG. Also, the Fab fragment derived from antibody H8 displays a significantly lower potency in this assay and has an about 100× lower potency on cells expressing minipig than on cell expressing human TPBG (
FIG. 6 A-D). -
TABLE 11 Cytotoxic activity of anti-TPBG Fab-PE sandwich constructs on human and minipig TPBG expressing CHO cells (EC50 in [nM]) Fab + anti-kappa- CHO-K1/human TPBG CHO-K1/minipig TPBG Fab-PE replicate 1 replicate 2 replicate 1 replicate 2 Unspecific Fab — — — — H8 0.41 0.52 47.97 45.86 A1 3.63 4.12 — — A2 9.81 11.33 — — A3 0.26 0.47 — — 051 0.28 0.38 6.18 5.04 091 0.23 0.24 1.05 1.20 097 0.30 0.33 2.08 2.15 - Cytotoxicity of Immunoconjugates Comprising Anti-TPBG Antibodies (Anti-TPBG Fab-PE Fusion Proteins) on Human and Minipig-TPBG Expressing CHO Cells
- A surrogate assay to evaluate the potency of Fab-PE constructs (anti-TPBG Fab-PE fusion proteins as expressed in Examples 13 and 14) on cells expressing human (hu) or minipig (pg) TPBG was established. To this end, CHO-K1 cells were stably transfected with full length TPBG from the respective species. Single clones were selected and expanded. Clones expressing cell surface TPBG in a similar range were selected for subsequent proliferation assays. While the clones were maintained under selection pressure, the actual proliferation assays were performed in medium without selection pressure.
- 10.000 cells were seeded per well in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series of Fab-PEs were prepared in medium spanning a concentration range from 133 to 0.002 nM. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- All immunoconjugates comprising antibodies of the invention (i.e.
antibodies FIG. 7 A). - For comparison a Fab-PE version of the prior art antibody H8 was used. For this immunoconjugate only a low cytotoxic activity on cells expressing minipig TPBG was observed. On parental CHO-K1 none of the Fab-PEs displayed activity (
FIG. 7 C). -
TABLE 12 Cytotoxic activity of anti-TPBG Fab-PE fusion proteins on CHO cells stably expressing either human or minipig TPBG (EC50 in [nM]) X-fold lower Fab-PE comprising stable CHO-K1 transfectants potency pgTPBG antibody huTPBG pgTPBG versus huTPBG Unspecific Fab — — H8 0.07 5.98 83.9 051 0.03 1.37 51.7 091 0.05 0.15 3.3 097 0.04 0.14 3.4 - Cellular Binding of Immunoconjugates Comprising Anti-TPBG Antibodies (Anti-TPBG Fab-PE Fusion Proteins) on Human TPBG Expressing MCF7 Cells
- Binding of anti-TPBG Fab-PE fusion proteins as provided in Example 13 and 14, as well as binding of Fabs coupled to PE fragment via sortase coupling as provided in Example 12 to human tumor cells was studied using the breast cancer tumor cell line MCF7. Cells growing in the logarithmic growth pase were detached using Accutase (Sigma). In brief, cell suspensions were prepared in ice cold PBS (Gibco) containing 2% fetal calf serum (PAN Biotech).
- 2.5×10e5 cells were dispensed per well in a v-shaped 96well-MTP. Fab-PE dilution series ranging from 133-0.001 nM prepared in the same buffer were added as twofold concentrated solution. Samples were incubated on ice for 45 min upon which they were washed twice with 150 μL ice cold PBS containing 2% fetal calf serum. In between, cells were spun down at 300 g for 5 min at 4° C. Cells were resuspended in 50 μL ice-cold buffer containing 10 μg/mL anti-kappa light chain RE-PE (phycoerythrin) labeled secondary antibody (Life Technologies). The suspension was incubated for 45 min on ice. Cells were washed twice as described and resuspended in 50 μL ice-cold buffer containing 1 μg/mL Hoechst 33258. After 10 min cells were washed once more and finally resuspended in 200 μL ice-cold fixation buffer (BD CellFix). Samples were measured on a FACSCanto II (BD). Data processing was done using the FlowJo Software. Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in.
- All anti-TPBG Fab-PE fusion proteins display low nM or sub-nM EC50 values in their binding to the human breast tumor cell line MCF7 (
FIG. 8 ). -
TABLE 13 Cellular binding of anti-TPBG Fab-PE fusion proteins on human TPBG expressing MCF7 cells (EC50 in [nM]) Fab comprised in immunoconjugate type of immunoconjugate EC50 [nM] H8 sortase-coupled 1.56 051 sortase-coupled 0.67 refolded 1.25 091 sortase-coupled 0.61 refolded 0.89 097 sortase-coupled 0.63 refolded 0.64 - Cytotoxicity Mediated by Anti-TPBG Antibodies (Anti-TPBG Fab Antibodies Bound by Anti-Kappa Chain Antibody-PE Fusion Protein) on Human TPBG Expressing MCF7 Cells
- The ideal properties of antibodies or antibody fragments suitable for delivery of payloads, specifically pseudomonas exotoxin, are not well defined. Theoretically, one could assume that every internalizing antibody would fulfill this purpose.
- To evaluate the suitability of anti-TPBG antibodies of the invention for payload delivery a surrogate assay was performed. In this assay, TPBG-specific Fabs were co-incubated in a 1:3 molar ratio for 30 min prior addition to cells with a second Fab binding to the kappa-light chain of the TPBG-specific Fab. The kappa binding Fab carried in addition a pseudomonas exotoxin (PE) moiety. The so formed complex (“Fab-PE sandwich construct”) was added to human MCF7 breast cancer cells.
- In brief, 20.000 cells were seeded per well in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series were prepared in medium spanning a concentration range from 133 to 0.002 nM as calculated for the respective TPBG-specific Fab. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- The complex consisting of TPBG-specific Fab and anti-kappa-Fab-PE elicited a strong cytotoxic response on MCF7 cells (
FIG. 9 ). All Fab-PE sandwich constructs displayed low nM to sub-nM activity while an unrelated Fab co-incubated with an anti-kappa-Fab-PE had no toxicity in this dose range. All Fab-PE sandwichconstructs comprising antibodies - This observation could be reproduced in an independent experiment as shown in the last column of (Table 14) for the calculated potency difference. This assay setup differs in the absolute nM values obtained for biological replicates by a factor of about 2-3 fold. All generated values were therefore referenced to the H8-comprising construct.
-
TABLE 14 Cytotoxic activity of anti-TPBG Fab-PE sandwich constructs on human TPBG expressing MCF7 cells (EC50 in [nM]) X-fold higher potency compared to Fab MCF7 TPBG(H8)PE Unspecific Fab — H8 1.248 — 051 1.354 1.1/— 091 0.414 3.0/2.7 097 0.935 1.3/2.4 - As an additional comparative experiment, further prior art antibodies A1, A2 and A3 (U.S. Pat. No. 8,044,178) were assessed with respect to their suitability for payload delivery in an assay as outlined above, and compared with reference to prior art antibody H8.
- Functionality of antibodies A1, A2 and A3 was confirmed in surface plasmon resonance and cellular binding experiments (data not shown). To evaluate the suitability of these Fabs derived from antibodies A1, A2 and A3 for payload delivery a surrogate assay was performed. In this assay, TPBG-specific Fabs were co-incubated in a 1:3 molar ratio for 30 min prior addition to cells with a second Fab binding to the kappa-light chain of the TPBG-specific Fab. The kappa binding Fab carried in addition a pseudomonas exotoxin (PE) moiety. The so formed complex was added to human MCF7 breast cancer cells. In brief, 20.000 cells were seeded per well in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series were prepared in medium spanning a concentration range from 133 to 0.002 nM as calculated for the respective TPBG-specific Fab. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- Compared to the Fab fragment of prior art antibody H8, which has a potency of 1.85 nM on MCF7 in this experiment, the Fabs derived from antibodies A1, A2 and A3 displaed a significantly lower potency (
FIG. 10 ). -
TABLE 15 Cytotoxic activity of anti-TPBG Fab-PE sandwich constructs on human TPBG expressing MCF7 cells (EC50 in [nM]) X-fold lower potency compared to Fab MCF7 TPBG(H8)PE H8 1.85 — A1 62.08 33.5 A2 189.65 102.5 A3 5.45 2.9 - Cytotoxicity of Immunoconjugates Comprising Anti-TPBG Antibodies (Fabs Coupled to PE Fragment Via Sortase Coupling) on Human TPBG Expressing MCF7 Cells
- To evaluate potency of Fab-PE constructs (Fabs coupled to PE fragment via sortase coupling as provided in Example 12) on tumor cell lines the breast cancer cell line MCF7 was selected. 20.000 cells were seeded per well in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series of sortase-coupled Fab-PEs were prepared in medium spanning a concentration range from 133 to 0.002 nM. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- All evaluated sortase-coupled Fab-PE constructs displayed potent sub-nM activity on MCF7 cells (
FIG. 11 ). An unspecific Fab-PE not binding to the cell surface had no activity in this assay. For sortase-coupled Fab-PEconstructs comprising antibodies -
TABLE 16 Cytotoxic activity of sortase coupled anti-TPBG Fab-PE constructs on human TPBG expressing MCF7 cells (EC50 in [nM]) X-fold higher potency Fab-PE comprising compared to antibody MCF7 TPBG(H8)PE Unspecific Fab — H8 0.059 — 051 0.036 1.7 091 0.033 1.8 097 0.054 1.1 - Cytotoxicity Mediated by Anti-TPBG Antibodies (Anti-TPBG Fab Antibodies Bound by Anti-Kappa Chain Antibody-PE Fusion Protein) on Human TPBG Expressing H1975 Non-Small Cell Lung Cancer Cells
- To evaluate the suitability of Fabs for payload delivery to non-small cell lung cancer cells a surrogate assay was performed.
- In this assay, TPBG-specific Fabs expressed as described in Example 11 were co-incubated in a 1:3 molar ratio for 30 min prior addition to cells with a second Fab binding to the kappa-light chain of the TPBG-specific Fab. The kappa binding Fab carried in addition a pseudomonas exotoxin (PE) moiety. The so formed complex was added to human H1975 lung cancer cells. In brief, 10.000 cells were seeded per well in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech) and penicillin/streptomycin (Gibco). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series were prepared in medium spanning a concentration range from 133 to 0.002 nM as calculated for the respective TPBG-specific Fab. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- Sandwich constructs comprising Fab fragments of prior art antibody H8, as well as of antibodies of the
invention antibody 091 of the invention was consistently performing as the best candidate (Table 17). - Sandwich constructs comprising Fab fragments of prior art antibodies A1, A2 and A3 displayed no (for A1 and A2) or significantly lower cytotoxicity than the other tested constructs (
FIG. 12 ). -
TABLE 17 Cytotoxic activity mediated by anti-TPBG Fab-PE sandwich constructs on human TPBG expressing H1975 cells (EC50 in [nM]) H1975 Fab of antibody replicate 1 replicate 2 replicate 3 H8 0.698 0.451 0.656 051 0.522 0.397 0.527 091 0.166 0.129 0.182 097 0.826 0.656 0.706 A1 — — — A2 — — — A3 3.444 2.765 >3 - Cytotoxicity of Immunoconjugates Comprising Anti-TPBG Antibodies (Anti-TPBG Fab-PE Fusion Proteins) on Human TPBG Expressing H1975 Non-Small Cell Lung Cancer Cells
- To evaluate potency of anti-TPBG Fab-PE fusion proteins as expressed in Example 13 and 14 on tumor cell lines the non-small cell lung cancer cell line H1975 was selected. The number of cell surface TPBG molecules was approximately 30.000/cell as determined by flow cytometry based receptor quantitation. 10.000 cells were seeded per well in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series of Fab-PEs were prepared in medium spanning a concentration range from 3 to 0.00005 nM. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in. Experiments were performed as biological replicates.
- Potency of all anti-TPBG Fab-PE constructs was dose-dependent (
FIG. 13 ). An unspecific Fab-PE not binding to H1975 did not show significant activity in the measured dose range. All tested anti-TPBG Fab-PEs displayed sub-nM potency. The Fab-PE fusionprotein comprising antibody 091 of the invention was consistently about 3-4 fold more potent in this cell line than the fusion protein derived from prior art antibody H8 (Table 18). -
TABLE 18 Cytotoxic activity mediated by anti-TPBG Fab-PE fusion proteins on human TPBG expressing H1975 cells (EC50 in [nM]) X-fold higher Potency compared to H1975 Fab-PE fusion Fab of antibody replicate 1 replicate 2 protein of H8 Unspecific Fab — — H8 0.019 0.013 — 051 0.016 0.014 1.2/1.1 091 0.005 0.003 3.8/3.7 097 0.013 0.013 1.4/1.1 - Time Course Proliferation Assay of Immunoconjugates Comprising Anti-TPBG Antibodies (Anti-TPBG Fab-PE Fusion Proteins) Applied to Human TPBG Expressing H1975 Non-Small Cell Lung Cancer Cells
- In a different experimental setup the exposure time of of anti-TPBG Fab-PE fusion proteins as expressed in Example 13 and 14 to tumor cells was varied. The non-small cell lung cancer cell line H1975 was used to evaluate, if shorter incubation time with Fab-PE constructs has an impact on potency in a proliferation assay.
- 10.000 cells were seeded per well in a 98well-MTP in 100 μL medium (Gibco) containing 10% fetal calf serum (PAN Biotech). Cells were allowed to attach for 24 h prior addition of compounds. Dilution series of Fab-PEs were prepared in medium spanning a concentration range from 3 to 0.00005 nM. After 10, 30 and 60 min of incubation medium was replaced with fresh medium without Fab-PE and cells were further maintained for a total of 72 h. In addition, cells with continuous exposure to Fab-PE were cultivated. Individual data points were measured as triplicates. 72 h after compound addition CellTiter-Glo (Promega) assay was performed. Luminescence was recorded in a microplate reader (Tecan). Data analysis was performed with Excel (Microsoft) and XLfit 5.3.1 (IDBS) add-in.
- All tested Fab-PE fusion proteins displayed potent sub-nM potency on this human tumor cell line (
FIG. 14 A-D). Shorter incubation periods with Fab-PE fusion proteins resulted in a slight decrease of potency. Anti-TPBG Fab-PE fusion protein comprising the Fab fragment ofantibody 091 of the invention was more potent than the other tested molecules, which is consistent with the observation of Example 30 (Tables 19 and 20). -
TABLE 19 Time course proliferation experiment of human TPBG expressing H1975 cells contacted with anti-TPBG Fab- PE fusion proteins (EC50 in [nM]) Fab comprised in H1975 immunoconjugate continuous 60 min 30 min 10 min H8 0.013 0.180 0.201 0.229 051 0.014 0.180 0.204 0.241 091 0.003 0.043 0.062 0.057 097 0.013 0.203 0.189 0.211 -
TABLE 20 Time course proliferation experiment of human TPBG expressing H1975 cells contacted with anti-TPBG Fab-PE fusion proteins (X-fold hihger potency than anti-TPBG Fab-PE fusion protein of prior art antibody H8) Fab comprised in H1975 immunoconjugate continuous 60 min 30 min 10 min H8 1.0 1.0 1.0 1.0 051 1.1 1.0 1.0 1.1 091 3.7 4.2 3.3 4.0 097 1.1 1.1 0.9 0.9 - In Vivo Anti-Tumor Efficacy of Immunoconjugates Comprising Anti-TPBG Antibodies (Anti-TPBG Fab-PE Fusion Proteins) on Human TPBG Expressing Human Non-Small Cell Lunger Cancer H1975 Cell Xenografts
- The in vivo antitumor efficacy of anti-TPBG Fab-PE fusion proteins as expressed in Examples 13 and 14 was monitored in a human tumor cell line based model of transplanted nude mice. The non-small cell lung cancer (NSCLC) NCI-H1975 cell line was chosen as xenograft model. NCI-H1975 displays cell surface TPBG as was independently confirmed.
- NCI-H1975 were cultured in RPMI high glucose medium with 1.0 mM sodium pyruvate supplemented with 10% fetal calf serum, 2.0 mM L-glutamine, and 10 mM HEPES at 37° C. in a water-saturated atmosphere at 5% CO2. Culture passages were performed with trypsin/EDTA (Life Technologies) splitting every third day. Nude mice were purchased from breeder (e.g. Charles River, Sulzfeld, Germany) and maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government. After arrival animals were maintained in the quarantine part of the animal facility for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis. Diet food (Provimi Kliba 3337) and water (acidified pH 2.5-3) were provided ad libitum. Animals were controlled daily for clinical symptoms and detection of adverse effects. For monitoring throughout the experiment body weight of animals was documented.
- Animal treatment started after animal randomisation after cell transplantation when mean tumor size was about 100-200 mm3. Fab-PE fusion proteins were administered as single agent at 1 mg/kg i.v. once daily every second day for several times. The corresponding vehicle was administered on the same days. Fab-PE proteins were provided as stock solution from Roche, Penzberg, Germany. Buffer included histidine and injection solution was diluted appropriately in buffer from stock prior injections.
- NCI-H1975 NSCLC xenograft bearing mice were treated with the Fab-PE fusion proteins from
study day 17 to 44 at dose of 1.0 mg/kg for a total of 8 times (days - The strong efficacy of the immunoconjugated of the invention was statistically different from the immunoconjugated comprising prior art antibody H8 (
FIG. 15 ). - In Vivo Anti-Tumor Efficacy of Immunoconjugates Comprising Anti-TPBG Antibodies (Anti-TPBG Fab-PE Fusion Proteins) on Human TPBG Expressing Human Gastric Cancer NCI-N87 Cell Xenografts
- The in vivo antitumor efficacy of anti-TPBG Fab-PE fusion proteins as expressed in Examples 13 and 14 was monitored in a human tumor cell line based model of transplanted nude mice. The gastric cancer NCI-N87 cell line was chosen as xenograft model. NCI-N87 displays cell surface TPBG as was independently confirmed.
- NCI-N87 were cultured in RPMI high glucose medium with 1.0 mM sodium pyruvate supplemented with 10% fetal calf serum, 2.0 mM L-glutamine, and 10 mM HEPES at 37° C. in a water-saturated atmosphere at 5% CO2. Culture passages were performed with trypsin/EDTA (Life Technologies) splitting every third day. Nude mice were purchased from breeder (e.g. Charles River, Sulzfeld, Germany) and maintained under specific-pathogen-free condition with daily cycles of 12 h light/12 h darkness according to committed guidelines (GV-Solas; Felasa; TierschG). Experimental study protocol was reviewed and approved by local government. After arrival animals were maintained in the quarantine part of the animal facility for one week to get accustomed to new environment and for observation. Continuous health monitoring was carried out on regular basis. Diet food (Provimi Kliba 3337) and water (acidified pH 2.5-3) were provided ad libitum. Animals were controlled daily for clinical symptoms and detection of adverse effects. For monitoring throughout the experiment body weight of animals was documented.
- Animal treatment started after animal randomisation after cell transplantation when mean tumor size was about 100-200 mm3. Fab-PE fusion proteins were administered as single agent at 1 mg/kg i.v. once daily every second day for several times. The corresponding vehicle was administered on the same days. Fab-PE fusion proteins were provided as stock solution from Roche, Penzberg, Germany. Buffer included histidine and injection solution was diluted appropriately in buffer from stock prior injections.
- In the NCI-N87 gastic cancer xenograft model tumor mice were treated with Fab-PE fusion proteins from
study day 15 to 33 at dose of 1.0 mg/kg for a total of 7 times (days FIG. 16 ). - Protein Synthesis Assay Using BxPC3/Luc Cells Contacted with Immunoconjugates Comprising Anti-TPBG Antibodies (Anti-TPBG Fab-PE Fusion Proteins)
- Inhibition of protein synthesis was measured by exposing BxPC/luc cells to anti-TPBG Fab-PE fusion proteins as expressed in Examples 13 and 14.
- In brief, BxPC3 cells were stably transfected with a plasmid encoding for a luciferase which contains cellular degradation signals (Promega) and has a half-life of about 0.4 h. Single clones were derived and re-assessed for stable plasmid incorporation. Inhibition of protein synthesis by ADP-ribosylation conferred by the pseudomonas exotoxin results in a rapid loss of luciferase and can thus be measured upon cell lysis and incubation with luciferin as loss of signal in comparison to controls.
- BxPC3/luc in the logarithmic growth phase were detached with Accutase (Sigma) and counted. 40.000 BxPC3/luc cells were seeded per well in 96well-MTP in 100 μl medium containing 10% fetal calf serum and were incubated 24 h prior compound addition. TPBG-specific immunoconjugates were added in a concentration range from 3-0.0001 nM. All samples were measured in triplicates.
- An unspecific immunoconjugate has no effect on the luciferase signal (ct). All TPBG-specific immunoconjugates display sub-nM potency. Antibodies of this invention display higher potency than the prior art antibody H8 (
FIG. 17A and Table 21). -
TABLE 21 Cytotoxic activity mediated by anti-TPBG Fab-PE fusion proteins on human TPBG expressing BxPC-3 cells (EC50 in [nM]) X-fold higher Potency compared to BxPC-3 Fab-PE fusion Fab of antibody replicate 1 replicate 2 protein of H8 Unspecific Fab — — H8 0.058 0.020 051 0.027 0.015 2.2/1.4 091 0.014 0.007 4.3/2.8 097 0.022 0.008 2.7/2.6 - In addition, inhibition of protein synthesis by anti-TPBG Fab-PE sandwich constructs comprised of antibodies A1, A2, A3 and H8 was determined in BxPC3/luc. TPBG-specific Fabs were mixed with anti-human kappa Fab-PE (pseudomonas exotoxin) in a 1:3 molar ratio and kept at room temperature for 15 min to allow for sandwich construct formation. Dilution series of this mixture were prepared in medium. Final concentrations on cells ranged from 133 nM to 0.002 nM as calculated for the TPBG-specific Fab. 24 h post-addition Steady-Glo luciferase assay (Promega) was performed. All samples were measured in triplicates. Comparing Fabs co-inctubaed with anti-human kappa Fab-PE revealed that A1 and A2 did not display activity in the given concentration range, while A3 exibited an about 5-fold lower potentcy than H8 (
FIG. 17B ). - Affinity of Anti-TPBG Fab Fragments to Human TPBG
- Affinity of Fab fragments of
antibodies - Affinity to Human TPBG was Assessed as Follows:
- A CM5 sensor chip was mounted into a Biacore T200 System. Flow cell one was prepared as reference flow cell, by blank immobilization. On flow cell two, about 500 RU of 1.5 μg/ml huTPBG in pH 4.5 acetate buffer were immobilized (120 s at 10 μl/min). The amine-coupling was done as described by the manufacturer.
- The samples were injected in a concentration series of 4.9 nM, 14.8 nM, 44.4 nM, 133.3 nM, 400 nM and 0 nM for 150 s at a flow speed of 50 μl/min, followed by a dissociation phase of 660 seconds.
- The sample-antigen-complex was regenerated after every sample injection by one 40 s pulse of Glycine-HCl pH 1.5 at 30 μl/min and one 40 s long injection of a regeneration solution containing 0.31 M KSCN, 1.22 M MgCl2, 0.61 M urea, 1.22 M Gua-HCl and 6.7 mM EDTA at 30 μ/min followed by an extra wash after injection with buffer.
- Relevant kinetic data was calculated using the Biacore T200 evaluation software.
-
TABLE 22 Affinity constants of anti-TPBG Fab fragments to human TPBG Sample ka (1/Ms) kd (1/s) KD (M) 051 4.89E+05 7.83E−05 1.60E−10 091 4.87E+05 2.72E−05 5.58E−11 097 9.93E+05 8.14E−04 8.20E−10 H8 1.37E+05 2.17E−07 1.58E−12 - Affinity of Anti-TPBG Fab Fragments to Minipig TPBG
- Affinity of Fab fragments of
antibodies - Affinity to Human TPBG was Assessed as Follows:
- A CM5 sensor chip was mounted into a Biacore T200 System. Flow cell one was prepared as reference flow cell by blank immobilization. An <huFab> capture antibody (#28958325, GE-HC) was immobilized via amine coupling onto the
flow cells - The samples were successively captured on
flow cells - Relevant kinetic data was calculated using the Biacore T200 evaluation software. The data indicates no stable binding of antibody H8 to recombinant extracellular domain of minipig TPBG (
FIG. 19 and Table 23). -
TABLE 23 Affinity constants of anti-TPBG Fab fragments to minipig TPBG Sample ka (1/Ms) kd (1/s) KD (M) 051 9.40E+04 1.93E−04 2.05E−09 091 1.18E+05 2.05E−04 1.74E−09 097 1.89E+05 2.54E−04 1.35E−09 Fab(H8) No binding No binding No binding - pH Dependent Binding of Anti-TPBG Antibodies to Human TPBG Antigen
- A CM5 sensor chip was mounted into a Biacore T200 System. Flow cell one was prepared as reference flow cell, by blank immobilization. On flow cell two, 80 RU were the aim for the immobilization with 1.5 μg/ml huTPBG in pH 4.5 acetate buffer. The amine-coupling was done as described by the manufacturer.
- In one embodiment of the assay HBS-EP+pH 5.5 was used as running and sample buffer, in a second embodiment HBS-EP+pH 7.4 was used.
- The samples were injected in a concentration series of 1.9 nM, 5.6 nM, 2×16.7 nM, 50 nM, 150 nM and 2×0 nM for 300 s at a flow speed of 50 μl/min. The 50 nM, one 0 nM and one 16.7 nM sample were allowed to dissociate for 1200 s, all other dissociation phases were only 10 s long.
- The sample-antigen-complex was regenerated after every sample injection by one 40 s pulse of Glycine-HCl pH 1.5 at 30 μl/min and one 40 s long injection of a regeneration solution containing 0.31 M KSCN, 1.22 M MgCl2, 0.61 M urea, 1.22 M Gua-HCl and 6.7 mM EDTA at 30 μ/min followed by an extra wash after injection with buffer.
- Relevant kinetic data was calculated using the Biacore T200 evaluation software.
- Experimental results for Fab-PE fusions proteins clearly indicate that prior art antibody H8 binds in a pH dependent manner. A pH shift from 7.4 to 5.5 results in a significant decrease of KD while huTPBG-binding of
antibodies FIG. 18 ). -
TABLE 24 Affinity constants of anti-TPBG Fab-PE fusion proteins to human TPBG at different pH values Fab comprised in pH immunoconjugate ka (1/Ms) kd (1/s) KD (M) 5.5 H8 5.43E+04 1.47E−02 2.70E−07 051 3.86E+05 1.13E−04 2.92E−10 091 2.26E+05 2.01E−03 8.89E−09 097 8.08E+05 6.05E−03 7.49E−09 7.4 H8 1.97E+05 7.61E−05 3.85E−10 051 2.86E+05 3.46E−05 1.21E−10 091 2.80E+05 1.29E−04 4.61E−10 097 6.14E+05 1.21E−03 1.97E−09
Claims (17)
1-17. (canceled)
18. An isolated antibody that binds to trophoblast glycoprotein (TPBG) comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 12, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 13, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16.
19. The antibody of claim 18 comprising a variable heavy chain domain (VH) having at least 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 17 and a variable light chain domain (VL) having at least 95% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 18.
20. The antibody of claim 18 comprising a variable heavy chain domain (VH) with the amino acid sequence of SEQ ID NO: 17 and a variable light chain domain (VL) with the amino acid sequence of SEQ ID NO: 18.
21. The antibody of claim 1, wherein the antibody is a Fab fragment that binds to TPBG.
22. An isolated nucleic acid encoding the antibody of claim 18 .
23. A host cell comprising the nucleic acid of claim 22 .
24. A method of producing an antibody comprising culturing the host cell of claim 23 so that the antibody is produced.
25. An immunoconjugate comprising the antibody of claim 18 , and a cytotoxic agent.
26. The immunoconjugate of claim 25 , wherein the cytotoxic agent is Pseudomonas exotoxin A or a variant thereof.
27. The immunoconjugate of claim 25 , wherein the antibody is a Fab fragment that binds to TPBG.
28. A pharmaceutical formulation comprising the antibody of claim 18 , and a pharmaceutically acceptable carrier.
29. A pharmaceutical formulation comprising the immunoconjugate of claim 25 and a pharmaceutically acceptable carrier.
30. A method of treating cancer in a patient, comprising administering the antibody of claim 18 to a patient in need thereof.
31. The method of claim 30 , wherein the cancer is non-small cell lung cancer.
32. A method of treating cancer in a patient, comprising administering the immunoconjugate of claim 25 to a patient in need thereof.
33. The method of claim 32 , wherein the cancer is non-small cell lung cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/553,498 US20200108154A1 (en) | 2015-10-29 | 2019-08-28 | Anti-tpbg antibodies and methods of use |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15192002.2 | 2015-10-29 | ||
EP15192002.2A EP3184547A1 (en) | 2015-10-29 | 2015-10-29 | Anti-tpbg antibodies and methods of use |
PCT/EP2016/075881 WO2017072207A1 (en) | 2015-10-29 | 2016-10-27 | Anti-tpbg antibodies and methods of use |
US15/965,517 US10434184B2 (en) | 2015-10-29 | 2018-04-27 | Anti-TPBG antibodies and methods of use |
US16/553,498 US20200108154A1 (en) | 2015-10-29 | 2019-08-28 | Anti-tpbg antibodies and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/965,517 Continuation US10434184B2 (en) | 2015-10-29 | 2018-04-27 | Anti-TPBG antibodies and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200108154A1 true US20200108154A1 (en) | 2020-04-09 |
Family
ID=54360972
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/965,517 Expired - Fee Related US10434184B2 (en) | 2015-10-29 | 2018-04-27 | Anti-TPBG antibodies and methods of use |
US16/553,498 Abandoned US20200108154A1 (en) | 2015-10-29 | 2019-08-28 | Anti-tpbg antibodies and methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/965,517 Expired - Fee Related US10434184B2 (en) | 2015-10-29 | 2018-04-27 | Anti-TPBG antibodies and methods of use |
Country Status (6)
Country | Link |
---|---|
US (2) | US10434184B2 (en) |
EP (2) | EP3184547A1 (en) |
JP (1) | JP2019500853A (en) |
CN (1) | CN108350083B (en) |
HK (1) | HK1258850A1 (en) |
WO (1) | WO2017072207A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7436710B2 (en) | 2020-05-19 | 2024-02-22 | アニゲン カンパニー、リミテッド | Novel nucleolin-binding peptides and their uses |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
EP3765493A2 (en) | 2018-03-12 | 2021-01-20 | Genmab A/S | Antibodies |
AU2019410073A1 (en) | 2018-12-21 | 2021-06-10 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic CD28 antigen binding molecules |
EP4028424A1 (en) | 2019-09-12 | 2022-07-20 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5869053A (en) | 1988-03-04 | 1999-02-09 | Cancer Research Campaign Technology, Ltd. | 5T4 antigen from human trophoblasts |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
CA2053911C (en) | 1989-04-21 | 1999-11-02 | Ira H. Pastan | Recombinant antibody-toxin fusion protein |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
WO1991009965A1 (en) | 1989-12-21 | 1991-07-11 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | An improved toxin for construction of immunotoxins |
EP0509056A4 (en) | 1990-01-02 | 1993-02-17 | Us Health | Target-specific, cytotoxic, recombinant pseudomonas exotoxin |
AU7182791A (en) | 1990-01-05 | 1991-07-24 | Cornell Research Foundation Inc. | Rice actin gene and promoter |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (en) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | Immunoglobulin variants |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DE69334255D1 (en) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker for cancer and biosynthetic binding protein for it |
WO1993025690A1 (en) | 1992-06-18 | 1993-12-23 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant pseudomonas exotoxin with increased activity |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
JPH11513669A (en) | 1995-10-13 | 1999-11-24 | アメリカ合衆国 | Immunotoxins containing disulfide-stabilized antibody fragments |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
JP2001504334A (en) | 1996-11-06 | 2001-04-03 | アメリカ合衆国 | Protease-activatable Pseudomonas exotoxin A-like proprotein |
IL132596A0 (en) | 1997-06-04 | 2001-03-19 | Oxford Biomedica Ltd | Vector |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
BR9813365A (en) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Method for Production and Humanization of a Mouse Monoclonal Antibody |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1068241T3 (en) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antibody variants and fragments thereof |
PT1071700E (en) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
EP0972838B1 (en) | 1998-07-15 | 2004-09-15 | Roche Diagnostics GmbH | Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy |
US6291245B1 (en) | 1998-07-15 | 2001-09-18 | Roche Diagnostics Gmbh | Host-vector system |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (en) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
PT1914244E (en) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Method of modulating the activity of functional immune molecules |
WO2001025454A2 (en) | 1999-10-04 | 2001-04-12 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
CA2393869A1 (en) | 1999-12-15 | 2001-06-21 | Genetech,Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
WO2001049698A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2785941C (en) | 2000-10-06 | 2017-01-10 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ATE378403T1 (en) | 2000-11-30 | 2007-11-15 | Medarex Inc | TRANSCHROMOSOMAL TRANSGENIC RODENTS FOR PRODUCING HUMAN ANTIBODIES |
CN1555411A (en) | 2001-08-03 | 2004-12-15 | ���迨�����\���ɷݹ�˾ | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | Process for producing antibody composition |
JP4628679B2 (en) | 2002-04-09 | 2011-02-09 | 協和発酵キリン株式会社 | Cells in which the activity of a protein involved in GDP-fucose transport is reduced or deleted |
JPWO2003085107A1 (en) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | Genome-modified cells |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
JP4753578B2 (en) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | Synthetic antibody phage library |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2005035586A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF a1,6-FUCOSYLTRANSFERASE |
RS55723B1 (en) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Antigen binding molecules with increased fc receptor binding affinity and effector function |
BR122018071968B8 (en) | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | antibody-drug conjugate, pharmaceutical composition, article of manufacture and use of an antibody-drug conjugate |
ES2343965T3 (en) | 2003-11-25 | 2010-08-13 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | ANTI-CD22 ANTIBODIES AND MUTED IMMUNOCONGUJADOS. |
WO2005053742A1 (en) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
RU2386638C2 (en) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Humanised anti-tgf-beta-antibody |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
GT200500255A (en) | 2004-09-10 | 2006-04-10 | ANTI-5TA HUMANIZED AND CONJUGATED ANTIBODIES ANTI-5TA ANTIBODY / CALICHEAMICINA | |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
EP2284194A1 (en) * | 2004-12-21 | 2011-02-16 | AstraZeneca AB | Antibodies directed to angiopoietin-2 and uses thereof |
EP3006458B1 (en) | 2005-07-29 | 2017-11-22 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Mutated pseudomonas exotoxins with reduced antigenicity |
WO2007031741A1 (en) | 2005-09-14 | 2007-03-22 | Cambridge Antibody Technology Limited | Pseudomonas exotoxin a cd4+ t-cell epitopes |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
NZ571208A (en) | 2006-03-10 | 2011-12-22 | Wyeth Corp | Anti-5T4 antibodies and uses thereof |
AU2007249408A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
RS52643B (en) * | 2006-06-02 | 2013-06-28 | Regeneron Pharmaceuticals Inc. | High affinity antibodies to human il-6 receptor |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
CA2698357C (en) | 2007-09-04 | 2017-06-06 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
JP2012508017A (en) * | 2008-11-07 | 2012-04-05 | ファブラス エルエルシー | Anti-DLL4 antibody and use thereof |
JP5501439B2 (en) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | Multispecific antibody comprising a full-length antibody and a single chain Fab fragment |
KR101456326B1 (en) | 2009-04-07 | 2014-11-12 | 로슈 글리카트 아게 | Trivalent, bispecific antibodies |
RU2570633C2 (en) | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
JO3246B1 (en) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | High affinity human antibodies to human protease-activated receptor-2 |
AU2010292069B2 (en) | 2009-09-11 | 2015-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Improved Pseudomonas Exotoxin A with reduced immunogenicity |
JP5798193B2 (en) | 2010-08-30 | 2015-10-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Alkaline feed |
ES2641877T3 (en) | 2011-05-06 | 2017-11-14 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Mesothelin-directed recombinant immunotoxin |
KR20140033391A (en) | 2011-06-09 | 2014-03-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes |
AU2012308591B2 (en) | 2011-09-16 | 2017-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pseudomonas exotoxin a with less immunogenic B cell epitopes |
CA2926215A1 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
-
2015
- 2015-10-29 EP EP15192002.2A patent/EP3184547A1/en not_active Ceased
-
2016
- 2016-10-27 EP EP16790315.2A patent/EP3368576A1/en active Pending
- 2016-10-27 CN CN201680062256.2A patent/CN108350083B/en not_active Expired - Fee Related
- 2016-10-27 JP JP2018522057A patent/JP2019500853A/en active Pending
- 2016-10-27 WO PCT/EP2016/075881 patent/WO2017072207A1/en active Application Filing
-
2018
- 2018-04-27 US US15/965,517 patent/US10434184B2/en not_active Expired - Fee Related
-
2019
- 2019-01-25 HK HK19101320.8A patent/HK1258850A1/en unknown
- 2019-08-28 US US16/553,498 patent/US20200108154A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7436710B2 (en) | 2020-05-19 | 2024-02-22 | アニゲン カンパニー、リミテッド | Novel nucleolin-binding peptides and their uses |
Also Published As
Publication number | Publication date |
---|---|
HK1258850A1 (en) | 2019-11-22 |
CN108350083B (en) | 2021-11-26 |
EP3368576A1 (en) | 2018-09-05 |
US20180311371A1 (en) | 2018-11-01 |
US10434184B2 (en) | 2019-10-08 |
EP3184547A1 (en) | 2017-06-28 |
CN108350083A (en) | 2018-07-31 |
JP2019500853A (en) | 2019-01-17 |
WO2017072207A1 (en) | 2017-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220363755A1 (en) | Anti-tim3 antibodies and methods of use | |
EP2747781B1 (en) | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use | |
US10434184B2 (en) | Anti-TPBG antibodies and methods of use | |
EP3143049B1 (en) | Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2 | |
US10364290B2 (en) | Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4 | |
WO2014072306A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
EP3143048B1 (en) | Anti-her3 antibodies binding to the beta-hairpin of her3 | |
US20180100022A1 (en) | Her1 antigen binding proteins binding to the beta-hairpin of her1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |